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Introduction 
2 CHAPTER I 
Since the first recording of the human electrical activity ofthe heart by Waller 
in 1887 1 and the invention of the electrocardiograph by Willem Einthoven 
in 19022, the recording of the electrocardiogram (ECG) has evolved into 
one of the most important noninvasive diagnostic techniques of today-
cardiology3 In particular, the diagnosis of cardiac arrhythmias, myocardial 
ischemia and myocardial infarction depends on the use of routine ECG 
recordings. The development of continuous ECG recording techniques such 
as long term ambulatory ECG recording (Holter) made it also possible to 
document less frequently occurring cardiac arrhythmias or ischemic events 
occurring during daily life. 
It has now been well established that long term continuous Holter ST 
segment recording can identify unstable angina patients with silent myocardial 
ischemia who are at a high risk of sllstaining a major cardiovascular event4,5, 
However, Holter ST recording has the major limitation that it can only provide 
information on risk prediction using retrospective data (off-line analysis). 
As such, this technique is not suitable for on-line risk prediction of imminent 
cardiac events. Over the past 7 years, cOlllputer-assisted continuous lllultilead 
ECG monitoring techniques have become available for real-time ECG and 
ST segment monitoring6 These techniques have overcome the limitations 
of earlier ECG technologies as they can record and display the complete 
12-lead and / or vector ECG on-line and allow both on-line and retrospective 
analysis. It offers the possibility of on-line noninvasive monitoring of the 
vessel status in patients with unstable coronmy syndromes, which is becoming 
increasingly important to monitor the effects of thrombolytics, anti-thrombin 
and anti-coagulant therapy, platelet inhibitors, and advanced intracoronary 
intervention. 
The present thesis evaluates the usefulness of computer-assisted continuous 
multi lead ECG monitoring techniques for detection and quantitation of 
myocardial ischemia, prediction of coronaty vessel status and for identification 
of patients at risk of major coronary events. 
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ECG MONITORING OF VESSEL STATUS IN PATIENTS WITH AN 
ACUTE MYOCARDIAL INFARCTION RECEIVING REPERFUSION 
THERAPY 
Early reperfusion and sustained patency of the infarct-related coronary artelY 
are important determinants ofsurvival7 Thus, more aggressive therapy may 
be indicated if thrombolytic therapy fails to open up the occluded vessel or 
if reocclusion of an initially reperfused coronary artery occurs. In contrast, 
administration of thrombolytic agents might be discontinued to minimize 
bleeding risk in patients with a rapidly reperfused artery8 In this manner, 
therapy of acute myocardial infarction could be tailored to the status of the 
infarct-related vessel 9 In order to guide the therapy, continuous monitoring 
of the vessel status is mandatory. Coronary angiography is the gold standard 
to assess patency and (re )occlusion. However, angiography supplies only 
very momentary information on the status of the infarct-related vessel and 
this invasive technique is not useful for continuous monitoring. 
Noninvasive methods for monitoring ofreperfusion of the infarct-related 
vessel include clinical markers such as resolution of chest pain, electro-
cardiographic findings such as the occurrence of an accelerated idioventricular 
rhythm and normalization of the ST segments and monitoring of specific 
cardiac proteins in plasma IO-13 • Resolution of chest pain is very subjective 
and may frequently be related to analgesic medication. The occurrence of 
an accelerated idioventricular rhythm suggesting reperfusion is highly specific 
but not sufficiently sensitive to predict reperfusion. Thus, monitoring of ST 
segment normalization seems best suitable for reliable prediction of coronary 
vessel status. In this overview, the usefulness of the different electrocardio-
graphic techniques for detection of reperfusion and patency of the infarct-
related artery is discussed. 
The standard 12-lead electrocardiogram for detection of reperfusion and 
patency 
Rapid resolution of ST segment elevation after reperfusion, as documented 
by coronary angiography, occurs with an almost 5 fold faster time course 
than the changes associated with the natural evolution of acute myocardial 
infarction without reperfusion I4- 18 . Thus, rapid resolution of ST segment 
elevation is a marker of reperfusion. 
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Many studies evaluated the usefulness of ST segment recovery from serial 
12-lead ECGs as a marker of reperflIsion using coronary angiography as the 
golden standard I 1,19·24 For proper comparison, the ideal study design should 
allow for angiographic assessment to be performed immediately after (and 
not before) the final ECG assessment. Furthermore, assessment of patency 
is most important during the first few hours following thrombolytic therapy 
as this may directly intluence treatment strategies9. Unfortunately, many studies 
appear invalid because of late angiography22.24, intercurrent angiography 
before the final ECG assessment20,21, or absence of well defined criteria for 
ST recoveryll. One of the first studies in this field by Clemmensen et al. l? 
still appears to be the most valid. This study comprised 53 patients with an 
acute myocardial infarction treated with thrombolytic therapy. Two serial 
ECGs were recorded, one on admittance, the other approximately 180 minutes 
after thrombolytic therapy. Directly following the second ECG, angiographic 
patency was assessed, using the classification of the Thrombolysis in 
Myocardial Infarction trial (TIMI) at first injection of contrast25 . Reduction 
of the sum ST elevation of 2 20%(measured at the J-point) within the pre-
defined time interval of I80 minutes rendered sensitivity and specificity of 
88 and 80%, respectively, for ECG versus angiographic patency assessment. 
Reviewing all the results of the studies on early patency assessment using 
serial12-lead ECGs, it appears that a rapid reduction ofST segment elevation 
or depression of2 20-50% of the highest previous ST value, occurring within 
3 hours tl'om start of thrombolytic therapy, is a reasonably accurate predictor 
of reperfusion. Absence of rapid ST recovery suggests occlusion. Depending 
on the severity of ST elevation on the initial ECG, the use of either the 
single lead with maximal ST deviation ("worst lead") or the total ST change 
of the summated leads may be appropriate. Ifmajor ST deviations are present 
on the initial ECG, the ST recovery applied to the single worst lead is 
preferable, while the reduction of the summated ST deviation may be more 
useful in cases of mild ST deviation. 
The conflicting results of the studies using serial 12-lead ECG recording 
for prediction of reperfusion and patency reflect the limitations using this 
serial method. Coronary reperfusion is a dynamic, rapidly changing process 
which is often accompanied by intermittent or sustained reocclusion and 
cyclic flow changes26,27. These dynamic changes may remain unrecognized 
if serial ECG recording is used for monitoring. The time interval between 
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the serial ECGs may be crucial for accurate detection of reperfusion and 
interpretation of the coronary status. For example, serial ECG recording may 
suggest a persistent coronary occlusion if it is taken at the moment of an 
undetected delayed ST (re-)elevation peak which precedes the moment of 
ST segment elevation recovery. On the other hand, if an ECG is taken at the 
moment ofa re-elevation episode (reocclusion) that followed the first period 
of ST recovery, the initial reperfusion following thrombolysis will be missed 
(Figure I and 2). As failed reperfusion and reocclusion may require different 
treatment strategies (for example rescue PTCA, respectively directed anti-
platelet therapy), this time resolution problem may lead to erroneous decision 
making. Therefore it is more appropriate to use continuous ECG monitoring 
techniques, in order to avoid less accurate assessments of reperfusion and 
patency. 
Continllolls ECG monitoring techniques 
Several continuous ECG monitoring techniques have been evaluated for the 
assessment of repel' fusion and patency following repcrfusion therapy. Holter 
ST segment recording was the first technique to monitor the ST segment 
continuously. However, it has some major limitations. Firstly, only a restricted 
number of leads can be monitored, which may not always reflect the area 
with maximal ST deviation. Furthermore, Holter ST monitoring allows for 
retrospective analysis only. This makes immediate feedback impossible and 
thus the technique cannot be used for on-line ST segment monitoring and 
tailoring of reperfusion therapy. This may explain why only few studies are 
reported evaluating this technique for early patency assessment. The two 
most representative studies are those from Hohnloser and Krucof[l2,28 Both 
studies demonstrate that Holter ST segment recording may be used for ischemia 
monitoring. 
Building on this experience, computer-assisted continuous multilead ECG 
monitoring techniques have become available for real-time noninvasive patency 
assessment. These techniques use continuous ECG sampling and averaging 
techniques, offering a continuous real-time accurate measurement of the QRS 
complex and ST segment. 
Two different approaches for computer-assisted ECG analysis have been 
developed: continuous multilead ST segment monitoring, based on on-line 
analysis of the conventional12-lead ECG, using either measurements of the 
6 
o.a lA ST-VM 
0.6 C 
0.4 
0.2 
B 
o 2 4 
CHAPTER 1 
J:-J:LrL 
Jl~~LJ-
a 12 16 hours 
Time from start thrombolysis 
Figlfre I. Continllolls ECG recording (vector ECG leads X, Y, -Z) in a patient with an 
inferior wall myocardial infarction. Leads X, Y, -Z more or less resemble V5, II and V2. 
On admittance, (A) considerable ST elevation is present in lead Y. The ST vcctormagnitude 
(ST V I,\,I , magnitude of the sum-vector orthe ST deviation in X, Y, Z) decreases as a result 
of thrombolytic therapy (8), followed by recurrent ST elevation (C). Thereafter, the ST 
level stabilizes CD-E). iVlost probably rcperfusiol1 (B) and a short episode of "reocclusion" 
(C) occur, the latter most probably due to a washout and subsequent embolization of thrombus 
into the distal branches of the CUlprit coronary artery, followed by a permanent reperfusion 
of the infarcted area (D-E). Note: if only serial ECG measurements would have been taken, 
e.g. at moments A and C, the first moment of reperfusioll (8) might have been missed, 
resulting in erroneous interpretation of the myocardial perfusion status. 
single leads (Siemens Medical Electronics, Danvers, Massachusetts USA)29 
or the summated ST level (Mortara Instrument, Milwaukee, USA)JO and 
continuous vectorcardiographic ECG monitoring, which otTers the possibility 
to study both on-line vectorcardiographic QRS complex and ST segment 
changes simultaneously (Mida 1000 and Coronet, Ortivus Medical, Tiiby, 
Sweden)] I 
Using these continuous digital monitoring techniques, five distinct pattems 
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Figure 2. Continuolls ECG recording (vector ECG leads X, Y, Z) in a patient with an 
inferior wall myocardial infarction. After the start of thrombolytic therapy the ST 
vectofmagnitude decreases and increases over time, suggesting fluctuations of impaired 
myocardial perfusion. Peak ST elevation occurs at moment B, followed by a rapid ST recovery, 
which is completed at moment C. suggesting myocardial reperfusion. At moment D, coronary 
angiography is performed. A proximal stenosis of the right coronary artery was found, 
with TI~'II 3 flow at tirst injection of contrast. The small ST VM peaks reflect injections of 
contmst. 
of ST segment behavior following thrombolysis have been observed27,3I; 
(I) rapid ST recovery without re-elevation, (2) rapid ST recovelY following 
a delayed ST elevation peak, (3) persistent ST elevation without a recovery 
pattern, (4) rapid ST recovery followed by recurrent ST elevation and (5) a 
delayed ST elevation peak followed by a rapid ST recovery and recurrent 
ST elevation. The first three patterns may directly point to the status of the 
infarct-related vessel. Rapid ST recovery without re-elevation or a rapid ST 
recovery following a delayed ST elevation peak both are highly suggestive 
of reperfusion of the infarct-related artery. Persistent ST elevation without 
00 
Table I. Continuous ECG monitoring for prediction of coronary rcperfusion after thrombolytic therapy. 
Study Ttthnique Criteri:.l Interval No. "with S<n<. S"". Pas/neg. Comment 
ro' thrombolysis of criteria % % p"". onstudy 
reperfusiou anjljograpby p~ value % 
Hohnloser i:: Hoi(Cr 2::50%,!,STel. 60-90 min. 82 48 60 95 97 142 only 2 J~ds 
one of twO leads short =ment interval 
within 90 min. 
after thrJysi.~ 
Krucoff 23 Hoitel' achievement of 100 min. '6' 56 89 82 85/87 less confined criteria 
ST steady state selected group of pt:;, 
wilhin 100 min. 
aft~ thdysis 
Nucoff'1.7 cootinUQllS -< 50% J.. or re-el. < 6 hrs. 22 90" 92- l:u"ge. not defiucd 
12-lead sinsle lead or ~ ST assessment interv..ll 
at contrast injection small study 
Krucoffl:: continuous < 50% J, or re-cl. 90 min. 144 73 90 64 'C7171 larger study 
12·1c:ad single lead or ::: ST correct srudy design 
:It contrast injection shon assessment ime[V;'\l 
Ddlborg 31 vector~ QRSVD and STVM at least 21 76 94 SO 94/80 pUotstudy 
cardiography qualitative evaluation 15 min. assessmau intcrv:U not defined 
QRSVD increase 21 86 94 40 83/67 
;.; O.lIJ.Vs/min. 
plateau < 200. 
DeUborg 34 vector~ QRSVD increase 90 min. 96 65 83 73 89/61 correct study design 
cardiognpby <!: 0.1 INs/min. sbon assessment interv:l1 
plateau < 2 hrs. 
STVM decrease 
~ 0.83 ,.Vltnin 
qualitative evalWltion n 
~ 
* TOtally occluded vessel at initial angio. n Seru.itivity and specilidty for assessment of occlusion. >-
Positive predieti.ve v:tlue: predktive value for patency. Negative pl:edic;tive v;llue: predictive v;llue for occlusion. "0 
QRSVD: QRS Vector Difference. STVM : Sf Vector Magnitude. El "" elevation. ? ... unspecified. ..., 
tIl 
:;;:J 
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a recovelY pattern suggests persistent occlusion, provided that significant 
ST elevation is present at the start of the monitoring period. Rapid ST recovelY 
followed by recurrent ST elevation or a delayed ST elevation peak followed 
by a rapid ST recovery and recurrent ST elevation may be less specific and 
may suggest unstable reperfusion. Patency assessment may then be difficult. 
The first representative studies evaluating continuous multilead ECG and 
vectorcardiographic monitoring are listed in Table I. Krucoff e/ al. reported 
on either thc presence of one episode of ~ 50% ST recovery (worst single 
lead or the SUlll ST deviation of all 12 leads), its absence, or recurrent ST 
elevation, using continuous updated 12-lead computer-assisted ST 
monitoring27 Absence of ST recovery or re-elevation at the moment of 
angiographic assessment predicted occlusion of the infarct-related vessel with 
sensitivity of 90 and specificity of 92%. However, the time interval between 
start of thrombolysis and final ECG and angiographic assessment was rather 
long, up to 6 hours and only 22 patients were studied. Later that year, the 
same author reported a larger study-population of 144 patients with the moment 
of ECG assessment and angiographic validation situated at 90 minutes 
following thrombolysis. Sensitivity and specificity for prediction of occlusion 
were 64 and 90% respectively with predictive values for reperfusion and 
occlusion of 87 and 71 %32. 
Dellborg ef al. reported on vectorcardiographic assessment of reperfusion 
and patency using continuous vectorcardiographic monitoring31 ,33,34. All of 
his studies used both QRS vector difference and ST vector magnitude changes 
for prediction of patency. In a pilot shldy of 21 patients, sensitivity and 
specificity for patency at angiography were 94% and 80% respectively if a 
rapid change of both the QRS vector difference and the ST vector magnitude 
was observed, ending in a steady state. If only the QRS vector difference 
changes were used, sensitivity remained 94%, but specificity dropped to 
40%33. In a later study, Dellborg e/ al. studied 96 patients using computer-
assisted vectorcardiographic monitoring34. More refined criteria were used 
and the angiographic assessment interval was fixed at 90 minutes as much 
as possible. Sensitivity and specificity for identification of patency were 
83% and 73% respectively. 
This thesis reports the results of the GUSTO-I ECG-ischemia monitoring 
Shldy, a subshldy of GUSTO-I (GUSTO ~ Global Utilization of Streptokinase 
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and Tissue plasminogen activator for Occluded coronary arteries)35. In 
chapter 2, the usefulness of continuous ST segment monitoring for noninvasive 
prediction of rcpcrfusion and patency in this well defined large patient series 
is evaluated. Chapter 3 describes the differences in speed and stability of 
ST segment recovery in the four treatment groups of this GUSTO-I ECG-
ischemia monitoring substudy. Chapter 4 reports on the prognostic significance 
of ST segment shift early after thrombolytic therapy in this patient group. 
ECG MONITORING OF VESSEL STATUS IN PATIENTS WITH 
UNSTABLE ANGINA 
Patients with unstable angina who are treated with intensive medical therapy 
may still suffer from early unfavorable cardiac events. The identification of 
these high risk patients mainly depends on the presence of clinical symptoms 
coinciding with transient ST and T wave changes on the l2-lead ECG. It 
has been demonstrated that prognosis does not depend on the mere presence 
of symptoms but rather on the recurrence of either silent or symptomatic 
myocardial ischemia and the presence of minor myocardial damage or 
multivessel coronmy artery discasc4.5.36.37.38.39 Immediate relief of the ischcmic 
burden in the early phase of unstable angina either by percutaneous transluminal 
coronary angioplasty or surgical revascularization may improve clinical 
outcome and reduce the number of recurrent cardiac events in such patients4o. 
Real-time continuous ECG monitoring teclmiques may help to identify these 
high risk patients41 .43 . 
Chapter 5 reports a study in patients with unstable angina and describes 
a new, on-line method for detection and quantitation of ischemic events using 
computer-assisted continuous ECG ST recording. The study investigated 
whether the selection and number of ECG leads used for ST monitoring 
might influence the detection and quanti tat ion of ischemia. On-line continuous 
48-hours "12-lead" (except lead aVR) was compared with 3-lead ST monitoring 
in 130 unstable angina patients. 
The safety and efficacy of efegatran sulphate, a new anti-platelet dl'llg, 
compared to heparin in patients with unstable angina is assessed in 
chapter 6. Safety was assessed both clinically and by measurement of clinical 
laboratory parameters. Efficacy was assessed primarily by measurement of 
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the number of patients experiencing episode of recurrent ischemia as measured 
by computer-assisted continuous ECG-ischemia monitoring. 
Chapter 7 describes the results of the "CAPTURE" ST segment monitoring 
substudy (c7E3 Fab Anti Platelet Therapy in patients with Unstable REfi'actOlY 
angina). The ST monitoring subShldy of this large trial investigated if c7E3, 
now better known as abciximab, reduces recurrent ischemia during continuous 
ECG-ischemia monitoring in patients with unstable angina refractOlY to 
standard treatment. 
The overall results, therapeutic implications and fuhU'e directions of dynamic 
computer-assisted ECG monitoring are discussed in chapter 8. 
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Noninvasive prediction of reperfusion and 
coronary artery patency by continuous 
ST segment monitoring in the GUSTO-I trial 
P. Klootwijk, A. Langer, S. Meij, C. Green, R.F. Vcldkamp, A.M. Ross, 
P. W. Armstrong, M.L. Simoons, for the GUSTO-I EeG-ischemia 
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ABSTRACT 
In the GUSTO-I ECG-ischemia monitoring substudy, 1067 patients underwent 
continuous ST segment monitoring, using vector derived 12-lead ( 406 patients), 
12-lead (373 patients) and 3-lead Holter (288 patients) ECG recording systems. 
Simultaneous angiograms at 90 01' 180 minutes following thrombolytic therapy 
were performed as a part of the prospective study in 302 patients. 
Infarct vessel patency was established as TIMI perfusion grades 2 or 3 
and occlusion as TIMI perfusion grades 0 or I. Coronary artery patency was 
predicted from ST trends up to the time of angiography. Predictive values at 
90 and 180 minutes after the start of thrombolysis were 70% and 82% for 
patency and 58% and 64% for occlusion, respectively. In retrospect, accuracy 
appeared greatest (79-100%) in patients with extensive ST segment elevation 
(:2: 400 ~lV), ifboth speed ofST recovClY and extent ofST segment elevation 
were taken into account. Although the three recording systems differed 
considerably in signal processing, no significant difference in accuracy was 
demonstrated among these systems. 
We conclude that continuous ECG monitoring may help select high risk 
paticnts without apparent reperfusion who may benefit from additional 
reperfusion therapy. As ST recovery may occur early after the start of 
thrombolytics and accuracy of the test is related to peak ST levels, the use 
of on-line ECG monitoring deviccs on emergency wards and cardiac care 
units is recommended. 
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INTRODUCTION 
Early reperfusion and sustained patency of the infarct-related coronaJY artery 
are important determinants of survival in patients with myocardial 
infarctionl-3, More aggressive therapy may be indicated iftln'ombolytic therapy 
fails to open the occluded vessel or if reocclusion of an initially reperfused 
coronaJY mtelY occurs4, Thus, continuous monitoring ofthe degree of ischemia 
as a marker of vessel (re )perfusion status may help to guide thrombolytic or 
adjunctive therapy, Noninvasive signs of reperfusion of the infarct-related 
vessel include resolution of chest pain, the occurrence of accelerated 
idioventricular rhythm, normalization of the ST segment, or sudden worsening 
of ST elevation followed by a rapid decline, and measurement of specific 
cardiac proteins in plasma5-9, Continuous monitoring of the ST segment is a 
promising, readily available, noninvasive technique for assessment of 
reperfusion and patencyl°-12, Although many attempts have becn made to 
establish criteria that predict reperfusion from serial standard ECGs, only a 
limited number of studies have prospectively assessed the value of continuous 
ST segment monitoring for early patency assessment in comparison with 
angiography8,13-18, Therefore, we investigated the ability of continuous ST 
segment monitoring to predict reperfusion and patency in the context of the 
angiographic substudy in GUSTO-I (Global Utilization of Streptokinase and 
Tissue plasminogen activator for Occluded coronaIY mteries)2,3, The sensitivity, 
specificity and predictive value ofpredefmed criteria for prediction of patency 
were tested in a large group of patients, A secondary objective was to 
investigate the similarities and differences among the three monitoring systems 
which were used in this study, 
METHODS 
Study organization 
The GUSTO-I ischemia monitoring substudy mainly involved patients from 
the GUSTO-I angiographic substudy2,3 and, to a lesser extent, patients enrolled 
in the noninvasivc part of the main GUSTO-I study, All patients underwent 
continuous ECG monitoring using either a vector-derived l2-lead ECG 
recording system, a l2-lead ECG recording system or a 3-lead Holter ECG 
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recording system, as described below. Patients for this ECG-ischcmia 
monitoring substudy were recruited by a total of 45 participating hospitals, 
situated in Europe, U.S.A., Canada, Australia and New Zealand. Each site 
was restricted to using only one type of recording device. 
Patient selection 
Patients were eligible for enrollment in the GUSTO-I study if they had chest 
pain lasting for at least 20 minutes, were within 6 hours of onset of symptoms, 
and had electrocardiographic evidence of evolving myocardial infarction 
reflected by 2 0.1 m V ST segment elevation in two or more limb leads or 
2 0.2 mV in two or more contiguous precordialleads2• At the participating 
sites, all patients enrolled in the main GUSTO-I trial were considered eligible 
for the ECG-ischemia monitoring substudy except those with left bundle 
branch block, third-degree A V block, persistent arrhythmias or pacemakers. 
Continuous ST segment monitoring 
Eligible patients were monitored by either vector, 12-lead or 3-lead Holter 
continuous ECG, preferably within 30 minutes of the start of thrombolytic 
therapy. Continuous ECG recording was performcd for at least 18 hours 
from the start ofthrombolytic therapy. The timing of the start of thrombolytic 
therapy and the moment of angiography were obtained from the study case 
record forms. An extensive report on the study design and technical 
considerations was published recently'9. 
Dynamic vector-derived 12-lead electrocardiographic recordillg system (MIDA 
1000, Ortivlls Medical, Tiiby, Sweden) 
Twelve hospitals in Europe used the MIDA recording equipment. The MIDA 
system calculates averaged QRS-T complexes from the Frank orthogonal 
leads X-Y-Z at I-minute intervals. All averaged complexes were stored on 
the hard disk and uscd for calculation ofST trend information. After completion 
of the recording, the averaged ECG data were stored on a floppy diskette 
and sent to the core laboratoty at Cat'dialysis in Rotterdam, The Netherlands, 
for subsequent editing and atwlysis'5.2o. Averaged 12-lead ECG complexes 
and 12-lead ECG trends were generated from the MIDA X-Y-Z leads, using 
the transformation formulas of Dower et aFt. 
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Continuously updated 12-lead ECG recording system (ST 100, Mortam 
[nstrument, Milwaukee, U.S.A.) 
The Mortara system, used in IS hospitals in the U.S.A., calculates median 
beats of the l2-lead ECG evety 15 scconds. These median beats are compared 
with the patient's baseline ECG in regard to ST segment changes over time 
in any lead. The system was programmed to store median beats if, in at least 
four consecutive median complexes, ? 200 ~IV ST change was present in 
one lead, or if? 100 flY ST change was present in two contiguous leads. If 
less 01' no ST change was present, a median ECG complex was stored every 
20 minutes. Subsequent editing and analysis were performed at the core 
laboratory of Duke University, Durham, U.S.All,l3. 
3-lead Holter ECG recording system (Marquette Electronics, Milwaukee, 
U.S.A. 
The Marquette Holter system, which continuously records three bipolar ECG 
leads, was used in 18 hospitals in Canada, U.S.A., Australia and New Zealand. 
Special lead configurations were applied to record inferior (left clavicle to 
left iliac crest), lateral (right clavicle to VS position), and anterior (spinous 
process between scapulae to V2 position) ECG leads. The ECG recordings 
were archived on magnetic tape and sent to the core laboratOlY of St. Michael's 
Hospital in Toronto, Canada, for editing and analysis. ST trends of the three 
leads were generated by the Marquette review station, which averages ST 
levels from the recorded analogue ECG evety IS seconds22 • 
Differences among recording methods of the ECG 
As described above, the methods and ECG handling properties of the three 
systems for generation of the ST trends were differcnt: I-minute averaging 
for the vector-derived 12-lead system, IS-second medians for the 12-lead 
system (requiring a consistent change ofST amplitude during four consecutive 
median complexes, rcpresenting I minute) or evety 20 minutes and IS-second 
averaging for the 3-lead Holter system. This implies that the Holter system 
would be most sensitive to abrupt ST changes and noise. To assess whether 
this would influence the ST trends, the other two algorithms were simulated 
using Holter trend data. One-minute averages (simulating the vector system) 
were obtained by averaging fOllr consecutive Holter ST measurements (each 
originally representing IS seconds of data). Similarly, the l2-lead (Mortara) 
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algorithm was simulated by the requirement that a new measurement would 
be stored only after 20 minutes and whenever four consecutive measurements 
exceeded the boundaries as described above. 
Editing and analysis of recorded data 
ST trends of all recorded leads were produced at the three core laboratories. 
The ST segment level was measured at J-point + 60 milliseconds. All ECG 
recordings and ST trends were manually scanned and edited for artifact, bundle 
branch block, detection or marker errors, positional changes and data gaps. 
Visual patency assessment was performed until the moment of angiography. 
Patients whose recording began 2 I hour after initiation oftlu'ombolytic therapy 
or who had an ECG recording gap of 2 1 hour before angiography were 
excluded from the analysis. Patients with low-level ST amplitudes of less 
than 200 f.l V during the complete recording were also excluded. 
The lead with maximal ST deviation at the onset of recording was selected 
for final ST analysis and visual patency assessment. If a 12-lead ECG prior 
to the start of the recording was available, this was used for selection of the 
lead with maximal ST deviation. For the Holter group, the most comparable 
lead of the three bipolar leads was chosen. As a consequence, the ST value 
of the first available ECG was considered to be the first ST valuc of the ST 
trend. 
A visual analysis of the ST trend, validated by inspection of the actual 
ECG, was performed until the start of angiography. ST recovelY criteria 
derived from previous studies were used for prediction of vessel status 
(Table 1)8,11,19,23,24. If2 50% ST recovery from the first peak ST level was 
present immediately before angiography, the infarct-related vessel was 
predicted to be patent at angiography (Figure I A). In the absence of 2 50% 
ST recovery before angiography, the vessel was predicted to be non-patent 
(Figure 10). Similarly, the vessel was predicted to be non-patent if 250% 
ST recovelY was followed by re-elevation of 2 100 f.l V occurring within a 
la-minute time interval and lasting until the start of angiography (recurrent 
ischemia, Figure 1 C), If before angiography, a transient ST segment 
re-elevation fell below 50% of its own peak ST level or decreased within 
100 f.l V of the previous baseline ST level, the vessel was again predicted to 
be patent (Figure IB), All visual readings were done blinded to angiographic 
characteristics. 
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Table 1. ECG criteria for prediction of vessel status at angiography. 
ECG criteria for prediction of 
vessel status 
2:: SOX, ST recovery from first peak 
ST level. no re-elevation 2: 100 ~l V 
2: 5(},X, ST rectwery from first peak 
ST level. followed by transient 
fe-elevation 2: 100 ~I V. recovering 
bcrorc moment of angiography 
Absence of 2: 50'X, ST recovery 
before angiography 
2: 5IYX, ST recovery from first peak 
ST level, followed by re-elevation 
z100 ~l V, persisting until 
moment of angiography 
Expet.:lcd vessel status 
at angiography 
'patent' 
TIMI flow 2-3 
'occluded' 
TIMI flow 0- I 
21 
As it was expected that patency prediction would be influenced by peak 
ST levels and speed of ST recovery, retrospectively, four ST patterns related 
to pre-angiogram peak ST levels were studied for ability to predict vessel 
status at angiography: fast ~ 50% ST recovery within 45 minutes following 
thrombolysis or, compared to the previous study ently ECG, ~ 50% ST recovelY 
already present at the start of the recording; ~ 50% ST recovery occurring 
within 45-90 minutes following thrombolysis; absent or late ~ 50% ST recovery 
(later than 90 minutes following thrombolysis); and persistently high or 
increasing ST levels. In the absence of ST re-elevation as described before, 
the first two patterns were regarded as predicting patency at angiography. 
The latter two were thought to predict a non-patent vessel. 
Coronary angiography and angiographic analysis 
In the GUSTO-I angiographic substlldy, coronary angiography was performed 
according to stratified randomization at 90 minutes, 180 minutes, 24 hours 
or one week after start of thrombolytic therapy3. Only patients with 90- and 
180- minutes angiography were selected for early electrocardiographic patency 
assessment. The coronmy angiograms were sent to the core laboratory at 
the George Washington University, Washington, D.C .. Angiographic 
assessments were made by experienced angiographers without knowledge 
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Figure 1. Assessment of patency frolll ST trend graphs. Visual analysis was performed until 
the moment of angiography (vertical line),. = peak ST level;"" = first moment 0[50% ST 
recovery from peak ST level. (A) ST recovery within 45 minutes from start of thrombolytic 
therapy. No recurrent ST elevation. The vessel is predicted to be patent at the moment of 
angiography. (B) ST recovery within 45 minutes f)'om start of thrombolytic therapy. Recur-
rent ST elevation episodes are present, but not on the moment of angiography. The vessel is 
predicted to be patent at the moment of angiography. (C) ST recovery followed by recurrent 
ST elevation, still present at the moment of angiography. The vessel is predicted to be 11011-
patent at the moment of angiography. (D) Persistently high ST levels, no 50% ST recovery. 
of the electrocardiographic data3. The angiogl'ams were evaluated for flow 
in the infarct-related segment using the classifications of the Thrombolysis 
in Myocardial Infarction trial (TIMI) at first injection of contrast25 . TIMI 
perfusion grade 0-1 indicated an occluded coronary artery, TIMI perfusion 
grade 2-3 an open artery. Collateral flow was graded as none or minimal 
and moderate or large. 
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Data management 
The edited and analyzed data and final patcncy assessment scores were 
forwarded from the other corc laboratories to the Ischemia Monitoring 
Laboratory at Duke University, Durham, N.C., U.S.A., for data entry, 
gcneration of queries for missing or inconsistent data, and final data-analysis. 
Subsequently, all data wcre returned to the other two core laboratories. 
RESULTS 
A total of 1067 patients were included in the ECG-ischemia monitoring 
substudy. Four hundred and six patients wcre monitored with the vector-
derived l2-lead, 373 with the l2-lead system and 288 with thc 3-lcad Holtcr 
system. Four hundred and fourteen patients (39%) wcre excluded 11'0111 analysis, 
mainly because of technical failures duc to error on the part of the investigator 
(143 patients) or because thc recording started more than 60 minutes after 
initiation of thrombolytic therapy (139 patients). Sixty-three patients were 
excluded because of missing ECG and ST trend data for more than I hour 
prior to the start of angiography. Sixty-nine patients had low-level ST 
amplitudes less than 200 ~lV during the complete recording. Thus, 653 patients 
had ECG recordings suitable for further study and dctermination of the moment 
of first 50% ST recovery. Within thc dcsign of the GUSTO-I angiographic 
substudy, 302 of those patients also underwent angiography at 90 (224 patients) 
or 180 minutes (78 patients) after initiation of thrombolytic therapy. This 
group of 302 paticnts was used for asscssment of ECG prediction of vessel 
status. The infarct-related vessel was the left anterior desccnding artcIY in 
137 paticnts, the right coronary artery in 121 and the left circumflex artery 
in 36. 
Time to 50% ST recovery 
Seventy-five pcrcent of the 653 paticnts had 50% ST recovery within 90 
minutes of initiation of thrombolytic therapy. Median times (25%,75%) from 
initiation of thrombolytic therapy to 50% ST recovery were 50 (25, 107),52 
(25, 105) and 33 (15, 54) minutcs for vector-derived l2-lead, l2-lead and 
3-lead Holter, respectively (Figure 2). The Holter system identified the moment 
of 50% ST recovery significantly earlicr than either the vector-derived 
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Figure 2. Cumulative percentage of patients exhibiting ST recovery plotted against the time 
from initiation of thrombolytic therapy to the first moment of 50% ST recovery for each ST 
monitoring system ..... ~ Holter (145 patients); - ~ vector (282 patients); - - - ~ 12-lead 
(226 patients). 
12-lead or the 12-lead system (P=O.OOO I). The 12-lead entty ECG contributed 
to the determination of the moment of 50% ST recovery in 37%, 35% and 
53% for vector-derived 12-lead, 12-lead and 3-lead Holter, respectively. If 
these patients were excluded from the analysis, the differences in median 
time from initiation of thrombolytic therapy to 50% ST recovery persisted: 
63 (35, 134),58 (33,126) and 47 (28, 71) minutes, respectively (P=0.002). 
To assess whether this effect could be attributed to the differences among 
the algorithms used by the three recording devices, the ECG sampling 
algorithms of the vector-derived 12-lead and 12-lead ECG recording systems 
were simulated using the Holter ST trend data as the source data. Figure 3 
illustrates a shift in detection of the moment of first 50% ST recovery that 
may occur when the original data of a Holter ST trend are transformed into 
a simulated vector-derived 12-lead and 12-lead ECG ST trend. Transformation 
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Figure 3. Effects of different algorithms on the moment of 50% ST recovery. (A) Example 
of a Holter ST trend recording llsing original 15 M second averaged ST data. The flrst moment 
of 50% ST recovery occurs at 51 minutes from the start of the recording. (B) Simulated 
vector-derived 12-lead ECG ST trend of (A), using I-minute averaged ST data. The first 
moment of 50% ST recovery occurs at 56 minutes tiOl11 the start of the recording. 
(C) Simulated 12-1ead ECG ST trend of (A), using either IS-second intervals, in the case of 
consistent toO pV changes of ST amplitude, or 20-minute intervals. The first moment of 
50% ST recovery occurs at 110 minutes from the start of the recording. 
of ST trend data from 145 Holter recordings confnmed that 50% ST recovery 
was present earliest in the Holter and later in the simulated vector-derived 
12-lead and 12-lead ST trends: 33 (15, 54), 37 (19, 66) and 49 (23, 90) 
minutes, respectively. 
Visual patency assessment 
Within the design of the GUSTO-I angiographic substudy, 302 patients 
underwent early angiography at either 90 (224 patients) or 180 minutes 
(78 patients) after initiation of thrombolytic therapy. A patent artelY at first 
injection of contrast was present in 139 (62%) of the 224 patients with 
angiography at 90 minutes and in 58 (74%) ofthe 78 patients with angiography 
at 180 minutes following thrombolytic therapy. 
Overall accuracy and predictive values for visual assessment of patency 
from the pre-angiogram ST trends of these 302 patients are presented in 
Table 2. Patency predictive value using the predefined criterion of 50% 
recovery was 74% against non-patency predictive value of 59%. Overall 
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Table 2. Predictive values from pre-angiography ST trends. 
Time of Device (n) Patency predictive Occlusion predictive Overall 
angiogram (min) value (%) value (%) accuracy (%) 
Vector (122) 71 48 65 
12-lead (57) 73 63 70 
90 Holter (45) 63 73 67 
All (224) 70 S8 67 
No collaterals (193) 76 53 69 
Vector (45) 89 67 84 
12 lead (15) 75 67 73 
180 Holter (18) 75 67 73 
All (78) 82 64 79 
No collaterals (69) 89 50 84 
Vector (167) 76 52 70 
12-lead (72) 74 63 71 
90 or 180 Holter (63) 67 71 68 
All (302) 74 S9 70 
No collaterals (262) 80 52 73 
Patency predictive value = number of tme ECG predictions of a patent artery at angiography 
divided by the number oftme + false EeG predictions ofa patent at1ery. Occlusion predicliw 
wilue = Humber of tmc ECG predictions of an occluded artery at angiography divided by 
the Humber of true + false ECG predictions of an occluded artery. Overall accuracy = 
number of true ECG predictions of vessel status at angiography divided by the number of 
true + false ECG predictions of vessel status at angiography. 
accuracy was 70%. If patients with collateral filling of thc infarct-rclated 
vessel were excluded (40 paticnts), patcncy predictive value increased to 
80%, but non-patency predictive value decreased to 52% and overall accuracy 
remained almost unchanged. The 95 percent confidencc limits of predictive 
values and accuracies of thc three recording devices were wide, and no 
significant differences among the tluee systems were demonstratcd. 
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Figure 4. Visual assessment of patency from pre-angiogram ST trends and relation to TIMI 
flow grade at either 90 or ISO minutes following thrombolytic therapy. The white parts and 
shaded parts of the bars represent the percentage of patients with ECG indications of patent 
and nOll-patent vessels, respectively. 
The visual patency assessment appeared correct in 75-92% of patients 
with TIMI grade 2 or 3 flow (sensitivity, Figure 4). A small, non-significant 
differencc between assessment of TIMI grade 2 and 3 flow was observed in 
the 90-minute angiography group. ECG assessmcnt correctly predicted TIMI 
grade 0 and I flow in 44-45% of patients (specificity). ECG prediction of 
TIMI gradc 0 and I flow was slightly better for the left circumflex artcry 
and for the left anterior descending artcry than for the right coronary artery. 
However, no significant differences could be demonstratcd between the site 
of the infarct-related artery and the prediction of vessel status. 
Pre-angiography ST levels and ST pattel'l1s 
The peak ST level, speed ofST recovery and 2: 50% ST recovelY with transient 
rc-elcvation before angiography affcctcd the accuracy of prediction of vessel 
status. A peak ST level of 2: 400 flV was present in 116 patients (38%). 
Patency predictivc value, non-patency predictive value and overall prcdictive 
accuracy of this group were 79%, 64% and 75% respectively, which were 
slightly better than those of patients with lower ST levcls: 67%, 41 % and 
61 % respcctivcly (ns). As a retrospective observation, it appeared that if 
both 2: 400 fl V peak ST elevation and 2: 50% ST recovery with transient 
re-elevation within 90 minutes from start oftlu'omholytic therapy were present 
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Figure 5. Predictive value of ST patterns and peak ST levels in relation to the speed of 8T 
recovery ancl the presence or absence of transient re-elevation before angiography. The cross-
hatched, dotted and dark parts of the bars represent the percentage of patients with TIMI 
grade 0·1 now, TIM! grade 2 now and TIM! grade 3 now, respectively. 
before angiography, the predictive value for TIMI grade 2-3 flow was 100% 
(33 patients, Figure 5). Similarly, a predictive value of 79% was found for 
TIMI grade 0-1 flow ifboth;:> 400 ~IV STelevation and a pattern of persistently 
high or increasing ST levels were present (18 patients). Thus, by the 
combination of peak ST levels, speed of ST recovety and ST recovery with 
transient ST re-elevation before angiography, prediction of vessel status was 
79-100% accurate in a subgroup corresponding to 29% of all angiographic 
patients studied. 
DISCUSSION 
The present report is part ofthe GUSTO-I ECG-ischemia monitoring substudy 
and represents the largest series comparing ST recovery analysis and early 
angiography during thrombolytic therapy. The purposes of the GUSTO-I 
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ECG-ischenua monitoring substudy were (I) to compare the speed and stability 
of ST segment recovery across the four treatment arms of the GUSTO-I 
study, (2) to compare noninvasive patency assessment with simultaneous 
angiographic assessment and (3) to investigate whether different ECG recording 
techniques would give equal and comparable rcsults. The present report focuses 
on the latter two objectives. The comparison among the four GUSTO-I 
treatment arms has been described recently in a separate report. In contrast 
to the results of the GUSTO-I main trial, this study did not demonstrate a 
difference in ST recovery and recurrent ischemia across treatment arms38 . 
Many smaller studies have been conducted to determine the value of ECG 
monitoring for noninvasive prediction of vessel status after thrombolytic 
therapy for acutc myocardial infarction 7,8,11-18,23,24.26-31 . The total numbers 
of patients reported in the literature who wcre studied via early angiography 
plus serial ECG, Holter, or continuous ECG monitoring are 171, 118 and 
261, respectively7,S,14-ls,24,2s. The present study used simple, objective and 
unequivocally defined ST recovery criteria, derived from previous 
studies8,11,2J,24. The study design and the relatively large number of patients 
allowed us to study noninvasive patency assessment at both 90 minutes and 
180 minutes following thrombolytic therapy. The study demonstrates that 
noninvasive patency prediction using continuous ECG recording teclmiques 
is possible and may be used in clinical practice. The technique appears better 
for prediction of patency (70-82%) than for occlusion (58-64%), depending 
on the extent of the initial ST segment elevation. Prediction of vessel status 
appeared 79-100% accurate in the subgroup of patients with initially-high 
ST levels, which is the group of patients with the highest risk of adverse 
cardiac events and receiving the greatest benefits of reperfusion 
therapy4,J2. 
ST analysis criteria 
The criteria for ST segment recovery used in this study were a simplification 
of ST criteria published previously8,11,23,24. This simplification was applied 
to facilitate the use of three ST monitoring systems with different ECG handling 
properties and to allow uniform analysis of the ST trends by the three core 
laboratories. 
The prcsence of 50% ST recovery before either 90- or 180-minute 
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angiography was taken as a sign of rcperfusion, absence of 50% recovery 
was considered to predict a non-patent vessel, recurrence of ST elevation 
was considercd to represent reocclusion or re-ischemia. The speed and stability 
of ST recovery were not taken into account in this primary assessment, as 
ECG sampling intervals were different for the three recording systcms. 
Moreover, for the sake of uniformity of this study, only single-lead ST trend 
analysis was performed. Thus, these "simplified" ST recovery criteria may 
have resulted in less accurate patency assessment. The additional use of more 
refined analysis criteria, which also took into account initial peak ST levels, 
the time to 50% ST recovery and the various ST reeovelY patterns, substantially 
improved predictive accuracy of vessel status in a subgroup of patients. Indeed, 
the ~ 50% ST recovery criterion reflects reperfusion only if it occurs early, 
preferably within a time interval of 90 minutes following the start of 
thrombolysis. Otherwise a non-patent infarct-related vessel should be suspected. 
Time intervals and technical limitations 
Assessment of patency is relevant mainly during the first hours following 
tln'ombolytie therapy. The longer the time from onset of chest pain to start 
of the recording, the less the ST segment deviation at the start of the recording. 
As our study demonstrated, the amount of ST elevation present during the 
recording is a major determinant of the accuracy of patency prediction: less 
ST deviation at the start of the recording and during subsequent recording 
may result in less accurate prediction of vessel status. The same is true for 
thc delay from start of tlu'ombolytic therapy to start of the recording. The 
time from initiation of thrombolytic therapy to first evidence of 50% ST 
recovery was less than 90 minutes in 75% of patients. Thus, in order to 
detect ST recovery, the recording should be started early, preferably before 
the start of thrombolytic therapy. If the start of the recording is delayed and 
thrombolytic therapy has already been effective, the first moment of 50% 
ST recovery may not be properly recorded, which would result in false 
assessment of vessel status. 
Finally, the results of this study were limited by the usc of three different 
ECG recording devices, which demanded adaptation of ST analysis criteria, 
and by the relative inexperience of participating ccnters in using these devices 
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in the setting of acute myocardial infarction. Thc number ofteclmical problems 
should decrease if continuous multilead ECG-ischemia monitoring systems 
becomc integratcd in emergency wards and coronary care units. 
Differences among recording methods of the ECG 
The ST criteria were simplified to facilitate uniform ST recovery analysis 
across the three ECG systems. Thus, additional benefits of individual devices, 
such as the use of the QRS vector diffcrence for vectorl4, the summated ST 
deviation for l2-lead I6, and continuous rhythm documentation for 3-lead 
Holtcr33 , were not takcn into account. 
The use of the l2-lead study-entry ECG to select the lead with maximal 
ST deviation may have contributed to a less accurate assessment of the moment 
of 50% ST recovery in somc instances. This may especially have been the 
case with the 3-lead Holter system, as onc of only three bipolar leads was 
selected for comparison with the l2-lead entry ECG. 
Optimal comparison would monitor all three devices simultaneously and 
a report on such a comparison during PTCA-induced transient occlusion and 
reperfusion has been published recently34. Howcvcr, significant differences 
in time to 50% ST recovery were apparent among the three systems 
(Figure 2). The Holter system appeared to detect 50% ST recovery earliest. 
If ECG recordings were excluded in which the 50% ST recovery moment 
was dctermined by the enhy ECG, this difference persisted, which confirms 
that the moment of 50% ST recovery is indeed dependent on the sampling 
algorithms used for generation ofST trends. Rccalculation ofHoltcr ST trend 
data into vcctor-derived l2-lead or l2-lead ST trend data confirmed that the 
carlier detection of 50% ST rccovelY was related to the short (Holter) averaging 
interval of 15 seconds. In fact, such shorter recording intervals will both 
facilitate early detection of rapid changes in the ST amplitude and be more 
sensitive to noise. Thus, adaptation ofST analysis criteria to the characteristics 
of each device may result in an improvement of predictive performancc of 
these devices and of subsequent study results. It should be emphasized that 
in spite of the major differences in teclmologies, the reliability for prcdiction 
of vessel status appeared similar aeross the tll1'ee recording devices. 
Nevertheless, the users of different systems must be aware of the teclmical 
features of these systems for correct interpretation of the signaJ35. 
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Coronary angiography 
Coronmy angiography was used to validate ST monitoring of vessel status. 
This technique is regarded as the "gold standard" for assessment of patency 
and (re)occlusion. However, its limitations may have influenced the accuracy 
and predictive values of electrocardiographic patency assessment in a negative 
manner. It should be appreciated that angiography supplies only very 
momentmy information on the status of the infarct-related vessel. As such, 
the rapidly changing dynamics of coronary blood flow in an injured vessel 
through active thrombus formation, clot lysis, vasoconstriction and 
vasodilatation, cannot be assessed properly by this technique. Moreover, Ito 
et al. demonstrated that restoration of epicardial bloodflow, as visualized by 
angiography, does not always correlate with restoration of perfusion at the 
cellular leveJ36. Thus, angiographically successful reflow cannot be equated 
with achievement of myocardial reperfusion and oxygenation, and it may 
well be that continuous ECG monitoring reflects the oxygenation status of 
the myocardium at risk more accurately than the "gold standard" of angiography 
itself. 
The lack of precision of registration of the first contrast injection in relation 
to the ECG recordings may also have negatively influenced ECG prediction 
outcome. The ECG recordings were analyzed until the start of the procedure 
in the catheterizationlaboratOlY. Accordingly, the status ofthe infarct-related 
vessel may have altered in some patients between the time ofECG assessment 
and achml angiography. Inaccurate tracking of the exact time of the start of 
thrombolytic therapy, the start of the ECG recording, or the first injection of 
contrast in the present multicenter study may have contributed to incorrect 
ECG patency assessment. In addition, the recording system (vector) sometimes 
had to be disconnected during transportation from the coronary care unit to 
the angiography room. The resulting ST trend data gaps between the moment 
of ECG assessment of patency and the start of angiography may also have 
resulted in less accurate prediction of vessel status, particularly for the 
vectorcardiographic system. 
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CONCLUSIONS 
The present large study confirms the results of previous small studies that 
continuous ST segment monitoring techniques may become clinically useful 
for prediction of reperfusion, patency and reocclusion during thrombolytic 
therapy. 
Ellis e/ al. demonstrated that rescue PTCA aftcr failed thrombolysis may 
improve clinical outcome, rcflected by a reduction of combined heart failurc 
and death (P=0.055) and an increase of left ventricular ejection fraction during 
exercise (P=0.04), within 30 days from the onset of myocardial infarction37 . 
This strongly points towards tailoring of repel' fusion therapy4. In this respect, 
continuous ECG monitoring techniques may assist the clinician in decision-
making and may help to select patients who may benefit from additional 
reperfusion therapy. 
The simple ST recovery criteria used in this study resulted in a correct 
prediction of vessel patency in 70-82% of patients with ST recovery, but 
apparently persistent ST elevation predicted a non-patent vessel in only 
58-64% of patients. However, if speed ofST recovery, stability ofST recovery 
and recognition of ST patterns that suggested either complete reperfusion, 
unstable reperfusion, occlusion or reocclusion were taken into account, 
prediction of vessel status appeared 79-100% accurate for those patients having 
high initial ST levels. This subset of patients is at the highest risk of adverse 
cardiac evcnts32 and will benefit most from additional "rescue" procedures 
for failed reperfusion. Dynamic trend analysis and adaptation of ST analysis 
criteria to each recording method may yield cven better results. Further study 
of the ECG and ST trends in the GUSTO-I database may help establish more 
refined ST recovery criteria for each recording method. 
Finally, as the prediction of vessel status is most accurate in patients with 
high initial ST levels, the usefulness of continuous ECG monitoring systems 
may be greatly improved if the recording is begun as soon as the patient is 
admitted. Therefore, the use of on-line ECG monitoring devices may be 
recommended in emergency wards and coronary care units in order to avoid 
delay and to improve the clinical usefulness of noninvasive patency assessment. 
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ABSTRACT 
Objectives. The ST segment monitoring substudy of the Global Utilization 
of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary 
Arteries (GUSTO-I) trial compared the speed and stability of ST segment 
recovclY among four thrombolytic strategies for acute myocardial infarction. 
Background. Rapid rcsolution of ST segment elevation has been suggested 
as a noninvasive marker of infarct-related artery patency. We expected that 
patients treated with accelerated recombinant tissue-type plasminogen activator 
(rt-PA) would show a quicker recovery than that of other patients but that 
those treated with streptokinase would show greater stability of recovery. 
Methods. ST segmcnt monitoring was initiated in 1,067 patients within 30 
minutes of the start of tln'ombolysis and continued for> 18 hours with the 
use of a three-channel continuous vectorcardiographic monitor, a l2-lead 
continuous electrocardiographic (ECG) monitor or a thrcc-channel (V2, V5, 
a VF) Holter ambulatory ECG monitor. 
Results. Time to 50% recovery could be assessed in 618 patients and was 
similar in the four treatment groups: median 45 minutes with streptokinase/ 
subcutaneous heparin, 45 minutes with streptokinase/intravenous heparin, 
42 minutes with accelerated rt-PA and 47 minutes with combination therapy 
(P=0.7). No significant difference among the thrombolytic regimens was 
shown with thc three monitors used. Time to initiation of ST segment 
monitoring was directly related to the time to 50% recovery (P=O.OOO I) and 
was its best predictor in a multiple regression model. ST segment elevation 
recurred equally in each treatment group (-36%, P=0.9) but was significantly 
more common in patients with a patent infarct-related artery (P=0.033) or a 
low ejection fraction (P=O.OO I) 
Conclusions. Thc greater 90 minute patency seen with accelerated rt-PA in 
the angiographic substudy did not correlate with a shorter timc to 50% ST 
segment recovclY, possibly because oftechnicallimitations and study design. 
The similar rates of recurrent ischemia (as assessed by ST elevation) among 
the regimens support the similar infarction and reocclusion rates seen in the 
main trial and angiographic substudy. 
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INTRODUCTION 
Rapid resolution of ST segment elevation has been related to early arterial 
patency in patients with acute myocardial infarction 1-6 and can be used as a 
simple and readily available marker for assessment of thrombolytic efficacy? 
The recently reported GUSTO-J trial (Global Utilization of Streptokinase 
and t-PA for Occluded coronary arteries)s and its angiographic substudy9 
have demonstrated improved clinical outcomes and arterial patency in patients 
treated with an accelerated regimen of tissue-type plasminogen activator 
(rt-PA) as compared with findings in patients treated with streptokinase. The 
goal of the GUSTO ST segment monitoring substudy was to provide a 
noninvasive assessment of the speed and stability ofreperfusion. The primaIY 
hypotheses were (1) that resolution of ST segment elevation as mcasured by 
time to 50% ST segment recovery would be faster in patients treated with 
regimens of accelerated rt-PA than in patients treated with streptokinase, 
and (2) that recurrent ST elevation, reflecting early reocclusion, would occur 
less frequently in patients treated with streptokinase than in those treatcd 
with rt-PA. 
METHODS 
Thc protocol and the results of the GUSTO trial have been published 
previouslys. Eligible patients presented to a participating hospital < 6 hours 
after the onset of symptoms with chest pain lasting at least 20 minutes, 
accompanied by electrocardiographic (ECG) signs of;:> 0.1 m V ST segment 
elevation in two or more limb leads or ;:> 0.2 m V elevation in two or more 
contiguous precordial leads. Exclusion criteria were those conventionally 
used for administration of thrombolytic therapys. Eligible patients were 
randomized to reccive one of four regimens: 1) streptokinase, 1.5 million U 
over 60 minutes, with subcutaneous heparin in a dose of 12.500 U twice 
daily, beginning 4 hours after the start of thrombolytic therapy; 2) streptokinase, 
1.5 million U over 60 minutes, with an intravenous heparin bolus of 
5,000 U then 1,000 U per hour; 3) accelerated rt-PA bolus of 15 mg, 
0.75 mg/kg body wcight over 30 minutes and 0.5 mg/kg over the next 60 
minutes with the same intravenous heparin regimen; or 4) the combination 
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of intravenous rt-PA (1.0 mg/kg over 60 minutes, not to exceed 90 mg, with 
10% given as a bolus) and streptokinase (1.0 million U over 60 minutes) 
given simultaneously with the same intravenous heparin. All patients received 
chewable aspirin, 2 160 mg, followed by a dose of 160-325 mg/day. Patients 
without a contraindication to beta-adrenergic blockade received intravenous 
atenolol, 5 mg, given in two divided doses, followed by oral therapy of 
50-200 mg daily. All other medications were prescribed at the discretion of 
the attending physician. 
The majority of patients who underwent continuous ST segment monitoring 
as part of this substudy were also participants in the angiographic substudl 
in which patients were randomly assigned to coronary angiography after 
thrombolytic therapy at 90 minutes, 180 minutes, 24 hours or 5 to 7 days. 
Half of the patients were assigned to the 90-minute and 5- to 7-day follow-
up angiographic study to allow analysis ofreocclusion and ventricular function9. 
ST segment monitoring was begun preferably within 30 minutes of the 
start of thrombolytic treatment and continued for at least 18 hours. To allow 
a universal evaluation of ST segment response, one of three ST segment 
monitoring devices was used: a three-channel (Franks orthogonal X,Y,Z leads) 
continuous vectorcardiographic monitor (MIDA 1000, Ortivus Medical, 
Stockholm, Sweden), a 12-lead continuous ECG monitor (ST-IOO, Mortara 
Instrument, Milwaukee, USA) or a three-channel (bipolar modified V2, V5, 
A VF) Holter ambulatory ECG monitor (Marquette 8000 Holter Scanner, 
Marquette Electronics, Milwaukee, USA). ST segment analysis was first 
performed with all personnel unaware of treatment assigmnent and 
angiographic outcome in three core laboratories. Electrocardiographic editing 
and interpretation were performed by an experienced operator using a 
computer-assisted device. The technical details of the ST segment analysis 
for the three monitoring devices have been summarized elsewhere 10. 
Comparison across the four treatment groups was carried out with respect 
to two endpoints: (I) resolution of ST segment elevation, defined as time to 
50% ST reeovelY observed in the lead with the greatest baseline ST segment 
shift identified from either the monitoring device or the admission 12-lead 
ECG; (2) episodes of recurrent ST segment elevation in the same lead, defined 
as 2 0.1 mV shift from baseline after 50% resolution had occurred, lasting 
2 I minute and separated from other episodes by 2 I minute. 
Patients were excluded from analysis of time to 50% recovery because of 
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time delay of ~ 1 hour in initiating recording from the time of onset of 
thrombolytic therapy; inadequate « 0.2 mY) peak ST scgmcnt elevation to 
allow detection of ST segment elevation recovery; or a significant data gap 
(absence of data or inability to interpret ST segments) for ~ I hour during 
the first 3 hours of recording. Excluded from analysis of recurrent ST elevation 
were patients with < 18 hours of effective monitoring time or a data gap of 
> 50% of monitoring time and patients without 50% recovery. To exclude 
ST segment shift in response to contrast injection or mechanical 
revascularization, ST segment analysis was not performed during the time 
of the coronaty angiogram. 
Statistical Analysis 
The prill1atY endpoints of time to 50% recovery and recurrent ST segment 
elevation were not distributed normally and are therefore described using 
median, 25th and 75th percentiles. Comparisons for the primary endpoints 
betwecn thc predefined rt-PA-containing and streptokinase combincd groups 
were performed with a Wilcoxon test and all four treatment groups were 
compared by using the Kl'uskal-Wallis test. The distribution of the primary 
endpoints was normalized by means of log transformation, and a multiple 
regression model was employed to define the best predictors of time to 50% 
recovery of ST segment elevation and recurrent episodes of ST elevation. 
Because three monitoring devices were used for ST segment analysis, time 
to 50% recoveIY of ST segment elevation was compared among the four 
thrombolytic regimens by a two-way analysis of variance. 
Baseline clinical characteristics of patients in the four treatment groups 
were compared by analysis of variance (for continuous variables distributed 
normally) and chi-square analysis (for discrete variables). 
RESULTS 
Of 1,067 patients who underwent ST segment monitoring with one of the 
three deviccs, the data of 97 were technically not analyzable. With respect 
to assessment of time to recovery, 176 patients were excluded because of 
time to monitor hookup ~ I hour after initiation of thrombolytic therapy, 
94 because of peak ST elevation < 0.2 mY, 60 because of a data gap and 
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Table J. Baseline clinical characteristics of the four treatment groups. 
SK + Sc Heparin SK + IV Heparin Acee! rt-PA rt-PA + SK p 
(IFI69) (1I~144) (1I~152) (1I~153) value 
Age (yr) 60 (52,69) 62 (51,70) 61 (50,70) 59 (53,70) 1.0 
Gender (!,v1lF) 112140 109135 118135 132137 0.8 
History of 56 (33%) 55 (38%) 57 (38%) 66 (43%) 0.3 
hypertension (%) 
Diabetes fv[cllitlls (%) 21 (12%) 15 (10%) 19 (12%) 27 (18%) 0.3 
History of Smoking (%) 126 (75%) 95 (67%) 96 (64%) 102 (72%) 0.15 
Previous tvlI 23 (26%) 19 (21%) 22 (25%) 25 (28%) 0.9 
Admission heart rate 72 (62,84) 75 (65,85) 70 (60,84) 73 (61,86) 0.3 
(bplIl) 
Admission systolic BP 126(110,140) 130(114,142) 130(115,145) 130(115,143) 0.5 
(mmHg) 
Admission diastolic BP 78 (70,85) SO (70,90) 80 (70,90) 80 (70,90) 0.5 
(mmHg) 
Killip class 
151 128 138 129 
II 15 14 II 20 0.9 
III 2 1 2 3 
IV 
f,,11 Location Anterior 73 53 62 61 
Inferior 90 84 87 90 0.5 
Other 6 7 3 2 
Ejection Fraction (%) 60 (51,70) 59 (49,71) 60 (47,70) 60 (48,67) 0.6 
In-hospital deaths 7 (4%) 10 (7%) 6 (4%) 9 (6%) 0.6 
Continuous variables shown are median ,'allies, with 25th and 75th percentiles in parentheses. 
Acee! rt-PA = accelerated tissue plasminogen activator; BP = blood pressure; F = female; 
IV = intravenous; J'vf = male; !,vtl = myocardial infarction; Sc = subcutaneous; SK = streptokinase. 
22 because of data entry problems that precluded adequate assessment of 
the relation between initiation oftln'ombolytic therapy and onset of monitoring . 
In the remaining 618 patients assessment of 50% ST recovery was possible. 
Comparison of the baseline features and in-hospital mortality for these 
618 patients among the four treatment groups (Table I) revealed no significant 
differences and showed similarity to the overall population of the GUSTO 
trialS. Comparison of the baseline characteristics and in-hospital mortality 
of patients who were and were not included in this study did not show 
significant differences. With respect to detection of recurrent ST segment 
elevation, 171 patients were excluded because of a monitoring time < 18 hours, 
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65 because of a > 50% data gap during monitoring and 49 because of an 
absence of resolution of ST segment elevation? 50%. Thus there were 694 
patients for whom assessment of recurrent ST elevation was possible. Again, 
these patients had characteristics similar to those of the other GUSTO patient 
groups. 
Speed of l'epel'fusion 
Time to 50% recovery ofST segment elevation (as a marker ofreperfusion) 
was similar in patients receiving rt-PA-containing regimens (accelerated 
rt-PA and combination group) and those who received streptokinase only 
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Figure I. Boxplot summary statistics for time to 50% recovery of ST segment elevation in 
the four treatment groups. Median values arc shown by lines and mean values by plus 
signs within the boxes; the length of each box is bounded by 25th and 75th percentiles. 
Outliers are shown by smaiJ squares (> 1.5 to < 3 interquartile ranges above the 75th 
percentile) and triangles (> 3 interquartile ranges above the 75th percentile). IV = intravenous; 
Sc = subcutaneous; SK = streptokinase; Time 0 = start of thrombolytic therapy. 
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Table 2. Time to thrombolytic therapy, monitoring and 50% ST segment recovery in the 
four treatment groups. 
SK + Sc Heparin SK + IV Heparin Aceel rt-PA 
(n=169) (n=144) (n=152) 
Pain onset to therapy 156 (110,232) 161 (109,224) 160 (120,200) 
(min) 
Qualifying ECG to 43 (28,57) 41 (28,63) 46 (32,68) 
therapy (min) 
Therapy to monitor 5 (-3,59) 6 (·6,21) 7 (-7,22) 
hool,:up (min) 
Therapy to 50% ST 45 (22,73) 45 (24,76) 42 (20,72) 
segment recovery (min) 
Times (min) shown arc median values, with 25th and 75th percentiles in parentheses. 
ECG = electrocardiogram; other abbreviations as in Table 1. 
rt-PA + SK Pvalue 
(n=153) 
175 (128,251) 0.10 
49 (36,70) 0.004 
11 (-5,22) 0.9 
47 (24,66) 0.7 
(median 45 [25th and 75th percentiles 22, 68] minutes vs, 45 [23, 75] minutes, 
P~O.4). The distribution of time from initiation of thrombolytic therapy to 
50% recovery of ST segment elevation (Figure I) also revealed no significant 
difference among treatment groups. All but 10 of the 618 patients had 50% 
recove1Y of ST segment elevation within the first 24 hours (ofthese 10 patients, 
I received streptokinase with subcutaneous heparin, 2 received streptokinase 
with intravenous heparin, 4 received accelerated rt-PA and 3 received 
combination rt-PA and streptokinase). Comparison of time intervals from 
the onset of pain to the initiation of thrombolytic therapy and from the initiation 
of tln'ombolytic therapy to the commencement of ST segment monitoring 
revealed no significant differences, although a trend toward a longer time to 
thrombolytic therapy in the combination ann was evident (Table 2). 
Time to 50% recovery of ST segment elevation from the onset of 
tln'ombolytic therapy as detected by each of the tln'ee monitoring devices 
also did not differ significantly among the four thrombolytic regimens 
(Figure 2). Two-way analysis of variance using four thrombolytic regimens 
and three monitoring devices revealed no significant interaction between these 
two classes of variables (F~0.79, P~0.58) and no difference among four 
thrombolytic regimens (F~0.19, P~0.90); however, the difference among the 
monitoring devices was significant (F~4.38, P~0.013), with time to 50% 
resolution being the shortest for Holter monitoring and longest for continuous 
12-lead ECG monitoring. 
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Figure 2. 13oxplot summary statistics for time to 50% recovery of ST segment elevation in 
the four treatment groups as assessed by the three monitoring devices. F0l111at and abbreviations 
as in Figure 1. 
A multiple regression model revealed that time to initiation of ST segment 
monitoring (F~54.87, P~O.OOOI) and type of monitoring device used (F~9.88, 
P~O.OOO I) were the best predictors of time to 50% recovery of ST segment 
elevation, whereas time to initiation of thrombolytic therapy (F~3.35, P~0.07) 
and thrombolytic regimen (F=0.63, P=0.59) did not significantly predict time 
to 50% of ST segment recovery. 
Stability of reperfusion 
Comparison ofrecurrent ST segment elevation (an indicator ofreocclusion) 
revealed no difference between patients treated with streptokinase-containing 
regimens (streptokinase with intravenous or subcutaneous heparin and 
46 CHAPTER 3 
combination group) and those who received acceleratcd rt-PA (median 0 
[25th and 75th percentiles 0, I] episodes vs. 0 [0, I] episodes, P=0.6). Recurrent 
ST segment elevation was equally frequent (P=0.9) in patients treated with 
streptokinase with either subcutaneous (36%) or intravenous (36%) heparin 
and similar to that in patients receiving accelerated rt-PA (37%) or the 
combination treatment (34%). No difference in the frequency of recurrent 
ST elevation in the four treatment groups was evident with the use of any 
one of the three monitoring devices. Nevertheless, the frequency of recurrent 
ST elevation detected by Holter monitoring (55%) was greater (P=O.OOO I) 
than that seen with either continuous vectorcardiography (28%) or 
electrocardiography (33%). 
Recurrent ST segment elevation showed a weak trend in a relation with 
patency of infarct-related vessel (r=-O.I 0, P=0.033) and ejection fraction 
(\=-0.16, P=O.OOI). 
DISCUSSION 
The principal findings of this study arc a similarity in time to 50% recovery 
of ST segment elevation and similarity in the frequency of recurrent ST segment 
elevation among the four tll1'0mbolytic regimens used in the GUSTO trial. 
Comparison of the patients ell1'olled in the main GUSTO trial and those 
participating in the ST segment monitoring substudy revealed no difference 
in baseline clinical characteristics and outcome. The difference in mortality 
in the ST monitoring substudy between patients treated with accelerated 
rt-PA (4.0%) and those receiving streptokinase (5.4%), although not statistically 
significant, was directionally similar to findings in the main trials. This 
observation indicates that the sample of patients participating in the substudy 
was a representative subset of GUSTO patients. The inability to demonstrate 
a difference in time to 50% recovery, a presumed noninvasive surrogate 
measure of infarct-related artClY patency, is somewhat surprising considering 
that the main GUSTO trials and the angiographic substudy9 revealed grcater 
patency at 90 minutes and better outcomes in patients treated with accelerated 
rt-PA than in those treated with streptokinase. 
Several possible explanations for the observed results deserve consideration. 
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First, there may be no differences in time to repcrfusion among the treatment 
regimens. Second, our ability to demonstrate a difference in timc to 50% 
recovclY ofST elevation may have been hampcred by uncontrolled and variable 
time to initiation of ST segment monitoring or by differences among the 
devices, such as the algorithms used to detect and evaluate ST segment shift lo 
These concerns are supported by thc regression model that revealed that 
time to initiation of ST segment monitoring was the most significant factor 
associated with time to 50% recovery, followed closely by the type of ST 
segment monitoring device used. The inability to meet technical requirements 
in > 40% of patients reduced the power to detect differences, although we 
found no evidence of bias introduced by technical failurc. Finally, the choicc 
of the endpoint was based on the presumption that timc to 50% recovery 
would represent the most sensitive measure of the effect of the thrombolytic 
agcnt in achieving reperfusion. This endpoint has not been validated as the 
best measure related to patient outcome or to coronmy angiographic outcome, 
and subsequent analyses ll have suggested that other endpoints representing 
the time to stable evidence of ST segment recovery may be better. These 
factors notwithstanding, the current study represents a large prospective 
assessment in the rapidly evolving field of the study of the speed and stability 
of methods of achieving coronary reperfusion. 
Recurrent ischemia as measured by episodes of recurrent ST segment 
elevation occurred in approximately one third of thc patients and was similar 
in the four treatment groups; however, significant differences existed among 
monitoring devices. It remains unclear whether differences in ST segment 
monitoring algorithmslo, patient selection, intervention rates or continuity 
of monitoring may explain the more frequent detection of ST elevation with 
Holter monitoring. 
Recurrent ST segment elevation was more frequent than the observed ratesS,9 
ofreocclusion (4.9% to 6.4%), reinfarction (3.4% to 4.0%) or even clinically 
determined recurrent ischemia (18.8% to 19.9%). Our findings of a similar 
frequency of recurrent ST elcvation across four treatment groups supports 
the previous findings8,9 of similar rates of reocclusion and reinfarction, The 
greater frequency of ST elevation than of angiographic reocelusion may be 
partly related to differences in the assessment of myocardial perfusion and 
recurrent ischemia as detected by continuous ST segment monitoring versus 
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a single determination of patency with coronary angiography. Our findings 
of a weak relation between recurrent ST segment elevation and patency of 
the infarct-related vessel and ejection Jiaction extend our previous observations 
ofthe prognostic significance of ST segment depression on Holter monitoring 
after acute myocardial infarction in relation to severity of stenosis of the 
culprit lesion and lack of improvement in left ventricular function 12. 
CONCLUSIONS 
ST segment monitoring for detection of myocardial reperfusion and recurrent 
ischemia after thrombolytic therapy as defined in this GUSTO substudy did 
not demonstrate a difference among patients treated with accelerated rt-PA, 
streptokinase with intravenous or subcutaneous heparin, or combination 
rt-PA and streptokinase. The technical and study design limitations resulted 
in diminished sensitivity to detect differences in time to 50% recovery of 
ST segment elevation among the four treatment groups. Although assessment 
of the frequency of recurrent ischemia was related to the type of monitoring 
device, the lack of difference in this primary endpoint among treatments 
supports the observations of similar reocclusion and reinfarction rates in the 
main GUSTO trial and angiographic substudy. Further insight regarding the 
pathophysiology of myocardial perfusion early after tlll'ombolysis based on 
ST segment monitoring may come from additional post hoc analyses of these 
data. Nevertheless, ST segment monitoring may be used to compare different 
reperfusion strategies in the future, provided that the methodology of 
monitoring is improved. 
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ABSTRACT 
Objectives. We sought to study the relation between recurrent ST segment 
shift within 6 to 24 hours of initial resolution ofST elevation after tlll'ombolytic 
therapy and 30-day and I-year mortality. 
Background. Rapid and stable resolution of ST segment elevation in relation 
to thrombolytic therapy in patients with acute myocardial infarction is an 
indicator of culprit artery patency. Whether recurrence of ST segment shift 
during continuous ST monitoring after initial resolution is related to poor 
prognosis has not been studied. 
Methods. ST segment monitoring was performed within 30 minutes after 
thrombolytic therapy for acute myocardial infarction. The predictive value 
ofa new ST segment shift (assessed as ~ O.lmV deviation from the baseline) 
6 to 24 hours after thrombolytic therapy was studied with respect to 30-day 
and one-year mortality. 
Results. Of 734 patients, 243 had a new ST segment shift (33%). The 
30-day mortality rate in patients with an ST shift (7.8%) was significantly 
higher than that in patients without an ST shift (2.25%, P~O.OO I), as was 
the I-year mortality rate (10.3% versus 5.7%, respectively, P~0.025). 
Multivariable analysis revealed an independent predictive value of ST shift 
with respect to 30-day mortality (P~0.008), even after consideration of multiple 
clinical risk factors in the overall Global Utilization of Streptokinase and 
Tissue Plasminogen Activator for Occluded CoronaIY Arteries (GUSTO)-I 
mortality model (P~O.OOOI). Moreover, the duration of the ST shift bore a 
direct relation with I-year mortality (P~0.008). 
Conclusions. Detection of ST segment shift early after thrombolytic therapy 
for acute myocardial infarction is a simple, noninvasive means of identifying 
patients at high risk and is superior to other connllonly assessed clinical risk 
factors. Thus, patients with a new ST shift after the first 6 hours, but within 
24 hours, represent a high risk group that may benefit from more aggressive 
intervention, whereas patients without evidence of an ST shift represent a 
low risk subgroup. 
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INTRODUCTION 
In the setting of acute ischemic syndromes, continuous ST segment monitoring 
can be used for the detection of culprit vessel reperfusion on the basis of 
rapid and stable resolution ofST segment elcvation l -9 , There is also evidence 
of a more frequent unfavorable outcome among patients with an ST segment 
shift on continuous monitoring after presentation with unstable angina 10- 15 
or after myocardial infarction l6-22 , Although recurrent symptoms and the 
admission electrocardiogram (ECG) have predictive valuc23,24, several studies 
have found that continuous ST segment monitoring has additional prognostic 
value l4, independent of such prognostic indicators as left ventricular 
dysfunction or angiographic extent of coronary artery disease l5 Thus, ST 
segment shift reflects a variety of adverse underlying pathophysiological 
processes in patients with acute ischemic syndromes and has been related 
not only to angiographic detection ofthrombus25 but also to cardiac adrenergic 
dysfunction26 and cycles of thrombosis and thrombolysis,27, 
The recently reported Global Utilization of Streptokinase and Tissue 
Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial28 
and its angiographic substudy29 showed improved clinical outcomes and 
angiographic patency in patients treated with an accelerated regimen of 
rt-TPA versus streptokinase, The primaty goal of the GUSTO-I ST segment 
monitoring substudy was to provide a noninvasive assessment of the speed 
and stability of reperfusion9, The prognostic significance of recurrent ST 
shift after initial resolution of ST segment elevation in patients presenting 
with ST elevation and acute myocardial infarction has not been studied, Thus, 
we studied the relation between recurrent ST shift 6 to 24 hours subacutely 
after initial resolution of ST elevation after thrombolytic therapy and 
3D-day and I-year mortality, 
METHODS 
Patients 
The protocol and results of the GUSTO-I trial have been published elsewhere28, 
Eligible patients were randomized to receive streptokinase with subcutaneous 
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or intravenous heparin, accelerated rt-PA with intravenous hcparin or the 
combination of intravenous rt-PA and streptokinase with intravenous heparin. 
ST segment monitoring 
The details of ST segment monitoring have been reported prcviously9.30. 
Wc aimed to start ST segment recording within 30 minutes of thrombolytic 
treatment, and monitoring continued for 24 hours. The GUSTO- I ECG 
monitoring substudy was a collaborative effort30 of three core laboratories, 
which used one of three ST segment monitoring deviccs: a three-channcl 
(Franks orthogonal X, Y, Z leads) continuous vectorcardiographic monitor 
(MIDA 1000, Ortivus Medical, Stockholm, Sweden); a 12-lead continuous 
electrocardiographic monitor (ST- I 00, Mmtara instrument, Milwaukee, USA); 
or a thrcc-channel (bipolar modified V2, V5, and aVF leads) Holter monitor 
(Marquette Electronics, Milwaukee, USA). ST segment analysis was tlrst 
performed in blinded manner as to treatment assignment at the three core 
laboratories. ECG editing and interpretation were performed by an experienced 
operator with a computer-assisted device. The technical dctails of ST segmcnt 
analysis for the three monitoring devices have been summarized clsewhere3o• 
The three core laboratories provided edited ST segment trends as a data stream 
containing the ST segment level at 60 ms after the I-point, which was used 
for this analysis. 
We cvaluated new ST segment shift after resolution of initial ST clevation 
within 6 hours of thrombolytic therapy (Figure I) on the basis of the following 
criteria: (I) ~ 50% resolution of initial ST shift (elevation or dcpression) in 
the lead with maximal ST deviation at the initiation of monitoring6•9 or if 
maximal ST deviation was not detected, for example, because ofa late hook-
up of the ST monitoring device, an ST segment level within 6 hours of 
thrombolysis < 0.2 mV (elevation or depression); otherwise, the resolution 
of initial ST elevation was not thought to have occurrcd; (2) duration of 
~ 50% resolution of ~ 10 minutes within 6 hours of thrombolysis; and (3) 
new ST segment elevation or depression, defined as ~ O. I m V from the average 
ST segment baseline> 6 hours after thrombolysis and lasting ~ I minutc. 
The average ST segment baseline value was calculated from all ST segment 
data points for the duration of monitoring beyond the initial 6 hours. Thus, 
ST shift as discussed here represents a recurrent ST shift> 6 hours from the 
time ofthrombolytic therapy. Because the duration of monitoring varied among 
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Figure 1. Average duration of ST shift per hour (min) for all patients from the time of 
thrombolysis. Vertical lines indicate standard deviation. 
patients, the duration of the ST segment shift for each patient was normalizcd 
for 24 hours: Normalized duration ofST segment shift ~ (actual ST segment 
shift duration/Hours of monitoring) x 24 hours. Total ischemic burden (total 
ST shift) consisted of ST depression and ST elevation duration. If both ST 
segment depression and elevation were seen in different leads at the same 
time, the ST shift with greatest ST deviation magnitude was chosen. Excluded 
from analysis were patients with < 12 hours of effective monitoring time or 
a data gap of> 50% of monitoring time or those in whom recurrence of ST 
shift could not be assessed. Many patients who underwent continuous ST 
segment monitoring as part of this substudy also pmiicipatcd in the angiographic 
substudy29. ST segment analysis was not performed during coronary 
angiography to exclude ST segment shift in response to contrast injection or 
mechanical revascularization. 
Statistical analysis 
The primary endpoint was death at 30 days, with a secondary endpoint of 
death at one year. A comparison of baseline clinical characteristics of patients 
in and excluded from this study as well as patients with and without ST 
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segment shift was performed with chi-square analysis or an unpaired t test 
(mean value ± SD for continuous variables). The variable of ST duration 
was normalized with the logarithmic transformation. The relation between 
ST segmcnt shift and death was studied with univariate logistical regression 
analysis. The variable "ST scgment shift" was then added to the multivariablc 
model containing the overall 3D-day GUSTO-I mortality modeP 1. One-year 
survival analysis based on the presence of ST shift was performed with Kaplan-
Meier curves. To study the relation between duration of ST shift and death, 
3D-minute increments of ST shift duration were chosen on the basis of previous 
observations 11,12,14,32. 
RESULTS 
Patient characteristics 
Of 1,067 patients who undcrwent ST segment monitoring with one of the 
three devices, 333 were excluded because of a monitoring time < 12 hours, 
a data gap duration> 50% of monitoring time, or other technical difficulties. 
An additional 41 patients were excluded because resolution of initial ST 
shift was not achieved. Patients who were excluded from the study (n~333) 
were significantly older, more frequently had an anterior myocardial infarction, 
received thrombolytic therapy later and had a higher mortality rate at 30 
days and I year than those included in the study. Among 734 patients evaluated 
in this study, 243 (32%) had an ST segment shift, whereas 491 (67%) patients 
did not. Among patients with an ST shift, the median duration of the ST 
shift was 30 minutes, with 25th and 75th percentile of 7 and 110 minutes, 
respectively; the average duration of the ST shift is shown in Figure I. 
A Comparison of baseline clinical and presenting characteristics of patients 
with and without ST segment shift is shown in Table I; patients with ST 
shift were older and more frequently had diabetes mellitus. There was a 
trend for a more frequent history of anterior infarction and cerebrovascular 
disease, as well as elevated systolic blood pressure on admission. No differences 
were seen in the frequency of administration of various tlu'ombolytic regimens 
or in time to treatment (Table I). 
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Table 1. Clinical Characteristics. 
No ST shift ST shift P value 
(n ~ 491) (n ~ 243) 
Age (yr) * 60±12 62±12 0.005 
Male 75.2% 76.5% 0.68 
Weight, (kg) * 80±16 79±16 0.38 
Height (em) * 172±9 171±10 0.45 
Smoking history * 68% 71% 0.47 
Family history 46% 42% 0.31 
Hypercholesterolemia 36% 31% 0.15 
Hypertension * 36% 41% 0.26 
Systolic blood pressure (mm Hg) * 128±20 131±24 0.09 
Diastolic blood pressure (nnn Hg) * 78±14 79±15 0.21 
Heart rate (beats/min) * 74±16 74±17 0.92 
Previous bypass surgery * 4.7% 4.5% 0.92 
Previous angina 40% 35% 0.22 
Previous myocardial infarction * 12% 15% 0.26 
Previolls cerebrovascular accident * 0.6% 2.1% 0.08 
Diabetes * 11% 17% 0.03 
Killip Class * 0.72 
I 89% 89% 
II 10% 10% 
III 0.8% 1.7% 
IV 0.2% 0.4% 
Site of myocardial infarction * 0.07 
Anterior 33% 42% 
Inferior 62% 55% 
Other 5% 3% 
Time to treatment (hours) * 3.0±1.5 3.0±1.6 0.91 
Treatment * 0.55 
Accelerated rt-PA 25% 23% 
Streptokinase + IV heparin 21% 26% 
Streptokinase + Sc heparin 26% 24% 
rt-PA + Streptokinase 28% 28% 
Peak creatine kinase-MB (IV/liter) I62±I62 191±165 0.10 
* included in GUSTO-I mortality modept. Data presented are mean value ± SO or percent 
of patients. IV = intravenous; Sc = subcutaneous. 
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Figure 2. Kaplan-Meier survival curves for patients with ST shift (dashed line) and those 
without ST shift (solid line) demonstrating a significant difference in I-year mortality rates. 
Overall number of patients available for follow-up at each point in time is also shown. 
Recurrent ST segment shift and death 
The survival disadvantage in patients with versus those without an ST segment 
shift can be appreciated early and persists for up to one year (Figure 2). The 
mortality rate at 30 days (7.8% vs. 2.25%, odds ratio [OR] 3.7, 95% confidence 
interval [CI] 1.7 to 7.9, P=0.008) and at I year (10.3% vs. 5.7%, OR 1.9, 
95% CT 1.1 to 3.3, P=0.025) was higher in patients with than those without 
an ST segment shift, respectively. Aftcr adjustmcnt for significant baseline 
inequalities (Table I), there continued to be greater mortality in patients 
with an ST shift at 30 days (P=O.O 15). 
To further define the prognostic significance ofST shift, this variable was 
added to the overa1l30-day GUSTO-I mortality mode]3'.When ST shift was 
added to the overall mortality model (OR for the model 2.65, 95% CI 1.9 to 
3.7) the duration of the ST shift had an independent and significant incremental 
value whcn considercd with 1- or 30- minute interval increases (OR 1.13, 
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Figure 3. Relation between duration of ST shift within the first 24 hours after myocardial 
infarction and I-year mortality rates (1=0.88). Duration of ST shift was grouped on the 
basis of 30-minutc intervals and plotted against the respective moriality (average) rate for 
each group of patients. Significance level is based on univariate analysis of ST shift. 
9S% CI 1.03 to 1.24, P~0.008). To examine whether a continuous relation 
existed between the duration of the ST shift and I-year mortality rates, we 
partitioned the ST shift duration into 30-minute intervals. As shown in 
Figure 3, a good dircct relation existed between duration of ST shift and 
I-year mortality (t=0.88, P~0.008). 
Direction of ST segment shift 
Among patients with an ST shift, 92 (38%) had ST depression, and lSI 
(62%) had ST elevation. Compared with patients without an ST shift, there 
was an increase in the 30-day mortality rate both among those with ST 
depression (9.78% vs. 2.2S%, P~0.0009, OR 4.71, 9S% CI 1.89 to 11.72) 
and those with ST elevation (6.62% vs. 2.2S%, P~0.012, OR 1.76, 9S% CT 
1.13 to 2.72). The relation with higher mortality was maintained after 
adjustment with the GUSTO-I mortality modePl in patients with ST depression 
60 CHAPTER 4 
(OR 3.64, 95% CI 1.38 to 9.61, P=0.009) or ST elevation (OR 2.43,95% CI 
0.96 to 6.12, P=0.06). 
Similarly, there was an increase in I-year mortality rates among patients 
with ST segment depression compared with those without an ST shift (11.96% 
vs. 5.7%, P=0.03, OR 2.25, 95% CI 1.08 to 4.69) and ST elevation (9.3% 
vs. 5.7%, P 0.13, OR 1.30, 95% CI 0.93 to 1.82). 
The 30-day prognostic significance ofST depression and elevation persisted 
after the elimination of two deaths that occurred within the first 24 hours. 
DISCUSSION 
The principal novel finding of this study is that a recurrent ST segment shift 
detected within 6 to 24 hours of thrombolytic therapy and after the initial 
resolution of ST elevation is an independent predictor of 30-day mortality 
in patients with an acute myocardial infarction. We also found a direct relation 
between the duration of the ST shift and I-year mortality. Previous studiesl6.22 
have related poor outcome to rccurrent ischemia detected beyond the first 
day. Our study extends those findings of prognostic significancc by 
demonstrating the importance of early (i.e., within the first 24 hours) detection 
of ischemia when other noninvasive modalities such as stress testing are not 
applicable and within a time fi'ame in which therapeutic intervention is feasible. 
Multiple studies have demonstrated that rapid and stable resolution of ST 
elevation in patients with acute an myocardial infarction is related to patency 
of an infarct-related artelyl.9. Our goal in this respect was to study early 
risk stratification beyond the initial 6 hours when patency status has been 
established. We were interested in ST segment monitoring beyond this point 
to identify high risk patients beyond the time frame for immediate intervention, 
such as rescue angioplasty. 
ST segment elevation 
We observed a higher mortality rate in patients with recurrent ST segment 
elevation than in those without an ST segment shift; however, the 
pathophysiology and specificity of ST segment elevation for identifying 
recurrent ischemia could not be determined from our analysis and remain 
uncertain. Recurrent ST elevation is thought to reflect a culprit vessel 
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occlusion6,33-35, Thus, recurrent ST elevation in our analysis may have been 
indicative of recurrent thrombosis in the infarct-related artery; alternatively, 
mechanical changes in left ventricular geometry in response to transient 
alterations in loading conditions, for example, may account for the recurrent 
ST elevation6-38 , 
ST segment depression 
The pathophysiology of ST segment depression after myocardial infarction 
is related to the severity of culprit lesion stenosis and the dynamic aspects 
ofthe culprit lesion activity, including thrombosis and vasospasm; these result 
in more frequent recurrent ischemia, persistent left ventricular dysfunction, 
electrical instability and poor outcome!6,!9-22,39 , Based on our observations, 
ST segment depression appears to have a stronger relation to mortality than 
does ST segment elevation, especially after adjustment for other variables 
with the GUSTO-I mortality modeI3!, This may suggest that recurrent ST 
segment depression is a more specific marker of recurrent ischemia than ST 
scgment elevation, 
Total ischemic burden 
We demonstrated the prognostic significance of ST segment depression and 
ST segment elevation with respect to 30-day or I-year mortality, suggesting 
that the measure of overall ST segment shift can be used for prognostic risk 
stratification, at least when acquired within thc first 24 hours after acute 
myocardial infarction, Further insight into the mechanism of our findings 
would have been provided by concurrent measures of infarct size and 
ventricular function as well as the status of thc culprit vessel. 
With acute ischemic syndromes, ST segment shift may be a marker of 
myocardial ischemia or necrosis depending on the underlying pathophysiology, 
which can include intra coronary thrombosis, vasoconstriction, distal 
embolization and microvascular injury. Dynamic changes in ST segments 
on continuous monitoring have been related to angiographic detection of 
intracoronary thrombosis25, cardiac adrenergic dysfunction26 and thrombus-
mediated cycles in coronary flow27 . Thus, ST segment shift represents a 
convenient surrogate measure of underlying pathophysiology because it is 
readily available, can be continuously updated, quantitatively relates to the 
extent of myocardial cell injury in real time and bears a relation to prognosis. 
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Thc relation of ST segment monitoring to otber markers of higher risk 
patients40,4! rcquires further evaluation. 
In this era of fiscal restraint and diminishing acccss to more intense therapy, 
our findings provide support for the use of this noninvasive and universally 
available marker of recurrent ischemia for risk stratification. Studies have 
shown a lack of benefit from tbe indiscriminate usc of target lesion angioplasty 
in patients early after myocardial infarction42. 5!. Our study provides support 
for the triage of patients with ST shift who represent a high risk group; this 
increased risk may be mediated by reocclusion of tbe infarct-related artery 
or recurrent ischemia. This approacb is further supported by the findings of 
a continuous relation between the duration of ST segment shift and death 
(Figure 3) and by the independent predictive nature ofST shift in multivariable 
analysis, which included the GUSTO-I 3D-day mortality modeP!. 
Study limitation 
The main limitation of our study relates to the arbitrary selection of a 6-
hour cut off period for detection of recurrent ST shift after thrombolysis. 
This choice was supported by three considcrations: (l) Resolution of the 
initial ST shift was rapid (Figure I), with an apparent "shoulder" at 6 hours. 
(2) Insight from concurrent participation in tbe angiographic substudy35 
indicated tbat by 3 hours, up to 80% of patients experienced? 50% resolution 
of initial maximal ST shift; only a few patients underwent angiography beyond 
3 hours in the first day29, precluding furtber assessment of patency in relation 
to recurrent ST shift. (3) We wished to study the prognostic significance of 
ST shift beyond the initial period of thrombolysis and relatcd instability. 
Approximately one third of patients initially enrolled into this substudy wcre 
excluded for teclmical reasons, which limits the generalizability of our findings. 
The observation of higher mortality rates in the excluded patients than in 
the included patients may have resulted in the dilution of the relation between 
the new ST shift and death. It should also be noted that the relationship of 
ST shift to death was independent of clinical variables and risk factors 
documented at the time of randomization. However, we did not study ST 
shift in relation to symptomatic recurrence of ischemia or heart failure or in 
relation to a particular QRS configuration (e.g., the development ofQ waves). 
Although the accuracy of ST shift detection may have been limited by the 
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use of three different techniques, the concurrence of our findings within each 
of the tecllllologies facilitates the generalizability of the results. 
CONCLUSION 
Recurrent ST shift at 6 to 24 hours after thrombolytic therapy for acute 
myocardial infarction is related to increased mortality at 30 days and I year. 
This simple, noninvasive monitoring tcchnique may be of additional prognostic 
value in the early pcriod after acute myocardial infarction when rapid decision 
making pertaining to the management of these patients is required. Patients 
with a recurrent ST shift within the first 24 hours represent a high risk group 
that may benefit from more aggressive intervention. Patients without a recurrent 
ST shift represent a low risk subgroup that, in the absence of other high risk 
features, may be suitable for early discharge. 
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Chapter 5 
Comparison of usefulness of 
computer-assisted continuous 48-hours 
3-lead with 12-lead ECG-ischemia 
monitoring for detection and quantitation 
of ischemia in patients with unstable angina 
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EliI' Hearl J 1997; 18: 931-940 
70 CHAPTER 5 
ABSTRACT 
Aims. The selection of ECG leads used for ST monitoring may influence 
detection and quantitation of ischemia. 
Methods. Wc comparcd on-line continuous 48-hours 12-lead against 3-lead 
ST monitoring in 130 eunstablc angina patients (Mortara, ELI-IOO). Onset 
and offset of ST episodes were defined by the lead with the first;:> 100 fl V 
ST change relative to baselinc and the lead with the latcst return to baseline 
ST level, respectively. ST episodes werc calculated for 12 leads and 3 leads 
(V2, V5, III) separately. 
Results. ST episodes were detectcd in 88 patients (77%) by 12-lead and in 
71 patients (62%) by 3-lead ST monitoring (P<0.02). The median number 
(25,75%) ofepisodes/patient was 1(0,3) for 3-lead and 2 (1,6) for 12-lead 
(P<O.OOO I). The total duration of ischemia detected during 12-lead far exceedcd 
3-lead monitoring: 12.3 (I, 58.2) and 1.7 (0, 23.3) minutes respectively 
(P<O.OOO I). The probability of rccurrent ischemia declincd most during the 
first 24 hours of monitoring. After a period without ST changes of I, 12, 24 
and 36 hours, the probabilities of recurrent ischemia were 63, 31, 14 and 
9%, respectivcly. 
Conclusions. Continuous 12-lcad ST monitoring increascs detection rate and 
duration of ST episodes compared to 3-lcad ST monitoring. The use of 
continuous 12-1cad ECG monitoring devices on emcrgency wards and coronary 
care units is recommended. 
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INTRODUCTION 
Patients with unstable angina may suffer from early unfavorable cardiac events 
in spite of intensive medical therapy. Prognosis is defined primarily by the 
recurrence and severity of silent or symptomatic myocardial ischemia and 
by the presence of multi vessel coronary artelY disease l.7 • The assessment of 
the total ischemic blll'den and the identification of patients at risk should 
preferably be based on continuous ECG monitoring teclmiques. Continuous 
ST monitoring, whether on-line 01' by Holter recording with subsequent off-
line analysis, has been limited by a restricted number of 2 or 3 ECG leads. 
Recently, new systems have been introduced for continuous on-line analysis 
of 12-leads or orthogonal vector lead ECGs, which have overcome the 
limitations of these earlier technologies8. 12 . However, the additional value 
of 12-lead ECG analysis over 201' 3 leads 01' single lead analysis in patients 
with unstable angina is not reported. Comparative studies of different lead 
systems have been performed to address the value of multilead exercise 
electrocardiography13.15. These results, however, may not be applicable to 
patients with unstable angina, since the pathophysiology of unstable angina 
differs from the pathophysiology of stable angina (plaque mptlll'e and coronmy 
tlu'ombosis vs. fixcd stenosis with ischemia due to increased myocardial oxygen 
consumption). 
The aim of the present study was to compare continuous 12-lead ST 
monitoring with more conventional 3-lead ST monitoring for detection and 
quantitation of ischemia in patients with unstable angina, and to investigate 
which leads most frequently contribute to the detection of ST episodes. A 
new algorithm for detection and quantitation of ischemic events is presented, 
which takes into account all 12 ECG leads simultaneously. 
METHODS 
Study patients 
One hundred and thirty patients, who were hospitalized for unstable angina 
and who participated in a dose-finding study of a new anti-thrombin agent, 
underwent continuous 12-lead ST monitoring in 18 hospitals (see 
appendix)16.17. Patients were eligible for the study if an episode of chest 
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pain was accompanied by dynamic ST and / or T wave changes indicative 
of myocardial ischemia. Patients with ECG abnormalities such as left bundle 
branch block, left ventricular hypertrophy or artificial pacemaker device, 
making ST segment interpretation ulll'eliable, were excluded, as were patients 
with a recent myocardial infarction. 
Continuous ST monitoring 
Continuous ECG monitoring was performed using the ELI-IOO continuously 
updated 12-lead ECG monitoring system (Mortara Instruments, Milwaukee, 
U.S.A.), which automatically calculates median ECG complexes of the 
12 ECG leads evelY 15 seconds. The system was programmed to store median 
ECG complexes every 20 seconds if ~ 100 11 V ST segment shift was present 
in one lead relative to the baseline ECG of that patient, or if ~ 50 IlV ST 
shift was present in any two leads of the 12-lead ECG. If less or no ST 
change was present, a baseline median ECG was stored every 20 minutes. 
Median ECG complexes and ST trend data were stored on a removable 
hard disk or floppy disk. After completion of the recording, this disk was 
sent to the Cardialysis core laboratOlY (Rotterdam, The Netherlands) for 
subsequent editing and analysis. 
Editing and analysis of recorded data 
Before editing, the 12-lead ECG templates at the start of the continuous 
ECG recording were compared with the study entry 12-lead ECGs in order 
to verify proper lead placement. In the case of discordance, the recording 
was rejected. 
All median QRST templates were manually sCalmed and edited for artifacts, 
intermittent bundle branch block, detection or marker errors and postural 
changes. The latter was defined as a sudden change of the frontal QRS axis 
and / or a sudden QRS amplitude change from VI to V6 or vise versa. After 
editing, the trends of the ST segment level measured at the J-point + 60 
mseconds were generated for each single lead of the 12-lead ECG, except 
aVR. 
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Reference ECG 
At study entry, an attempt was made to document both a standard 12-lead 
ECG during chest pain and a 12-lead ECG without chest pain. These ECGs 
were used to define a reference "non-ischemic" (without chest pain) median 
ECG complex during the continuous ECG recording. If the median ECG 
complex at the start of the recording was similar to the study enfty non-
ischemic 12-lead ECG, this ECG complex was used as the reference "non-
ischemic" continuous ECG complex. If the first ECG complex was not similar 
to the study entry non-ischemic 12-lead ECG, attempts were made to identify 
the most comparable "non-ischemic" ECG complex of the continuous ECG 
recording. Subsequently, this ECG complex was used as the reference "non-
ischemic" ECG. 
Definition of ST episodes 
The onset of an ST episode was defined as a change of ST amplitude in one 
or more leads of at least ± 100 ~lV from the baseline ST level, developing 
within a 10 minute period and persisting for at least I minute. The end of an 
episode was defined as a return of the ST level within ± 100 ~lV of the 
baseline ST level, again lasting for at least one minute. Episodes had to be 
separated from each other by at least one minute. If? 100 ~l V ST change 
was present in more than one lead simultaneously, the episode onset was 
defined by the lead exhibiting the first significant ST change. Similarly, the 
end of an episode was defined by the lead exhibiting the latest return to 
baseline ST level. An example of the ST trend analysis and representative 
ECG recordings is presented in Figures I and 2. 
Automated detection of ST segment changes? 100 f1V 
An algorithm programmed according to the previously described ST criteria 
for ischemia, was applied to each single lead ST trend, in order to detect 
both the time and ST values of onset and offset of an ST episode and its 
peak ST level. In order to prevent a reversal of baseline with a real ST episode 
(or false detection of an untrue ST episode), the algorithm was programmed 
to skip episodes of which the onset ST value was closer to the initial reference 
ST level than the baseline ST level during the predefined 10 minutes window. 
In such an instance, the ST value was used as baseline update for the detection 
of a possible next episode. 
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Figure I. Twelve-lead ST analysis in a patient with unstable angina. The ST trcnds of those 
leads in which ST episodes occurred arc displayed, together with the heart rate trend (bot-
tOIll trend curve). The black bars in each single lead ST trend represent the time during 
which the algorithm detected a ;;::: 100 ~lV ST change. At the bottom of the trend graphs, the 
black bars indicate the total ST episode duration (ischemia), taking into account all leads 
involved. 
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Figure 2. Samples of the computer-assisted 12-lead EeG recording of the patient in Figure 
1. The upper EeG row demonstrates the 12-lcad ECG (except aVR) which lws been select-
ed as the reference, "non-ischemic" EeG. The ECG rows directly below demonstrate the 
time and EeG lead (indicated in bold) in which the ST episode occurred. In the upper panel, 
ST changes arc present in multiple leads, but the ST changes of V I appear dominant. Thus 
the onset, maximum and ending of the episode is detected in this lead. However, in another 
episode shown in the lower panel, the onset and maximum of the ST episode is detected in 
lead V2, but the end of this combined episode is detected in lead VI. 
Subsequently, the digital trend analysis was confirmed by a second visual 
analysis of the real-time ECG, thus double checking template quality and 
excluding false-positive or false-negative automated ST measurements. The 
ECG at moments of interest, either detected by the algorithm or by the operator, 
was documented on hard copy for visual inspection (Figure 2). 
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ST episodes based on 12-lead and 3-lcad ST trcnds 
As a final sumll1aty analysis, the total number of ST episodes was calculated 
based on both the combination of either 3 leads III, V2 and V5 or the 
combination of all 12 leads (except a VR). 
Statistical analysis 
Continuous variables are expressed as median and interquartile range (25th 
and 75th percentiles). Unpaired variables were compared using the Mann-
Whitney test. Wilcoxon signed rank test was used for paired variables. Discrete 
variables are described with percentages and were compared using the chi-
square test. The number of episodes pel' patient during 3-lead and 12-lead 
ST monitoring might differ in two directions, since both more and less frequent 
ST episodes might be detected by 12 leads compared with 3 leads. The latter 
might be due to combining of multiple short episodes in one long episode. 
This would result in fewer episodes but a longer ischemic duration. Therefore, 
a two-tailed P value was calculated in all instances. A P value of ~ 0.05 was 
considered statistically significant. The Kaplan-Meier method was used for 
the evaluation of the time to the occurrence of a first ST episode and the 
possibility of a recurrent ST episode, with censoring of data. Statistical 
difference was tested with the log rank test. 
RESULTS 
ECG monitoring was initiated in 130 patients. Good quality recordings were 
eventually obtained in 114 patients (88%). The median (25, 75 percentiles) 
total ECG monitoring time was 53 (49, 55) hours. Total analyzable ECG 
monitoring time was 44 (38, 48) hours. Twelve-lead ST monitoring detected 
515 ST episodes suggestive of transient ischemia against 311 for 3-lead ST 
monitoring, respectively (Table I, P<O.OOO I). This resulted in detection of 
ischemia by 12-lead ST monitoring in 88 patients (77%) vs. 71 patients (62%) 
by 3-lead ST monitoring (P~0.02). Sixty-four of the 88 patients with ST 
episodes during 12-lead monitoring had more than one ST episode (73%), 
against 46 (65%) of the 71 patients during 3-lead monitoring (P~0.02). 
Several other observations support the greater sensitivity for detection of 
ST segment changes of 12-lead monitoring over 3 leads. For example, the 
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Table 1. Summary of ST analysis parameters. Comparison of computer assisted 3-lead 
against 12-lead ST monitoring in 114 patients with unstable angina. 
N=114 3-lead 12-lead 
ST monitoring ST monitoring 
ST episodes present (pts) 71 (62%) 88 (77%) 
> I ST episode present (pts) 46 64 
total number of episodes 311 515 
patients with symptomatic ST episodes 10 (9%) JO (9%) 
number of episodcs/pt* (0,3) 2 (1,6) 
total duration (min) of ST shift/pt* 1.7 (0,23.3) 12.3 (1,58.2) 
duration of ST episode (min)",* 5 (1.3,17.7) 7 (1.3, 20) 
mean duration of episode/pt (min)",*' 7.7 (1.8, 14.4) 10.2 (2.6, 15.2) 
time to first episode (lus)"'''' 12.7 (5.8, 28.4) 9.9 (4.0,21.2) 
median, 25, 75 percentiles, including patients without ischemia 
** median, 25, 75 percentiles, patients with ischemia only 
P value 
0.02 
0.02 
<0.0001 
n,s, 
<0.0001 
<0.0001 
<0.0001 
0.03 
<0.0001 
Table 2. Number of leads involved per ST episode. Comparison of computer-assisted 
3-lead and 12-lcad ST monitoring. 
Lead 
selection 
3 leads 
12 leads 
Number of leads involved per ST episode (%) 
2 3 4 5 >5 
252 (81) 47 (15) 12 (4) 
283 (55) 97 (19) 63(12) 24 (5) 14 (3) 34 (7) 
Total number 
of ST episodes 
311 
515 
first ST episode during monitoring was detected earlier by 12 Icads (Table I 
and Figure 3), and the duration of ischemia detected by 12 leads exceeded 
the duration in 3 leads (Figure 4). Furthennore, the number of leads involved 
per ST episode was higher for 12-lead than for 3-lead ST monitoring (Table 2). 
For 12-lead ST monitoring, episodes with precordial lead involvement only 
were far more frequently present than episodes with only standard or augmented 
lead involvement (77% against 11% respectively, P<O.OOOI). Simultaneous 
involvement of both the standard or augmented leads and the precordial leads 
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Figure 3. Time to the occurrence of the first ST episode after the start of ST monitoring 
plotted against the cumulative percentage of patients. - = 12-lcad; - - - = 3-Iead. 
was present in 60 out of 515 ST episodes (12%). A shift of ST episodes 
from either the standard or augmcntcd Icads to the precordial leads or vise 
versa occurred in 20 (31 %) of the 64 patients who had more than one ST 
episode during 12-lead ST monitoring. For 3-lead ST monitoring, the single 
lead episodes of V2 contributed most to the detection of the onset of ST 
episodes (Figurc 5, panel B, P<O.OOOI), while V2, V3 and V4 were equally 
sensitive in the 12-lead analysis (Figure 5, panel A). 
Figure 6 shows a Kaplan-Meier "survival" analysis with censoring of data 
of the probability to remain frcc of a new ST episode during the course of 
the monitoring period using 12 leads. The probability of a recurrent ST episode 
declined most during the first 24 hours of monitoring. Therc was no difference 
between the probability of occurrence of a new ST episode after the start of 
the ECG monitoring period or the probability of recurrence of a second ST 
episode after the first, or a third after the second episode. 
Forty-five patients (39%) had at least one episode of chest pain during 
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Figure 4. Comparison of 12-lead and 3-lead ST monitoring. (A) Demonstrates the number 
of episodes per patient for both techniques. (ll) The total duration of the ST episodes per 
patient. Note: Single dots may represent more than one patient. The encircled patients in 
(A) show more episodes during 3-lead than 12-lcad ST monitoring. In these patients, sever-
al isolated 3-lead ST episodes appeared to be part of one, longer lasting 12-lead ST episode, 
depending on the leads involved. 
ECG monitoring. However, ST changes of ~ 100 11 V were present during 
those episodes in 10 patients only (22%), during both 3- and 12-lead ECGs. 
If additional less promincnt ST and T wavc changes similar to the study 
cntty ECG were also taken into account, ECG signs of ischemia werc present 
during chest pain in 26 patients (58%). There was no significant difference 
between the number of ST episodcs in paticnts with and without episodes of 
chest pain. 
Nineteen patients (17%) sufferecl from an in-hospital cardiac event and / 
or underwent emergeucy angiography within the first seven days of admittance 
to hospital. There were no cardiac deaths. Clinical evcnts occurred more 
frequently in patients with chest pain during the monitoring period and in 
patients with chest pain and concomitant ST episodes compared to those 
without recurrent ischemia (Table 3). These observations were, however, 
not statistically significant in this small series of patients. 
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Table 3. Correlation of in-hospital cardiac events within 7 days i)-o111 admission to hospital 
with the presence of chest pain and / or ST episodes during the ECG monitoring period. 
During recording Number Myocardial PTCAJCABG Any clinical No clinical 
ofpts infarction event (%) event (%) 
Chest pain 45 5 7 II (24) 34 (76) 
No chest pain 69 7 8 (12) 61 (88) 
chest pain + ST episode(s) 37 4 7 9 (24) 28 (76) 
chest pain + corr. ST episode 10 0 3 3 (30) 7 (70) 
no chest pain, no ST episodes 18 2 0 2 (II) 16 (88) 
12 lead, ST episodes present 88 9 8 16 ( 18) 72 (82) 
12 lead, no ST episodes 26 3 0 3 ( 12) 23 (88) 
3 lead, ST episodes present 71 7 7 13 ( 18) 58 (S2) 
3 lead, no ST episodes 43 5 I 6 ( 14) 37 (SO) 
DISCUSSION 
Recently, computer-assisted continuous l2-lead ECG monitoring techniques 
havc bccome available for real-time ECG and ST segment monitoring in 
patients with acutc coronmy syndromes8,9,18. These techniques have outgrown 
the limitations of serial ECG recording, which provides snapshot information 
only, and Holter ST recording, which is limited by a restricted number of 
leads and allows for retrospective off-line analysis only. 
In patients with an acute myocardial infarction receiving thrombolytic 
therapy, computer-assisted continuous ECG monitoring has proven to be of 
clinical value for prediction of vessel status and identification of high risk 
paticnts lO. 12 . However, so far, no systematic studies have been conducted to 
evaluatc the usefulness of computer-assisted continuous 12-lead ECG 
monitoring techniques in patients with unstable angina. To our knowledge, 
this study is the first to demonstrate thc relationship between detection and 
quantitation of ischemia and ECG monitoring technology in these patients. 
Twelve lead ST monitoring appeared to be more sensitivc than the more 
generally applicd 3-lead technology. When only three leads were used for 
ST monitoring, ischemia was detected in 62% of patients, which is comparable 
to studies using Holtcr ST monitoring in patients with unstable angina 1,19. 
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Table 4. Differences of ST analysis in patients \vith acute myocardial infarction and unstable 
angina. 
Acute myoc3I'diai infarction 
ST monitoring of single lead with greatest ST shift 
will suffice in most instances 
baseline ST level is defined by the moment of ST 
recovery and ST steady state 
recurrent ischemia is reflected by ST rc~clevation 
instead of ST depression ill most instances 
gradual T wave changes only 
Unstable angina 
multilcad ST monitoring necessary, as the 
ischemic area may vary in time. Scanning of 
different leads for earliest onset, highest peak 
and latest end of ST episodes is necessary 
baseline ST level is not defined, a reference 
ReG is necessary 
ischemia may be reflected by both ST 
elevation, ST depression and T wave changes, 
which makes automated analysis lIsing 
computer algorithms difficult 
minor ST segment and T wave changes may 
reflect ischemia, which makes accurate 
quantitation of ischemia difficult 
With 12-lead ST monitoring, ischemia was detected in an additional 15% of 
patients. Both the number and duration of ischemic episodes far increased 
using l2-lead compared to 3-lead ST monitoring. 
The ST changes were found to disperse and shift among different leads in 
time in at least 31 % of patients with more than one ST episode during the 
monitoring period. This may depend on the flow balance of the coronary 
system, the degree of vessel injury and the duration and severity of ischemia. 
Thus, instead of monitoring the lead with maximal ST deviation or sum ST 
deviation in patients with myocardial infarction20,21, full l2-lead ST monitoring 
should be preferred for detection and quantitation of ischemia in patients 
with unstable angina. The major differences between ST monitoring of unstable 
angina patients vs. ST monitoring of acute myocardial infarction patients 
are listed in Table 4. 
ST episodes were most frequcntly present in the leads V2, V3 and V4. In 
addition, these leads also contributed most to the detection of the onset of 
ST episodes if all involved leads were taken into account. This is in contrast 
to previous studies on body surface mapping and optimal lead placement 
during exercise electrocardiography in patients with coronary artery dis-
ease I3,15. These studies demonstrated that the single lead with the greatest 
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Figure 5. Number of single ST episodes per lead and detection of earliest ST episode onset 
if all leads involved are taken into account. The bars represent the number of ST episodes 
detected in each single lead. The tinted areas represent the number of episodes which de-
tected the earliest episode onset. (A) Detection of onset of ST episodes when using 12-lcad 
ST monitoring. CD) Detection of an set orST episodes when using leads III, V2 and V5 only. 
sensitivity for detecting ST segment shift was between the right infraclavicular 
region area and the V5 position, which is in fact a bipolar V5 lead. Our data 
do not support these findings and suggest that studies on lead placement and 
ST shift during exercise testing in patients with stable angina may not be 
applicable to patients with unstable angina in whom both the underlying 
pathophysiological mechanism and the extent and area of ischemia is 
different22 . Tn addition, our results indicate that ST episodes with only standard 
lead involvement are rare. As such, it is conceivable that the applied cut-off 
value of? 100 11 V ST change is not adequate for standard lead monitoring 
in general practice. 
Previous studies on patients with unstable angina demonstrated that recurrent 
ischemia occurs 1110st frequently in the first 24-48 hours of admission to 
hospitaI22,23. This is in concordance with our finding that the majority of 
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Figure 6. Kaplan~Meier event free survival estimate. The curves indicate the probability of 
remaining free of an ST episode during the course of the monitoring period: (1) from start 
of the monitoring period ( ~ , median time 15.3 hours), (2) from the end of the first ST 
episode until the second ( - - -, median time 7.4 hours) and (3) from the end of the second 
ST episode until the third ( •••• , median time 9.6 hours), using 12-lead ST monitoring. The 
curves virtually overlap, suggesting similar pathophysiology for the different episodes. Plaques 
apparently become quiescent after a period without ischemia of approximately 24 hours. 
patients exhibited a recurrencc of ischemia within the first 15 hours of ST 
monitoring, with only 23% of patients remaining fi'ee of an STepisode during 
the total monitoring period (Figure 3). In addition, Figure 6 demonstrates 
that the distribution of the occurrence of an ST episode over time was similar 
for the first interval since the start of the ST monitoring period, as well as 
for the occurrence of a second episode after the first and a third after the 
second. This suggests similar underlying pathophysiological mechanisms of 
these episodes23 • Apparently, plaques stabilize and become "quiescent" after 
a period without recurrent ischemia of approximately 24 hours. 
In agreement with Holter ST studies in patients with unstable angina, ST 
changes of;>- 100 flY during moments of chest pain were infrequently present, 
occurring in only 22% of the patients with chest pain during the monitoring 
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period 19,24,25, This may be due to at least three factors: (I) complaints may 
not always be ischemic of origin, (2) the time of occurrence of complaints 
may not always have been correctly indicated by the patient or annotated in 
the case record forms, (3) the generally accepted ~ lOa ~IV STchange criterion 
for detection of ischemia may be too insensitive to pick up minor ischemic 
ECG changes that may occur in these unstable patients. The latter assumption 
is supported by the fact that minor ST and T wave changes, similar to the 
study entry ECG during pain were present during pain in 58% of all patients 
who had episodes of chest pain during the recording. This implies that not 
only ST changes of~ lOa IlV but also smaller ST and T wave changes should 
be taken into account as signs of ischemia in these patients. Until recently, 
the standardization and automated detection and quanti tat ion of these minor 
ST and T wave changes was hampered by the limitations of earlier ECG 
technologies such as Holter, because of baseline drift and restriction of number 
of leads. In contrast, the high quality ECG signals provided by computer-
assisted ECG monitoring technologies have overcome these limitations and 
may challenge us to develop new ischemia standards and algoritlnlls for its 
automated detection and quantitation. 
Finally, in contrast to other studies using Holter ST recording techniques1,19, 
we did not demonstrate a significant difference in the occurrence of in-hospital 
cardiac events within the first week from admittance between patients with 
and without ST episodes, although trends were similar to previous studies 
(Table 3). This may be due to the small number of patients who suffered 
from an in-hospital clinical event. 
We conclude that computer-assisted 12-lead ECG monitoring can be used 
for on-line ECG-ischemia monitoring of unstable angina patients both for 
clinical purposes and for quantitation of myocardial ischemia in studies. The 
use of continuous 12-lead ST monitoring significantly increased the detection 
rate of ST episodes as compared to more conventional continuous 3-lead ST 
monitoring. Furthermore 12-lead ST monitoring yields more episodes and 
longer duration of ischemia. Whether this also relates to a better specificity 
for prediction of impending clinical events could not be established from 
the small subset of patients who actually suffered an in-hospital clinical event 
during this study. Computer-assisted 12-lead ECG monitoring systems are 
recommended on emergency wards and coronary care units, not only for 
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monitoring of patients with an acute myocardial infarction recelvlllg 
thrombolytic therapy, but also for monitoring of unstable angina patients. 
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ABSTRACT 
Aims. Thrombin plays a key role in the clinical syndrome of unstable angina. 
We investigated the safety and efficacy of 5 dose levels of efegatran sulphate, 
a direct thrombin inhibitor, compared to heparin in patients with unstable 
angma. 
Methods. 432 patients with unstable angina were enrolled. Five dose levels 
of efegatran were studied sequentially, ranging from 0.105 mg/kg/ln' to 1.2 
mg/kg/ln·. during 48 hours. Safety was assessed clinically, with reference to 
bleeding and by measurement of clinical laboratory parameters. Efficacy was 
assessed by the number of patients experiencing any episode of recurrent 
ischemia as measured by computer-assisted continuous ECG-ischemia 
monitoring. Clinical endpoints were: episodes of recurrent angina, myocardial 
infarction, coronary intcrvention (PTCA or CAB G), and death. 
Results. Efegatran demonstrated a dose dependent anticoagulant activity with 
the highest dose level of 1.2 mg/kg/hr. rcsulting in steady state mean APTT 
values of approximately 3 times baseline. Thrombin time was also incrcased. 
Neither of the doses of efegatran studied were able to suppress myocardial 
ischemia during continuous ECG-ischemia monitoring to a grcatcr extent than 
that seen with heparin. There were no statistically significant differences in 
clinical outcome or major bleeding bctween the efegatran and heparin groups. 
Minor bleeding and thrombophlcbitis occurred more frequently in the efegatran 
treated patients. 
Conclusions. Administration of efegatran sulphate at levels of at least 0.63mgl 
kg/hour provided a level of thrombin inhibition which is at least comparable 
to APTT adjusted heparin infusion. There was no excess of major bleeding. 
Thc level of thrombin inhibition by efegatran, appeared to be morc stable 
than with heparin. Thus, like other thrombin inhibitors, efegatran sulphate 
is easier to administer than heparin. However, no clinical benefits of efegatran 
over heparin were apparent. 
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INTRODUCTION 
Acute coronary ischemic syndromes are usually the result of a ruptured 
atherosclerotic plaque, followed by platelet aggregation, often in combination 
with increased vasomotor tone, leading to sudden increase of the pre-existing 
stenosis!,2 This process may result in one or more episodes of impaired flow 
without myocardial necrosis and the syndrome of unstable angina3, or progress 
into total coronary occlusion and myocardial infarction. Thrombin plays a 
key role in this process. It causes fibrin fOllnation through proteolytic cleavage 
of plasma fibrinogen, and it induces platelet activation and aggrcgation4.5. 
Thus, drugs which dircctly inhibit thrombin, such as efegatran sulphate, have 
been considcred for the treatment of unstable angina, in order to prevent 
rccurrent ischemic episodes and progression into myocardial infarction. 
Efegatran sulphatc is a tripcptidc, direct acting tln'ombin inhibitor. Unlike 
heparin it has the capacity to bind directly to thrombin, and to inactivate 
both circulating and clot-bound thrombin6. Efcgatran sulphate also inhibits 
thrombin induccd platelet aggregation. The primary objective of the present 
study was to asscss the safcty and efficacy of different doses of efegatran 
sulphatc compared to heparin in patients with unstable angina. Safety was 
assessed clinically with particular referencc to blceding occurrences and by 
measurement of clinical laboratory parameters. Efficacy was assessed by 
comparison of the number of patients experiencing any episode of recurrent 
ischemia as measured by computer-assistcd continuous ECG-ischemia 
monitoring during diffcrent treatment regimens7• Furthermore, the incidences 
of clinical ischemic episodes of recurrent angina, myocardial infarction, 
coronary intervention (PTCA or CABG), and dcath were evaluated. The first 
stage of this shldy was a dose ranging program to assess the anticoagulant 
effect and the bleeding risk associated with administration of five dose regimens 
of efegatran sulphate in 132 patients with unstablc angina, compared to heparin. 
These results were used for selection of two dose levels of efegatran sulphate 
which were compared to heparin in a subsequent shldy of 300 patients. 
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PATIENTS AND METHODS 
Study patients 
Patients between 21 years and 75 years old with a clinical diagnosis of unstable 
angina were eligible for the study. For inclusion, patients should exhibit at 
least one episode of angina at rest or minimal exertion and have concomitant 
transient ST and / or T wave changes on their ECG, either at admission, or 
during observation in-hospital. Patients were excluded for any of the following 
reasons: ECG abnormalities making ST -T segment interpretation ulll'eliable, 
such as left bundle branch block, left ventricular hypertrophy or artificial 
pacemaker rhythm; recent myocardial infarction (within the hospitalization 
period), unless creatinekinase (CK) had returned to less than twice the normal 
upper limit; heparin treatment sincc the most recent episode of ischemia prior 
to study enrollmcnt; known aspirin-allergy or other contraindication for aspirin; 
concurrent use of oral anticoagulants (coumarins) at the time of study entry, 
or anticipated need for oral anticoagulants during the study period; recent 
administration of a thrombolytic agent, unless fibrinogen values had returned 
to more than 50% of the normal lower limit; APTT and PT values exceeding 
the normal upper limits, within the past 24 hours prior to study enrollment; 
active internal bleeding or peptic ulcer disease; bleeding risk factors such as 
recent surgelY, major trauma, gastro-intestinal or genito-urinary bleeding, 
puncture of noncompressible vessels or organ biopsy in a 3 months period 
prior to elll'ollment; a histOlY of cerebrovascular accident, transient ischemic 
attack, cranial or intraspinal surgery; underlying medical conditions such as 
persistent hypertension despite treatment, history of hemorrhagic diathesis, 
or a platelet count of less than 100 x 109 / liter within the 24 hours prior to 
the study; known, or suspected major hepatic or renal disease and known 
hemostatic defects, including those secondaty to hepatic, or renal insufficiency, 
or a bleeding time ~ 8 minutes (Ivy method), or ~ 20 minutes (Simp late method) 
while receiving aspirin; women with childbearing potential. 
Study design 
A single blind randomized multicenter comparison of different dose levels 
of efegatran sulphate versus heparin was performed in patients with unstable 
angina. The study consisted of a dose ranging phase, where five doses of 
efegatran were assessed in a sequential manner, followed by a parallel phase 
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in which two doses of efegatran (chosen following review of the data generated 
in the first phase) were compared to heparin. 
Study drug regimens 
In the dose ranging phase, the patients of dosage groups 1-4 received efegatran 
sulphate as an initial loading i.v. bolus of 0.1 mg/kg over 15 minutes, followed 
by continuous infusion of either 0.105, 0.32, 0.63 or 0.84 mg/kg/hr. In the 
5th dosage group, an i.v. loading bolus of 0.3 mg/kg over 1 minute was given, 
followed by continuous infilsion of 1.2 mg/kg/hr. The infilsions were continued 
for 48 ± 10 hours. The parallel design phase compared group 3 (loading dose 
of 0.1 mg/kg over 15 minutes followed by continuous infusion of 0.63 mgl 
kg/hr), and group 5 (loading dose of 0.3 mg/kg over 1 minute followed by 
1.2 mg/kg/hr) from the dose ranging phase with heparin. 
Control patients were treated with a bolus injection of 5000 IU heparin, 
followed by a continuous infilsion of 1000 IU/lli' heparin for 48 ± 10 hours. 
After this period, treatment could be continued with heparin at the discretion 
of the treating physician. Throughout any heparin infilSion, the hcparin dosage 
was adjusted to a APTT ratio of 2.0 to 2.5 times normal, based on local 
laboratory APTT values. Heparin treatment was not allowed before the start 
of the study, nor during the infusion of efegatran sulphate. After termination 
of the efegatran sulphate infilsion, heparin could be the initiated for treatment 
of recurrent, or continuing ischemia, at the discretion of the treating physician. 
All patients were concomitantly treated with aspirin. If the patient was on 
aspirin treatment prior to the start of study treatment, aspirin was continued 
at a dose of 80 mg once daily for the first four days. If a patient was not on 
aspirin, the initial dose was a minimum of 250 mg chewed, or intravenously, 
followed by an oral dose of 80 mg aspirin once daily during the first four 
days. After day four, aspirin was continued at the discretion of the physician. 
Nitroglycerin, beta-blockers, calcium channel blockers and other cardiovascular 
drugs were allowed. 
Laboratory tests 
The effect of efegatran sulphate and heparin on markers of thrombosis and 
hemostasis was assessed by measuring bleeding time (Ivy, Simplate, Surgicut 
and Duke method, local laboratOly, dose-ranging part only), the activated 
partial thromboplastin time (local, and central laboratory), protlli'ombin time 
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(local, and central laboratory) and fibrinogen levels (centrallaboratOlY). Levels 
of fibrinogen were measured using both the ACL and the Clauss method. 
Levels of the activatiou markcrs p-thromboglobulin, platelet factor 4, 
prothrombin fragment 1.2, fibrinopeptide A, thrombin-antithrombin complexes, 
and fibrin degradation products were measured in the dose finding phase 
only (central laboratory). Furthermore, general hematology (local laboratory); 
chemistry (central laboratory) and urinanalysis (local laboratory) were 
performed. 
Efficacy criteria 
The efficacy of efegatran sulphate as compared with heparin was assessed 
by its effect on the percentage of patients experiencing any episodes of recurrent 
ischemia, measured by computer-assisted continuous ECG-ischemia 
monitoring, as described below. Clinical ischemic episodes of recurrent angina, 
myocardial infarction, coronary intervention (PTCA wit balloon or other 
devices, CABG) and death were also evaluated from thc moment of 
randomization until 30 days follow-up. 
Dcfinition of a myocardial infarction required either documentation of an 
increase in CK or CK-MB levels, or electrocardiographic changes. CK or 
CK-MB levels should exceed two times the upper limit of nOll11al (in 2 samples 
collected at different sampling times) and increase by at least 50% over the 
baseline value. If both CK and CK-MB values were available CK-MB took 
preference. Electrocardiographic changes were defincd as new significant 
Q waves of;:> 0.04 seconds duration or having an amplitude of at least one-
fourth of the corresponding R wave amplitude in two or morc contiguous 
leads. The onset of a myocardial infarction was derived from the occurrence 
of chest pain of at least 30 minutes duration. In thc absence of chest pain, 
the time of measurement of the trough CK (-MB) level immediately preceding 
CK (-MB) rise was taken as the moment of onset of myocardial infarction, 
unless the time interval between these two samples was greater than 6 hours. 
Each patient was carefully observed for signs or symptoms of bleeding. 
Bleeding was classificd as major, or minor. Major bleeding was defined as 
clinically overt, and accompanicd by either transfusion of two or more units 
of blood, surgery for treatment of the blccding, or intracranial location of 
the bleeding. Bleeding was defined as minor if it was clinically overt but 
did not meet the other criteria for major bleeding. 
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Computer-assisted contin 1I0llS ECG-ischemia monitoring 
Continuous ECG monitoring was performed using the EU-I 00 continuously 
updated 12-lcad ECG monitoring system (Mortara Instruments, Milwaukee, 
U.S.A). ECG monitoring was started preferably bcfore the start of study-
drug and continued for at least 6 hours following the termination of study-
dl1lg infusion. 
The system was programmed to store median ECG complexes of the 
12 ECG leads every 20 seconds if;;-: 100 !l V ST segment shift was present 
in one lead relative to the baseline ECG of that paticnt, or if;;-: 50 ~IV ST 
shift was present in any 2 leads of the 12-lead ECG. If less or no ST change 
was present, a baseline median ECG was stored every 20 minutes. Median 
ECG complexes and ST trend data were stored on a removable hard disk or 
floppy disk. After completion of the recording, tltis disk was sent to the central 
ECG core laboratory of Cardia lysis Rotterdam, The Netherlands for subsequent 
editing and analysis. ST changes were evaluated in a blinded fashion and 
considered indicative of ischemia if greater than 100 !l V for more than one 
minute duration. 
The method of editing and analysis of the recorded data has recently been 
described in detailS. In brief, the onset of an ST episode was defined as a 
change of ST amplitude in one or more leads of at least ± 100 ~IV from the 
baseline ST level, developing within a 10 minute period and persisting during 
at least I minute. The end was defined as a return of the ST level within 
± 100 ~IV of the baseline ST level, again lasting for at least one minute. 
Episodes had to be separated from each other by at least one minute. If 
;;-: 100 !l V ST change was present in more than one lead simultaneously, the 
episode onset was defined by the lead exhibiting the first significant ST change. 
Similarly, the end of an episode was defined by the lead exhibiting the latest 
return to baseline ST level. 
Statistical analysis 
Continuous variables are expressed as median and interquartile range (25th 
and 75th percentiles). Unpaired variables were compared using the Mmm-
Whitney test. Discrete variables are described with percentages and were 
compared using Fischer's exact test. A two-tailed P value was calculated in 
all instances. A P value of <; 0.05 was considered statistically significant. 
The Kaplan-Meier method was used for the evaluation of the time to the 
Table J. Baseline data. '-0 0-
Efegatran 0.105 Efegatran 0.32 Efegatran 0.63 Efegatran 0.84 Efegatran 1.2 Heparin All 
(n~IO) (n~25) (n~122) (n~24) (n~128) (n~123) (n~432) 
Male 5 (50%) 17 (68%) 83 (68%) 19 (79%) 100 (78%) 77 (63%) 301 (70%) 
Mean (SD) age in years 60 (9) 60 (10) 62 (10) 59 (10) 60 (10) 61 (10) 61 (10) 
Anthropometry: mean (SD) 
Weight (kg. SD) 75 (9) 77 (12) 77 (12) 79 (10) 82 (13) 77 (12) 79 (12) 
Height (em, SD) 170 (11) 171 (10) 172 (9) 173 (7) 175 (9) 172 (9) 173 (9) 
Number of patients with 
previous myocardial Infarction 7 (70%) 10 (40%) 41 (34%) 11 (46%) 38 (30%) 43 (35%) 150 (35%) 
PTCA 0 (0%) 0 (0%) 15 (13%) 0 (0%) 13 (10%) 14 (11%) 42 (10%) 
CABG 0 (0%) 2 (8%) 15 (12%) 2 (8%) 13 (10%) 14 (11%) 46 (11%) 
Risk factors 
Diabetes 0 (0%) 2 (8%) 12 (10%) 3 (13%) 14 (11%) 10 (8%) 41 (10%) 
Hypercholesterolemia 5 (50%) 9 (36%) 45 (37%) 12 (50%) 56 (44%) 51 (42%) 178 (42%) 
Hypertension 2 (20%) 1 (4%) 14 (12%) 0 (0%) 11 (9%) 12 (10%) 40 (9%) 
Current smokers 4 (40%) 11 (44%) 42 (34%) 9 (38%) 58 (45%) 44 (36%) 168 (39%) 
Percentages only calculated for those patients in whom data were reported 
Table 2. Clinical events from randomization until seven days of follow-up or discharge. 
Efegatran 0.105 Efegatran 0.32 Efegatran 0.63 Efegatran 0.84 Efegatran 1.2 Heparin AlJ 
(n~IO) (n~25) (n~122) (n~24) (n~128) (n~123) (n~432) 
Composite endpoint reached * 7 (70%) 13 (52%) 77 (63%) 17 (71%) 84 (66%) 87 (71%) 285 (66%) 
Death 2 0.6%) 2 (0.5%) 
Myocardial infarction I 
reinfaretion 3 (2.5%) 3 (2.3%) 3(2.4%) 9 (2.1%) n Recurrent or refractory ::r: ischemia 6 (60%) 13 (52%) 76 (62%) 17 (71%) 84 (66%) 85 (69%) 282 (65%) ;J> 
PTCA 11 (9%) 10 (8%) 5 (4%) 26 (6%) "C 
-l CABG (10%) 1 (0.8%) 3 (2.3%) 4(3.3%) 9 (2.1%) tIl 
"'Composite endpoint defined as the occurrence of either death. myocardial infarction. recurrent or refractory ischemia or need for revascularization 
;;0 
0-, 
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occurrence of a first ST episode or a recurrent ST episode, with censoring 
of data. Statistical difference was tested with the log rank test. 
RESULTS 
A total of 432 patients were included: 132 paticnts in the dose finding phase 
and another 300 patients in the parallel phase. Baseline patient characteristics 
are summarized in Table I. The mean age of the patients was 60 years, 70% 
were male, and almost all were Caucasian (98%). There were no differences 
in the prevalence of previous myocardial infarction, diabetes mellitus, 
hypertension or a smoking history among the treatment groups. Fifty-eight 
patients (13.4%) were enrolled as having unstable angina, but actually had a 
myocardial infarction at presentation which became evident from subsequent 
CK elevation. 
Markers of coagulation and bleeding time 
Infusion of efegatran was associated with an increase of both the activated 
partial tlll'omboplastin time (APTT), prothrombin time (PT) and thrombin 
time (TT), which rapidly resolved following cessation of therapy (Figure I). 
The APTT increase appeared to be dose dependent. The increase in APTT 
associated with 1.2 mg/kg/hr efegatran was comparable to that observed with 
heparin (P=0.89). APTT levels wcre more stable with efegatran than with 
heparin. 
With respect to the three major treatment groups, PT was mildly increased 
following administration of efegatran, with a significant difference between 
the 1.2 mg/kg/hl' efegatran and heparin group (P=0.006). PT returned rapidly 
to normal after discontinuation of therapy (Figure IB). TT was influenced 
in a strong and dose dependent manner by efcgatran, while administration 
of heparin did not modify TT (Figure I C). Efegatran 0.63 mg/kg/hr was 
associated with an increase of TT levels of approximately 40%, while TT 
values doubled following the administration of efegatran 1.2 mg/kg/hr. These 
differences were all highly significant (P=0.0007). TT levels returned to nonnal 
rapidly after cessation of efegatran. 
Fibrinogen levels decreased following administration of efegatran, and 
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Figure 1. Activated partial thromboplastin times, prothrombin times, thrombin times and 
fibrinogen levels of the three major treatment groups. ~, efegatran 0.63 mg/kg/hr; - - -, 
efegatran 1.2 mg/kg/hr; •••• , heparin. (A) ratio of median activated partial thromboplastin 
times relative to baseline value. (B) Ratio of median prothrombin times relative to baseline. 
(C) Ratio of median thrombin times relative to baseline. (0) Ratio of median fibrinogen 
levels relative to baseline levels. 
returned to baseline levels immediately following discontinuation of therapy 
(Figure ID). The concentration of fibrinogen did not change under heparin. 
Different methods were employed to measure bleeding times. Local 
measurements were abnormal at baseline in 9.1 % of the patients. The number 
of abnormal values increased slightly during infusion of heparin and efegatran, 
but no consistent pattern emerged across the different treatment groups. 
Markers of coagulation activation 
Levels of activation markers were measured in the dose finding phase group 
only and were therefore available in a limited number of patients. It should 
be appreciated that the concentrations of all these parameters, with the exception 
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of the fibrin degradation products, could have becn affected artificially as a 
result of a traumatic vein puncture, although it was attempted to avoid this. 
Levels of ~-thromboglobulin and platelet factor 4 showed wide variability 
at baseline, during treatment with heparin and efegatran, and following 
discontinuation of medication. No consistent changes were observed, and 
no differences between the treatment groups could be established. Also 
fibrinopeptide A, prothrombin fragmcnt 1.2, thrombin-antithrombin complexes 
and fibrin degradation products did not change significantly during treatment 
with heparin or efegatran. 
Clinical outcomes 
Recurrent ischcmia was frcquent in all groups, but only 2.1 % and 0.5% of 
patients experienced a myocardial infarction or death within 7 days, respectively 
(Table 2). The percentage of patients that reached the composite endpoint 
(rccurrent or refractOlY angina, myocardial infarction, ischemia driven coronmy 
intervention or death) at seven days or discharge ranged from 52% to 71 % 
in the efegatran treatment groups and was 71 % in patients treated with heparin. 
No significant differences were observed among the treatment groups. 
At 30 days follow-up, the percentage of paticnts that reached the composite 
endpoint (parallel dose selection population only) was 62% and 67% in the 
efegatran treatment groups, and 68% in those treated with heparin. Only 2.7% 
and 2.0% of patients experienced a myocardial infarction or death at 30 days 
follow-up, respectively. 
Recurrent ischemia during computer-assisted continuous ECG-ischemia 
monitoring 
Good quality ECG recordings were obtained in 405 patients (93%). Hundred-
fourtccn patients werc randomized to one of the six treatment groups in the 
dose finding phase, and 291 patients to one of the three treatment groups of 
the parallel design phase. 
For all patients, the median (25-75 percentiles) total ECG monitoring time 
from the start of study drug until the end of monitoring was 51 (46-54) hours. 
Total analyzable ECG monitoring time was 46 (39-50) hours and did not 
differ across treatment groups. The median ECG recording data loss was 
6 % (2-6). 
Table 3. Number and duration of ischemic episodes. 
Efegatran 0.105 Efegatran 032 Efegatran 0.63 Efegatran 0.84 Efegatran 1.2 Heparin All 
Patients 
Ischemic episodes* 
';?: 1 ST episode 
';?: 2 ST episodes 
';?: 3 ST episodes 
7 
5 
4 
2 
2 
11 
(71%) 
(57%) 
(29%) 
(29%) 
(6. 14) 
pts. with;::: 30 min. of ischemia'" 
Total duration I pt (min)*>1< 
Time to first episode (hrs)** 13.7(2.1. 22.1) 
* normalized to 24 hours of recording 
21 
17 (81%) 
10 (48%) 
7 (33%) 
7 (33%) 
11 (4. 16) 
9.2 (4.0. 37.5) 
*'" median, 25, 75 percentiles. patients with ischemia only 
Table 4. Bleeding events. 
115 18 
68 (59%) 10 (56%) 
53 (46%) 7 (39%) 
37 (32%) 5 (28%) 
31 (27%) 2 (11%) 
8 (3. 16) II (3. 13) 
9.1 (1.8.21.5) 9.0(2.9.20.6) 
Efegatran 0.105 Efegatran 0.32 Efegatran 0.63 Efegatran 0.84 
(n=10) (n=25) (n=122) (n=24) 
Major bleeding (total) (0.8%) 
hematoma at puncture site (0.8%) 
gastro-intestinal bleeding 
m. psoas bleeding 
Minor bleeding (total) 2 (20%) 8 (32%) 35 (29%) 4 (17%) 
hematoma at puncture site (10%) 5 (20%) 16 (13%) 2 (8%) 
other (10%) 3 (12%) 19 (16%) 2 (9%) 
124 120 405 
80 (65%) 77 (64%) 257 (64%) 
55 (44%) 55 (46%) 184 (45%) 
34 (27%) 34 (28%) 130 (32%) 
28 (23%) 39 (33%) 109 (27%) 
8 (3. 16) 12 (5.20) 10 (4. 17) 
10.9(2.3.20.4) 7.5(1.9.21.6) 9.2(2.2.21.3) 
Efegatran 1.2 Heparin All 
(n=128) (n=123) (n=432) 
2 (1.6%) 3 (0.69%) 
1 (0.2%) 
(0.8%) 1 (0.2%) 
(0.8%) 1 (0.2%) 
39 (31%) 13 (11%) 101 (23%) 
17 (13%) 4 (3%) 45 (10%) 
22 (18%) 9 (8%) 56 (13%) 
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Recurrent ischemic episodes were observed in 64% of all patients. 
Symptomatic episodes occurred in 14% of patients. The median number of 
episodes (25-75 percentiles) per patient (normalized to 24 hours) was 0.6 
(0-3.4) and the total duration of ischemic episodes per patient in those patients 
having ischemia was 10 (4-17) minutes (Table 3). Ischemia of? 30 minutes 
duration was present in 27% of all patients. There was no significant difference 
between the number of patients with recurrent ischemia or the number or 
duration of ischemic episodes among the treatment groups, although there 
was a trend towards less prolonged ischemia with the higher doses of efegatran 
compared to heparin (P~0.068). 
Figure 2 demonstrates Kaplan-Meier estimates of the probability to remain 
free of recurrent ischemia during the course of the monitoring period for the 
three largest groups. Overall, the median time to the first episode in patients 
with recurrent ischemia was 9.2 hours. The risk of a first, second or third 
recurrent ischemic episode was comparable among the tln'ee treatment groups. 
Therc was no evidence of a rebound of ischemia following cessation of 
efegatran nor heparin administration (data not shown). 
The relationship of ischemic episodes during treatment with subsequent 
death and myocardial infarction was explored but the number of these 
complications was too low for a meaningful assessment of such an association. 
Adverse events and bleedings 
Patients receiving efegatran often developed a superficial thrombophlebitis 
that seemed to increase, although not significantly, in severity in the higher 
dose groups, the incidence ranging from 7.7% to 20%, which was significantly 
higher than with heparin (P~O.OOO 1). For this reason the infusion rate in the 
highest dose group during the dose ranging phase was increased from 4 ml!hr 
to 40 ml/hr with a subsequent decrease in the concentration of efegatran 
administered. This regimen was also used for the subsequent phases of the 
study, and did reduce the severity of the events. However, it did not reduce 
the overall OCCUll'enCe of phlebitis. In the second phase of the study, the number 
of patients with phlebitis in the 0.63 mglkg/ln' dose group was 13%, compared 
to 25% in the 1.2 mg/kg/hr dose group and 2% in the patients treated with 
heparin. In the great majority of patients, the severity of the phlebitis was 
only mild. 
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Figure 2. Kaplan-Meier estimate of the probability to remain free of a ST episode during 
the course of the monitoring period. (A) Probability to remain free from a recurrent ST epi~ 
sode from the start of medication. ~, patients treated with cfcgatran 0.63 mg/kg/hr (I 15); 
- - -, patients treated with efegatran 1.2 mg/kg/hr (124); •••• , patients with treated with 
heparin (120). (B) Probability to remain free tl'om a second ST episode from the start of 
medication. (C) Probability to remain free from a third ST episode from the start of mcdica-
tion. 
The incidence of minor bleeding events was significantly higher in patients 
treated with efegatran (P=O.OO I) ranging from 17% to 32%, against I I % in 
patients under heparin (Table 4). There were three major bleedings, 2 of which 
occurred in patients treated with heparin. Spontaneous gross hematuria was 
equally distributed and observed in three patients (0.7%). Most minor bleedings 
were associated with a previous punchlre site, and did not require specific 
measures. There were no strokes associated with administration of trial 
medication. 
DISCUSSION 
In this multicenter single-blind dose finding study, the anti-thrombotic effects 
of the direct acting thrombin inhibitor efegatran sulfate were compared with 
heparin in patients with unstable angina. At similar levcls of anticoagulation, 
APTT levels were more stable for the tln'ombin inhibitor. However, no clinical 
advantages for cfcgatran were apparent, while mild or moderate bleeding 
and thrombophlebitis were more frequent. 
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Anticoagulant effects 
A dose dependent anticoagulant activity of efegatran was demonstrated, with 
the highest dose level of 1.2 mg/kg/hr resulting in a steady state APTT value 
of about 3 times bascline. Furthermore, administration of efegatran was 
associated with a pronounced increase in thrombin time, suggesting this test 
to be the most sensitive for measuring the level of thrombin inhibition by 
efegatran. Fibrinogen levels decreased in patients treated with efegatran. 
However, there were no demonstrable effects on the levels of coagulation 
activation markers nor on the concentration of thrombin-antithrombin 
complexes. 
The level of thrombin inhibition by efegatran appeared to be more stable 
than with heparin especially during the first hours following initiation of 
therapy, during which APTT guided dose adjustments were made in the heparin 
treated patients. Similar observations have been reported for other direct 
thrombin inhibitors9. 13 
The incidence of minor bleeding was higher in patients trcated with efegatran 
compared to patients treated with heparin. However, there was no excess in 
major bleeding for either dose of efegatran and there were no strokes associated 
with trial trcatment. These results are similar to other studies in patients with 
unstable angina receiving anti-tlll'ombin therapy, which rcported no, or only 
a modest increase in minor bleeding events compared to heparinI2.13.16. A 
higher incidence of bleeding events was reported using thrombin inhibitors 
in combination with thrombolytic agents 10. 1 1,14,15.17. This lead to interruption 
of three trials studying the effects of him din in patients with an acute myocardial 
infarction or acute coronary syndromes I4,15,17. Two of these (TIMI 9b and 
GUSTO lIb) were restarted at lower doses of hirudin, with APTT guided 
dosing regimensIO,II. In GUSTO lIb, 25% of patients received concomitant 
thrombolytic therapy. Compared to heparin, the administration of low dosc 
himdin appeared to be associated with an increased major bleeding rate (7.9% 
vs. 6,9%, P=0.03), with an excess of intracranial hemorrhages in patients 
without ST elevation, who had not received concomitant thrombolytic therapy 
(0.2% vs, 0.02%, P=0.06). In TIMI 9b, all patients received concomitant 
thrombolytic therapy, and similar bleeding rates were observed for hirudin 
and heparin treated patients. 
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Clinical outcome 
Neither dose of efegatran studied did suppress myocardial ischemia to a greater 
extent than that seen with heparin, and there were no differences in clinical 
outcome between the efegatran and heparin groups. The composite clinical 
endpoint (death, myocardial infarction, recurrent or refractoty ischemia or 
need for revascularization) was reached by 62% and 67% of the patients treated 
with efegatran, compared to 68% in patients on heparin. Of note was the 
high incidence of patients with a myocardial infarction at the time of enrollment 
(58 patients, 13.4%) and the subsequent low incidence after enrollment into 
the study (14 patients, 3.2%). This was due to the selection process since 
the majority of patients was enrolled directly after admission to hospital, without 
knowledge of possibly elevated CK and CK-MB enzyme levels. 
These data confirm the results of other studies on direct thrombin inhibitors, 
which reported only equivalent or slightly improved outcome compared to 
heparin, sometimes at cost ofa higher incidence ofblceding1o. 18. Of all studies 
with direct thrombin inhibitors, only the OASIS study reported superiority 
of hirudin over heparin in preventing both short (7 clays) and long term (180 
days) ischemic outcome in patients with unstable angina and patients with a 
myocardial infarction without ST segment elevation 16. As in our study, there 
was no significant increase of major bleedings, while the incidence of minor 
bleeding events was higher for hirudin compared with heparin. In the 
HELVETICA study, treatment with hirudin peri-PTCA was associated with 
fewer early cardiac events during the first month, without an increased risk 
of bleeding, but no apparent benefit was present at 7 months follow-up I8,19. 
A similar study of hirulog versus heparin showed a reduction in immediate 
(in-hospital) ischemic complications in a predefined group of patients with 
post-infarction angina only13. Again, this difference was no longer apparent 
after 6 months follow-up. 
In the TIM! 9B and GUSTO lIb study, the effects of hirudin in patients 
with an acute myocardial infarction or acute coronary syndrome were 
investigated 10,11. Clinical benefits were modest or absent, with only GUSTO 
nb showing a reduction of myocardial infarction or death within 24 and 48 
hours from the start of treatment and a borderline effect at 30 days follow 
up (P=0.06) at the cost of more major bleedings. In another study, hirulog 
appeared to be more effective than heparin in promoting early patency in 
patients with an acute myocardial infarction treated with streptokinase and 
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aspirin, without increasing the risk of major bleeding, However, no benefit 
on cardiac events could be demonstrated (HERO)12 Finally, studies with 
another tlll'ombin inhibitor, argatroban, have not shown any beneficial effect 
over heparin in patients with an acute myocardial infarction20, 
The high expectations of direct thrombin inhibitors have not bcen confirmed 
by clinical trials so far. Dosing regimens and duration of treatment of both 
heparin and anti-tln'ombins varied widely across these studies, making 
comparisons difficult. As only one study demonstrated a pcrsisting beneficial 
effect ofthese agents, it may be questioned whether the duration of treatment 
(24 hours to five days maximum) may have been too short for obtaining 
long term clinical bencfit. Rebound effects may also have influenced long 
term outcome, although such were not observed in the present study l6, The 
lack of clinical benefit may be relatcd to the mechanism of action direct anti-
thrombins, which have a greater ability to decrease thrombin activity (also 
clot-bound thrombin) than heparin, while the latter has a greater ability to 
decreasc thrombin generation, as it inhibits earlier steps in the coagulation 
cascade, which are not affected by direct thrombin inhibitors21 , Such combined 
inhibition of both thrombin generation and thrombin activity may in fact be 
advantageous, 
CONCLUSIONS 
We compared the effect of efegatran, a direct tln'ombin inhibitor with hcparin, 
Administration of efegatran sulphate at levels of at least O,63mg/kg/hour 
provided a pronounced increase in thrombin time, reflecting a level of tin' om bin 
inhibition which is at least comparable to APTT adjusted heparin infusion, 
The level of thrombin inhibition by efegatran, as reflected by the APTT, 
appeared to be more stable than with heparin, especially during the first few 
hours following initiation of therapy, This may reflect a more predictable 
dose response, suggesting that efegatran sulphate is probably easier to 
administer than heparin, 
As thrombin plays a key role in the coagulation cascade it was expected 
that the direct effects of efegatran would result in a more potent anticoagulant 
effect compared to heparin, which acts indirectly, requiring antithrombin III 
as a cofactor. However, no clinical benefit of efegatran over heparin was 
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apparent whereas minor bleeding was more frequent. Our findings are III 
concert with other studies investigating direct thrombin inhibitors. 
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Reduction of recurrent ischemia with 
abciximab during continuous ECG-ischemia 
monitoring in patients with unstable angina 
refractory to standard treatment 
(CAPTURE) 
P. Klootwijk, S. Meij, R. Melkert, T. Lenderink, 
M.L. Simoons 
Circulation: in press 
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ABSTRACT 
Backgl'Ol/l/d. In the CAPTURE trial, 1265 patients with refractory unstable 
angina were trcated with abciximab or placebo, in addition to standard treatmcnt 
from 16-24 hours preceding coronary intervention through I hour post 
intervention. In order to investigate the incidence of recllrrent ischemia and 
the ischemic burden, a subset of 332 patients (26%) undcrwent continuous 
vector-derived 12-lead ECG-ischemia monitoring. 
J\1ethods al/d results. Patients were monitored from start of treatment through 
6 hours post coronary intervention. Ischemic episodes were detected in 31 
(18%) of the 169 abciximab and in 37 (23%) of the 163 placebo patients 
(ns). Only 9 abciximab patients (5%) vs. 22 placebo patients (14%) had::> 2 
ST episodes (P<O.O 1). In patients with ischemia, abciximab significantly 
reduced total ischemic burden (P<O.02), which was calculated alternately 
as eithcr the total duration of ST episodes pCI' patient, or the area under the 
curve of the ST vector-magnitude during episodes or the sum of the areas 
under the curves of 12 leads during episodes. 
Twenty one patients (6%) suffered a myocardial infarction (18) or died 
(3) within 5 days oftrcatment. Thc presence of asymptomatic and symptomatic 
ST episodes during the monitoring period preceding coronary intervention 
was associated with an increased relative risk of these events of 3.2 (95% 
CI 1,4,7,4) and 4.1 (95% CI 1,4, 12.2) respectively. 
COl/elusions. ReculTent ischemia predicts myocardial infarction or death within 
5 day follow-up. Treatment with abciximab is associated with a reduction 
of frequent ischemia and a reduction of total ischemic burden in patients 
with refractory unstable angina. As such, patients with ischemia derive 
particularly high benefit from abciximab. 
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INTRODUCTION 
Computer-assisted continuous ST monitoring is a practical noninvasive tool 
for detection and quantitation of myocardial ischemia and recognition of 
myocardial infarction in patients with unstable coronary syndromes'-4 From 
a recent study using computer-assisted continuous ST monitoring in patients 
with unstable angina, it appeared that up to 60% of patients exhibit at least 
one episode of ischemia within the first 24 hours of admission, with only 
23% of patients remaining free ofST episodes during an ST monitoring period 
of 48 hOUIA• In unstable angina patients, myocardial ischemia may develop 
as thc result of platelet aggregation and intracoronary thrombosis at the site 
of plaque fissuring or rupture5,6 Recurrent ischemia detected during computer-
assisted continuous ST monitoring may thus specifically rcflect episodes of 
platelet aggregation in these patients. 
Abciximab, an inhibitor of the platclet glycoprotein lIb-IlIa receptor, has 
been shown to reduce the rate of complications associatcd with concurrent 
percutaneous transluminal coronary angioplasty (PTCA) as well as during 
follow-up in patients with clinical or angiographic fcatures indicating increased 
procedural risk7-9 . In the CAPTURE study (c7E3 Fab Anti Platelet Therapy 
in Unstable REfractory angina), which was designed to asscss the value of 
treatment with abciximab in patients with refractOlY unstable angina during 
18-24 hours preceding PTCA, a major reduction of death, myocardial infarction 
or urgent intervention within 30 days after emollment was obtaincd from 
15.9% in the placebo group to 11.3% in patients receiving abciximab lO• 
ECG-ischemia monitoring was conducted as a substudy within CAPTURE. 
The primary objective of this subshldy was to investigate the effects of 
abciximab compared to placebo on the incidence and severity of recurrent 
ischemia during continuous vector-derived l2-lead ECG monitoring in patients 
with unstable angina refractory to standard drug-treatment, scheduled for PTCA 
within 24 hours. These effects were studied both before, during and up to 6 
hours post PTCA. A secondary objective was to asscss the relationship of 
recurrent ischemia during continuous vector-derived l2-lead ECG monitoring 
with the clinical events as defined in the main CAPTURE Shldy. 
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METHODS 
Study organization and patient selection 
This ECG-ischemia monitoring study was conducted as a substudy of 
CAPTURE. Patients were rccl1lited by 13 hospitals, which had the availability 
ofECG monitoring equipment, out of69 hospitals pmticipating in CAPTURE. 
All patients underwent continuous ECG monitoring using a vector-derived 
12-lead ECG recording system (MIDA 1000, Ortivus Medical, Tiiby, Sweden), 
as described below. 
For an extensive description of the CAPTURE study design, patient selection 
and inclusion and exclusion criteria we refer to the recently reported CAPTURE 
main trial lO. In brief, patients were eligible for the CAPTURE study if they 
had refractOlY unstable angina defined as: chest pain at rest with concomitant 
ECG abnormalities compatible with myocardial ischemia (ST segment 
depression, ST segment elevation or abnormal T waves) and one or more 
episodes of either typical chest pain and/or ECG abnormalities compatible 
with myocardial ischemia during therapy with heparin i.v. and nitroglycerin, 
started at least 2 hours previously. The most recent episode of ischemia should 
have occurred within 48 hours preceding enrollment, corresponding to 
Braunwald class III "acute" unstable angina 11,12. All patients had undergone 
coronary angiography and had significant coronary artery disease with a culprit 
lesion suitable for PTCA. Patients were enrolled within 24 hours following 
diagnostic angiography. Before el1l'ollment, all patients gave informed consent. 
The exclusion criteria applied for the CAPTURE main trial also applied 
for the present ECG-ischemia monitoring substudy. For the latter, patients 
with ECG abnormalities such as left bundle branch block, left ventricular 
hypertrophy or an artificial pacemaker device, making ST segment interpreta-
tion unreliable, were also excluded. 
After el1l'ollment, patients received a minimal daily dose of 50 mg aspirin. 
In patients not yet on aspirin, the first dose was a minimum of250 mg. Heparin 
was administered prior to randomization until at least I hour after PTCA 
and adjusted to an APTT between 2.0 and 2.5 times normal. All patients 
received nitroglycerin Lv .. Beta-blockers, calcium chalmel blockers and other 
cardiovascular drugs were allowed (Table I). In addition patients received 
an abciximab 0.25 mg/kg bolus followed by a continuous infusion of 
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Table 1. Baseline data and concomitant medication. 
ECG-ischemia monitoring .i\'laiu study patients 
substudy not included in 
substudy 
Placebo Abciximab All 
(n~163) (n~169) (n~933) 
Male III (68.1%) 107 (63.3%) 702 (75.2%) 
Mean (SD) age in years 62 (10) 60 (10) 61 (10) 
Anthropometry: mean (SD) 
Weight (kg, SD) 77 ( 13) 77 (13) 75 (12) 
Height (CIll, SD) 172 (10) 171 ( 9) 169 ( 9) 
Number of patients with 
Angina> 7 days previously 90 (56.3%) 89 (54.6%) 443 (48.2%) 
Infarction within previous 
7 days 16 (9.8%) 19 (11.2%) 131 (14.0%) 
Infarction 8-30 days 6 (3.7%) 9 (5.3%) 81 (8.7%) 
Inf.1rction> 30 days previously 33 (20.2%) 33 (19.5%) 153 (16.4%) 
PTCA 24 (14.7%) 25 (14.8%) 121 (13.0%) 
CABG 8 (4.9%) 3 (1.8%) 21 (2.3%) 
Risk factors 
Diabetes 17 (10.5%) 19 (11.2%) 141 (15.1%) 
Hypertension 58 (35.8%) 65 (38.9%) 409 (44.2%) 
Current smokers 71 (44.4%) 66 (39.1%) 353 (38.3%) 
Medication within 7 days 
before enrollment 
Aspirin 143 (89.4%) 149 (90.3%) 865 (94.2%) 
Intravenolls heparin 162 (99.4%) 169 (100%) 930 (99.7%) 
Nitrates 163 (100%) 169 (100%) 930 (99.9%) 
B-blockers 116 (72.5%) 125 (75.8%) 583 (63.5%) 
Calcium antagonists 86 (53.8%) 82 (49.7%) 445 (48.5%) 
iHedicatioll after enrollment 
Aspirin 158 (96.9%) 164 (97.0%) 890 (96.2%) 
Ticlopidin 4 (2.5%) 3 ( 1.8%) 43 (4.6%) 
Intravenous heparin 158 (100%) 160 (100%) 909 (100%) 
Nitrates 160 (98.2%) 166 (98.2%) 903 (97.6%) 
B-blockers I 18 (72.4%) 122 (72.2%) 567 (61.3%) 
Calcium antagonists 84 (51.5%) 86 (50.9%) 438 (47.4%) 
Percentages \vere calculated only for those patients for whom data were reported. 
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10 mg/min or matching placebo for 18-24 hours preceding PTCA and 
continuing for one hour after completion of the procedure. 
During the hospital stay and 30 day follow-up, all events and medication 
were recorded, with special attention to recurrent ischemic symptoms. 
Study endpoints 
The incidence and severity of recurrent ischemia were described in different 
parameters: the number of patients with recurrent ischemia, the number of 
ischemic episodes in patients with recurrent ischemia and total ischemic burden 
across the placebo and abciximab patient groups. 
As in the main study, myocardial infarction during the index hospitalization 
was defined by CK-MB or CK levels exceeding 3 times the upper limit of 
normal in 2 samples and increased by 50% over the previous value, or an 
ECG with new significant Q waves in two or more contiguous leads. 
Myocardial infarction following discharge was defined by CK-MB or CK 
levels exceeding 2 times the uppcr limit of normal, or new significant Q 
waves in two or more contiguous ECG leads. 
Continuous ST segment monitoring 
Continuous ECG monitoring was started preferably before, but not later than 
I hour after enrollment. It was continued for at least 24-36 hours, including 
6 hours following the PTCA procedure. The timing of the start of drug infusion 
and the moments of angiography and PTCA were obtained from the study 
case record forms. 
Continuous ECG monitoring was performed using the MTDA 1000 vector-
cardiographic ECG monitoring device (Ortivus Medical, Taby, Swedcn). This 
system calculates averaged QRS-T complexes from the Frank orthogonal 
x-Y -Z leads at I-minute intervals. These averaged complexes are stored on 
the hard disk and used for calculation ofST trend information. After completion 
of the monitoring period, the averaged ECG data were stored on a floppy 
diskette and sent to the core laboratory at Cardia lysis in Rotterdam, The 
Netherlands, for subsequent editing and analysis4.7. 
Editing and analysis of ECG data 
All averaged X-Y-Z complexes were manually scanned and edited for artifacts, 
intermittent bundle branch block, detection or marker errors and poshlral 
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changes. Postural changes were defincd as a sudden change of the electrical 
axis or a sudden QRS amplitude shift. After editing, averaged 12-lead ECG 
complexes and 12-lead ECG trends were generated from the MIDA X -Y-Z 
leads, using the transformation formulas ofDowerl3 . Trends of the ST segment 
level measured at J-point + 60 mseconds were generated for each single lead 
of this derived 12-lead ECG, except aVR. 
Definition of ST episodes 
The onset of an ST episode was defined as a change of ST amplitude of at 
least ± 100 flY from the baseline ST level in one or more of the 12 derived 
leads, developing within a 10 minute period and persisting during at least 
I minute. The end of an episode was defined as a return of the ST level 
within ± 100 flY of the baseline ST level, again lasting for at least one minute. 
Episodes had to be separated from each other by at least one minute. 
If~ 100 flV ST change was present in more than one lead simultaneously, 
the episode onset was defined by the lead exhibiting the first ~ 100 fI V ST 
change. Similarly, the end of an episode was defined by the lead exhibiting 
the latest return to baseline ST level. If chest pain was present during or 
within 15 minutes before or after a ST episode, this ST episode was classified 
as symptomatic. An example ofthe ST trend analysis and representative ECG 
recordings is presented in Figures I and 2. An algorithm progrannned according 
to these ST criteria for ischemia, was used for detection of ST episodes, with 
visual confirmation afterwards. The ECG at moments of interest, either detected 
by the algorithm or by the operator, was documented on hard copy for visual 
inspection (Figure 2). An extensive report on the method of editing and analysis 
of ECG data developed and used by our core laboratory has been published 
recently4. 
Ischemic burden 
Ischemic burden was calculated in four different ways: (I) the sum of the 
duration of all episodes per patient; (2) the smn of the area under the curve 
of the ST vector magnitude trend of all episodes per patient (Figure 3); (3) 
the sum of the area under the ST trend curve of all leads involved in the ST 
episodes per patient; (4) the sum of the area under the ST trend curve of all 
12 leads during ST episodes per patient (except a VR). 
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Figure 1. Example of the vector derived 12Mlead S1' analysis of a study patient with unstable 
angina who suffered from a myocardial infarction as a complication of a PTCA procedure. 
The S1' trends of the relevant leads in which S1' episodes OCClUTCd and in which the myocardial 
infarction developed are displayed. The black bars in each single lead ST trend represent the 
time during which the algorithm detected a;:::': 100 gV ST change. Note that the number and 
duration of S1' episodes differs across leads. At the bottom of the trend graphs, the black 
bars indicate the total duration and number of the ST episodes (ischemia), taking into account 
all leads involved. Before PTCA, 3 ischemic episodes occur around 17:30 Ins. and 18:00 
Ius. During angiography and PTCA, possibly at the moment of first injection of contrast, a 
sudden severe ST elevation develops in leads II and III with simultaneous ST depression in 
lead VS. Subsequently, this ischemic event partially resolves, followed by 2 short peaks of 
ST elevation I depression, which reflect the inflations of the balloon catheter. Following the 
PTCA procedure, a persistent elevation of the ST segment is observed with depression in 
lead VS, suggesting a persistent occlusion leading to acute myocardial infarction. Myocardial 
infarction in this patient was confirmed by a rise of CK and CK-MB to 4 and 3 times the 
upper limit of normal, respectively, and the development of Q waves. See also Figure 2. 
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Figure 2. Samples of the computer-assisted 12-lead ECG recording of the patient in 
Figure I. ( A) Ischemic episode before PTCA, detected by the algorithm. The upper ECG 
row (17:26 hrs) demonstrates the baseline "non-ischemic" 12-lcad EeG (except aVR). The 
ECG rows directly below demonstrate the time (17:34 1m) and ECG lead (indicated in bold) 
in which the ST episode occurred. ST changes are present in multiple leads, but the first ST 
change is detected in lead II. However, the maximum and ending of the episode arc detected 
in lead III (17:46 1m). (B) ECG sample during PTCA. Note the severe ST elevations in the 
inferior leads with simultaneous ST depressions in leads V3 to V6. (C) Following PTCA, 
ST elevations persist in the same area as during the procedure, suggesting an acute myocardial 
infarction. As the ST measurements during the PTCA procedure were not included in the 
analysis, the algorithm used the last ECG template before PTCA as the reference "non-ischemic" 
ECG (18:59 hI'S). As such, the "onset" of ischemia is again detected directly after the procedure 
(20:01 hrs). 
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Figure 3. Measurement of the ischemic burden. For simplification) only a magnification of 
the ST trend of a single lead is displayed. Three 8T episodes::::: I 00 ~l V are detected between 
07: 10 and 7:50 hrs. The ST elevations around 08:00 hrs and 08:50 hrs do not reach the threshold 
of 100 ~lV and are not classified as ST episodes. The area under the trcl1dcurvc of the episodes 
is measured from the baseline ST level which is present at the moment of the beginning of 
the episode. These ST measurements are repeated for all 12 leads except aVR. Subsequently 
these values are summated, thus reflecting the total area under the curve for all leads involvcd. 
The same procedure is followcd for the ST vector magnitude, but in this case the onsct and 
ending of episodes remain defined by the ST onset and ending measurements taken from the 
vectorMderivcd 12Mlead EeG. 
Statistical analysis 
Continuous variables arc expressed as median and interquartile range (25th 
and 75th percentiles) and compared using the Mann-Whitney test. Discrete 
variables are described with percentages and were compared using Fisher's 
exact test. A two-tailcd Pvalue 0[:0; 0.05 was considered statistically significant. 
The Kaplan-Meier method was used for the evaluation of the time to a recurrent 
ST episode and of the time to the next ST episode, with censoring of data. 
Statistical difference was tested with the log rank test. Relative risks are given 
as univariate variables with 95% confidence intervals. 
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RESULTS 
In the CAPTURE study, a total of 1265 patients were included at 69 sites in 
12 countries 10. Three-hundred and ninety-four patients were also enrolled in 
the ECG-ischemia monitoring substudy. Of these 394 patients, 62 (16%) were 
excluded from ECG analysis: 38 patients because of a late start of the ECG 
monitoring (later than I hour after the start of drug-infusion or less than 50% 
analyzable ECG data), 22 patients because of technical failures due to errors 
on part of the investigator and 2 patients because of a time mismatch of 
monitoring data and the case record form. Thus, 332 patients (84%) had ECG 
recordings suitable for final analysis. Most patients (67%) experienced their 
ischemic episode qualifying for study entry within 12 hours before thc start 
of the study-drug, with 39% patients having their qualifying episode within 
6 hours before enrollment. The majority of patients (193, 58%) had either 
ST depression, clevation or both of at least 0.1 mV on their 12-lead ECG 
during the ischemic event which qualified them for inclusion into the study. 
Seventy-five patients (23%) had T wave changes only and in 64 patients 
(19%) the entry ECG did not exhibit any ischemic abnormality, although 
ST segment changes had been recorded during previous ischemic episodes. 
CAPTURE main study versus ECG-ischemia monitoring substudy 
Of the 332 patients suitable for ST analysis, 163 patients received placebo 
and 169 patients abciximab. Baseline data were well balanced among the 
two treatment groups and representative of the baseline data of the CAPTURE 
main study (Table I). Death or myocardial infarction within 5 days occurred 
in 17 (10.4%) of the placebo patients and in 4 (2.4%) of the abciximab patients 
in the ECG-ischcmia monitoring patient group (P=0.006), versus 40 (9.2%) 
and 23 (5.3%) of the patients receiving abciximab or placebo who were not 
included in the ECG-ischemia monitoring substudy (P=0.04). 
ECG-ischcmia monitoring sllbstlldy 
The duration of the ECG monitoring periods before and after the PTCA 
procedure did not differ among the treatment groups (Table 2). 
Recurrent ischemia was detected in 31 (18%) of the 169 abciximab and in 
37 (23%) of the 163 placebo patients. This difference was not statistically 
significant (P=0.34, Figure 4A). Yet, repetitive ischemia and total ischemic 
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Table 2. Duration of ST monitoring periods. 
placebo abdximab all patients 
Patients 163 169 332 
total monitoring time (hrs)* 28 (26, 29) 27 (26, 29) 28 (26, 29) 
duration of slay at cath-Iab (hrs)* 1.3 (1.0, I. 7) 1.3 (1.0, 1.7) 1.3 (1.0, 1.7) 
total analyzable monitoring time (hrs)* 27 (24,28) 26 (25, 28) 26 (25, 28) 
start study - > PTCA (hrs)* 20 (18,21) 19 (18,21) 20 (18,21) 
end PTCA - > end monitoring (hrs)* 6 (6,7) 6 (6,7) 6 (6,7) 
RCG data loss (%)* 2 (1,7) 2 (I, 5) 2 (1,6) 
* median (25, 75 percentiles) 
burden were significantly decreased in patients receiving abciximab, both 
for the period preceding the PTCA procedure and the complete monitoring 
period (Table 3). Excluding the time period of the PTCA and the stay at the 
catheterization laboratory, only 9 abciximab patients (5%) versus 22 placebo 
patients (14%) had 2 or more ST episodes (p~0.01) and only 5 abciximab 
(3%) versus 15 placebo patients (9%) had 3 or more ST episodes (P~0.02). 
Symptomatic episodes occurred in 5 abciximab (3%) and in 13 (8%) placebo 
patients (P~0.05). These treatment effects were also apparent in the subgroup 
of 136 patients who exhibited ST depression of 2: 0, I m V on their 12-lead 
ECG during the ischemic event which qualified them for entry into the study. 
The latter patients had more ischemic episodes than patients without ST 
depression at study entry (P~0,055). In tIus subgroup, only I abciximab patient 
(2%) versus 9 placebo patients (12%) had 3 or more ST episodes (P~0.02). 
Total ischemic burden parameters as defined by either the duration of ischenua 
per patient or the SUlll of the area under the curve of the ST vector magnitude 
during ST episodes, the SUlll of the area under the ST trend curve of all leads 
involved or the sum of the area under the curve of all 12 leads during ST 
episodes were reduced in favor of abciximab (Table 3), Thus, patients receiving 
abciximab had significantly less frequent and fewer severe ischenuc episodes. 
Both the probabilities to remain free from a second ischemic episode after 
the start of monitoring and to remain free from a second ischemic episode 
after the first one were significantly higher for abciximab (P~O.O I and 0.02, 
respectively, Figure 4B and 4C). 
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Table 3. ST monitoring results. 
period from start of study until balloon period following balloon angioplasty total monitoring period 
angioplasty 
placebo % abciximab % P value placebo % abciximab % P value placebo % abciximab % P value 
Patients 163 169 155 162 163 169 
ST episodes 
> 1 29 18 24 14 n.s. 16 10 9 6 n.s. 37 23 31 18 n.s. 
~2 18 11 9 5 0.07 15 10 8 5 D.S. 22 14 9 5 0.01 
>3 12 7 3 0.02 2 0 0 D.S. 15 9 5 3 0.02 
symptomatic episodes 9 6 4 2 n.s. 6 4 0.06 13 8 5 3 0.05 
Ischemic burden * 
total duration / pt (min) 12 6 n.s. 61 9 0.10 38 S 0.02 
ST VM (mY.min) 1293 677 n.s. 7084 796 0.06 4819 796 0.01 
12-1ead ST area (mY.min) 8832 4682 D.S. 45599 3876 0.10 29392 5376 0.01 
ST arca of leads :::::100 mY 2394 1383 D.S. 27026 1858 n.s. 8558 1858 0.03 
(mY.min) 
The number of ST episodes was compared using Fisher's exact test. Ischemic burden variables are given as medians and were compared using the Mann-
Vihitncy test. A two-tailed P value ofs 0.05 was considered statistically significant. Borderline significant P valucs:5 0.10 arc also indicatcd. 
'" patients with ischemia only. Total duration=the sum of the duration of all episodes per patient; ST VM=the sum of the area under the curve of the ST 
vcctor magnitude trend of all ST episodcs per patient: 12-1cad ST area=the sum of the area under the ST trend curve of all 12 leads during ST episodes per 
patient (except a VR); ST arca of leads;:: 100 m V=the sum of thc area undcr the ST trcnd curve of all leads involved in the ST episodcs per patient (except 
aVR). 
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Figure 4. Kaplan~Meier estimate of the probability to remain free of a ST episode during 
the course of the monitoring period. (A) Probability to remain free from a reCUlTcnt ST episode 
from the start of medication. - = patients treated with placebo (l63); - - - = the patients 
treated with abciximab (169), (B) Probability to remain free from a second ST episode from 
the start of medication. (C) Probability to remain free from a second ST episode after the 
first one has ended. - = patients with at least one ST episode treated with placebo (37); 
- - - ~ patients with at least one ST episode treated with abciximab (31). Both the probability 
to remain free from a second ischemic episode after the start of medication and the probability 
to remain free from a second ischemic episode after the tlrst onc appear significantly bettcr 
for abciximab. 
The majority of clinical events occurred during and within 24 hours following 
PTCA. Eighteen patients suffered from a myocardial infarction and three 
died within 5 days of treatment. Eventually, twenty-four patients developed 
a myocardial infarction or died within 30 days of follow-up (7.2%). The 
presence of chest pain without concomitant ST episodes during the monitoring 
period preceding the PTCA procedure was not related to an increased relative 
risk of subsequent events. However, the presence of any ST episode and 
especially of any symptomatic ST episode was associated with an increased 
relative risk of 3.2 (95% confidence interval lA, 7A; absolute risk 15%) 
and 4.1 (95% confidence intervals lA, 12.2; absolute risk 23%), respectively. 
This association also remained apparent for the occurrence of myocardial 
infarction or death within 30 days. 
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DISCUSSION 
In the CAPTURE study, treatment with abciximab (c7E3 Fab, ReoPro) rcsulted 
in a 50% rcduction of myocardial infarction and 29% reduction in the primary 
composite endpoint of death, myocardial infarction or urgent (re-)intclvcntion 
in patients with refractory unstable angina 10. The results of the present ECG-
ischemia monitoring sub study including 332 out of the 1264 patients of 
CAPTURE are consistent with these fIndings. Compared to placebo, treatment 
with abciximab resulted in a reduction of frequent ischemia and symptomatic 
ischemic episodes during continuous ECG-ischemia monitoring, and in a major 
reduction of ischemic burden in patients with ischcmia. This extends the 
obscrvation in CAPTURE that treatment with abciximab reduced the 
occurrence of myocardial infarction during the 16 to 24 hours period of 
treatment bcfore PTCA was performed. It is likely that the reduction of 
recurrent ischemia reflected stabilization of the plaque, resolution of thrombus 
and prevention of recurrent thrombosis by abciximab, which lead to the 
reduction of clinical events. This is supported by the observation that the 
presence of recurrent ischemia during the ST monitoring period before PTCA 
appeared strongly predictive of myocardial infarction and death within the 
next 5 days, which is in concordance with previous studies using Holtcr ST 
monitoring, demonstrating that ischemic ST episodcs relate to clinical outcome 
in patients with unstable angina 14-17. 
Our study demonstrates that ischemia, detected during veetor-derivcd 
multi lead ECG-ischemia monitoring, can be used as a study cndpoint in patients 
with unstable coronary syndromes. Thc prcvalence of ischemia using Holter 
ST monitoring or continuous ECG-ischemia monitoring techniques in paticnts 
with unstablc angina has been reported as 50_70%4.14-17. This is in contrast 
to the lower percentage of patients (21 %) exhibiting ischemia in the present 
study. It may be explained by the intensive therapy of these patients bcfore 
enrollment in CAPTURE, which included aspirin, heparin, nitroglycerin and 
P blockers in most patients. It suggests that a part of these patients may already 
have been stabilized by this intensive therapy. 
In patients without recurrent ischemia, as in patients without elevated 
troponin T levels 18-20, the risk of myocardial infarction and death is low, 
particularly whcn trcated with a glycoprotein IIb-IlIa receptor blocker. Thus 
it may be questioned whether early PTCA is necessary. In patients who appear 
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to have stabilized on medical therapy (e.g. abciximab), a PTCA procedure 
could possibly be deferred to a later moment in order to allow further 
stabilization of the unstable plaque. On the other hand, patients with recurrent 
ischemia during ECG-monitoring (as well as patients with elevated troponin 
T levels) exhibited a higher risk of myocardial infarction or death20 This 
suggests that those patients who remain nnstable will benefit from immediate 
or urgent invasive therapy and may benefit from treatment with abciximab 
both before and during PTCA. If urgent intervention is not possible, these 
patients should be stabilized with a platelet glycoprotein lIb / IlIa receptor 
blocker. 
CONCLUSIONS 
The present ECG-ischemia monitoring study, which was conducted as a 
substudy of CAPTURE 10, demonstrates that treatment with abciximab, 
compared to placebo, is associated with a reduction of frequent ischemia 
and a reduction of total ischemic burden in patients with refractory unstable 
angina both before PTCA (thus stabilizing patients) and post PTCA. The 
incidence of recurrent ischemia appeared lower than observed in patients with 
unstable angina studied shortly after hospital admission4,14-17. Thus, most 
patients tend to stabilize over time, particularly when treated with abciximab. 
The presence of recurrent ischemia predicts myocardial infarction or death 
both within 5 days and at 30 days follow-up. As such, continuous vector-
derived 12-lcad ECG monitoring appears to be a useful noninvasive tool for 
further risk stratification and selection of high risk unstable patients who 
may require invasive intervention and / or platelet glycoprotein Ilb / IlIa 
receptor blocker therapy. 
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APPENDIX 
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J Col (Belgium); A Adelman (Canada); C Macaya (Spain); H Miller (Israel); MJ de Boer (The 
Netherlands); R McCloskey and H \Veisman (Cenfocor, U.S.A.). Clinical Endpoint Committee: 
The Netherlands: F Bar (Chairman) Maastricht; J\V Deckers, Rotterdam; 11 Pick, Amsterdam; 
APJ Klootwijk, Rotterdam; V l\'Ianger Cats, Leiden; \V Bmggelillg, Oosterhout; F Jonkman, 
Rotterdam; P van der Meer, Rotterdam; V Umans, Alkmaar; D Foley, Rotterdam; T Ansink, 
Rotterdam; D Keane, Rotterdam; 0 Sane, Rotterdam (thrombocytopenia review); P Koudstaal, 
Rotterdam (stroke review, Rotterdam); Belgium: P Block, Bmssels. Angiography Committee: 
MJBi'vl van den Brand (Chainnan, 111e Netherlands), GJ Laannan (The Netherlands), G Hendtickx, 
I de Scheerder (Belgium), PG Steg (Paris), K Beat (United Kingdom). Coordillatillg Cellter: 
M Hoynck van Papcndrecht, M Daniels, T Poulussen, J de Graaf(Centocor, The Netherlands); 
T Lel1derink (Cardialysis, The Netherlands); T de Craen (Academic Medical Center, Amsterdam, 
The Netherlands); S Cabacowic (Euro-Biophanll, The Netherlands);); T Schaible, K Anderson, 
A \\fang, S FitzPatrick (Centoeor, U.S.A.); S Malbrain, J Paul, 1'\'1 Dijkhuizen, K Verhamme, 
I Nelissen (Besselaar, Belgium), M Gibbs (Besselaar, United Kingdom), S Marron (Besselaar, 
Ireland), S Loehu, C Guiot (Besselaar France); P Fen11ri, A Vizzotto (Besselaar, Italy); A AU:many, 
E Mahillo (Besselaar, Spain); S Hoffmann (Besselaar, Gennany); L Stahl (Besselaar, Sweden); 
D Kafka (13esselaar, Israel). 
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ischemia monitoring substudy 
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Liem, G Velsillk; Gnze Licvc Vrouwe Gasthuis, Amsterdam: GJ Laal'11Iun, R wm del' Wieken, 
JP Ezeclliels, S ZOllllel'eld; Thoraxcentrum Erasmus Universiteit en Academisch Ziekenhuis 
Rotterdam-Dijkzigt: i\lL Simoolls, 1\1 vall den Brand, C vall der Zwaan, PP Kill!; Catharina 
Ziekenhuis, Eindhoven: RM Michels, P Vall der Voorl, I v.d. Kerkhof, C Hallekamp; Acadcmisch 
Ziekcnhuis Groningen: J Peels, L Drok, P dell HeUer; St. Antonius Ziekenhuis, Nieuwegein: 
T Plokker, EG 111asl, K Afarqllez. 
France: I-I6pitai Tenon, Paris: A Valumiall, E Garbarz, 0 Nallet, B Farrah; H6pitai Bichat, 
Paris: JJM Juliard, PG Sfeg. 
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Germany: UniversiUitsklinikum Rudolf VirchO\v, Berlin-Buch: D. Gulba, R. Dechend, S 
Christow; UnivcrsWitsklinikul11 Charih~b, Berlin: TV Rutsch, C Brllnck/lOrst; Klinikul11 der 
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With the ongoing development of new reperfusion regimens, new anti-
coagulants and anti-platelet agents as well as intracoronary intervention, the 
monitoring of the perfusion status of the myocardium in patients with acute 
coronary syndromes (unstable angina and myocardial infarction) is becoming 
increasingly important. The easiest noninvasive method for monitoring the 
perfusion status of the myocardium is recording of the ST segment of the 
electrocardiogram. Computer-assisted continuous real-time vectorcardiographic 
or multilead ECG-ischemia monitoring teclmiques are nowadays available 
and have outgrown the limitations of earlier ECG technologies as they can 
record and display the complete l2-lead ECG or vector lead ECG on-line 
and store the data for retrospective analysis (full disclosure). 
In this thesis the application of computer-assisted continuous vectorcardio-
graphic and multilead ECG monitoring techniques for detection and 
quantitation of myocardial ischemia, prediction of coronary vessel status and 
for identification of patients at risk of major coronmy events is evaluated. 
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CONTINUOUS ECG-ISCHEMIA MONITORING IN PATIENTS WITH 
AN ACUTE MYOCARDIAL INFARCTION RECEIVING REPER-
FUSION THERAPY (GUSTO-I ECG-ISCHEMIA MONITORING 
SUBSTUDY). 
In chapters 2, 3 and 4, the results of the GUSTO-I ECG-ischemia monitoring 
substudy are rcported (GUSTO ~ Global Utilization ofStreptokinasc and Tissue 
plasminogen activator for Occluded coronmy arteries). One thousand and sixty 
four patients underwent continuous ST segment monitoring, using vector-derived 
12-lead (406 patients), 12-lead (373 patients) and 3-lead Holter (288 patients) 
ECG recording systcms. Chapter 2 evaluates these three different monitoring 
techniqucs for on-line prediction of the pcrfusion status of the infarct-related 
vessel in 302 GUSTO-I patients who underwent angiography at either 90 or 
180 minutes after the start of thrombolysis. This study demonstrates that 
noninvasive patency prediction using continuous ECG recording techniques 
is feasible and can be used in clinical practice, particularly in patients with 
cxtensive initial ST segment elevation. Prediction of vessel status appcared 
79-100% accurate in the subgroup of patients with initially high ST levels, 
which is the group of patients having the greatest risk of adverse cardiac events 
and benefiting most from rcperfusion therapy. Although the three recording 
systems differed considerably in signal processing, no significant difference 
in accuracy was demonstrated among these systems. Thc study demonstrates 
that tailoring of therapeutic strategies guided by computer-assisted continuous 
ECG monitoring teclmiques is feasiblc in patients with acute myocardial 
infarction. 
In Chapter 3, the speed and stability of ST segment recovery is compared 
among the 4 different thrombolytic strategies for acute myocardial infarction 
studied in GUSTO-II. It was expected that patients treated with accelerated 
rt-PA would exhibit a faster ST recovery than patients receiving the other 
regimens, and that those treated with streptokinase would show greater stability 
of recovery. Although the angiographic substudy of GUSTO-I indccd 
demonstrated a greater 90 minutes patency with accelerated r-tPA2, we were 
not able to correlate this finding with a shorter time to 50% ST segment 
rccovery, mainly because of technical limitations and the use ofthree different 
ECG monitoring teclmiques. Recurrent ST segmcnt shift (mainly ST elevation), 
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suggestive of reocclusion of the infarct-related vessel was present in 
approximately 36% of patients. 
As a consequence, chapter 4 addresses the question whether those patients 
with recurrent ST segment shift after an initial ST recovery suggestive of 
successful reperfusion exhibit a higher mortality compared to those patients 
without. Indeed, both 30 days and I year mortality in patients with recurrent 
ST segment shift is higher than in patients without such ST segment shift. 
The presence of either recurrent ST elevation or ST depression 6-24 hours 
after the initial 50% ST recovery following thrombolytic treatment was an 
independent prognostic predictor of mortality at 30 days, even after adjustment 
for multiple clinical risk factors derived from the overall GUSTO-I mortality 
modeP. The duration of the ST segment shift appeared directly related to 
subsequent mortality. Thus, continuous ECG-ischemia monitoring is useful 
not only for selection of high risk non-reperfused patients, but also for selection 
of high risk patients who reperfused but subsequently exhibit recurrences of 
ischemia and / or reocclusion. 
ECG-ISCHEMIA MONITORING IN PATIENTS WITH UNSTABLE 
ANGINA 
ECG-ischemia monitoring in patients with unstable angina is more complex 
than in patients with evolving myocardial infarction. The latter most commonly 
have ischemic ST shifts (ST elevation) at the start of ST monitoring and 
normalization of the ST segment after ST recovery. In contrast, patients with 
unstable angina may exhibit very different patterns. Ischemia may be reflected 
by both ST elevation, ST depression and T wave changes, making automated 
analysis using computer algorithms difficult. Some patients have abnormal 
non-ischemic ECGs with ST shift and T wave inversions at baseline and 
pseudo-normalization during ischemia. Thus, when monitoring patients with 
unstable angina, a baseline ST level (without ischemia) should be defined 
first, which requires the selection of a reference (non-ischemic) ECG. ST 
monitoring of the single lead with the greatest initial ST shift is sufficient in 
many patients with myocardial infarction, but may not be appropriate in patients 
with unstable angina, as ischemia may shift from one lead to another (see 
below). 
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IMPACT OF THE NUMBER OF LEADS AND LEAD SELECTION FOR 
DETECTION AND QUANTITATION OF ISCHEMIA IN PATIENTS 
WITH UNSTABLE ANGINA 
In chapters 2-4, we demonstrated that computer-assisted continuous ECG 
monitoring in patients with an acute myocardial infarction is of clinical value 
for prediction of vessel status and for identification of high risk patients. 
For monitoring and patency assessment we had selected the ECG lead with 
the greatest ST shift at the onset of monitoring as it was assumed that tllis 
lead would optimally reflect the area which was injured by the occlusion of 
the culprit coronary vessel. In contrast, in patients with unstable angina the 
site of the ischemic area may vmy, depending on the flow balance of the 
coronary system, the degree of vessel injury and the duration and severity 
of ischemia. Thus, the selection and number of ECG leads used for ST 
monitoring may influence detection and quantitation of ischemia in patients 
with unstable angina. As such, standard 12-lead ST monitoring might be 
preferred. In order to validate tllis assllmption, we compared on-line continuolls 
48-hours 12-lead (except a VR) with 3-lead ST monitoring in 130 unstable 
angina patients (chapter 5). 
Twelve lead ST monitoring appeared to be more sensitive than the 3-lead 
technology more generally applied at cardiac care units. With three leads, 
ischemia was detected in 62% of patients, which was comparable to studies 
using Holter ST monitoring in patients with unstable angina4•5. With 12-lead 
ST monitoring, ischemia was detected in an additional 15% of patients. Also 
the number and duration of ischemic episodes increased using 12-lead 
compared to 3-lead ST monitoring. Most importantly, the ST changes 
were found to disperse and shift among different leads in time in at least 
31 % of patients with more than one ST episode during the monitoring 
period, confirming that the use of multiple leads (8-12 standard leads) or 
vectorcardiographic leads is mandatory in these patients. 
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RISK ASSESSMENT AND ASSESSMENT OF THERAPEUTIC 
EFFICACY IN PATIENTS WITH UNSTABLE ANGINA USING 
ECG-ISCHEMIA MONITORING 
In unstable angina patients, myocardial ischemia may develop as the result 
of platelet aggregation and intracoronary thrombosis at the site of plaque 
fissuring or rupture6,7, Recurrent ischemia detected during computer-assisted 
continuous ST monitoring may thus specifically reflect episodes of platelet 
aggregation in these patients. We conducted two studies with continuous ECG-
ischemia monitoring in patients with unstable angina, evaluating the therapeutic 
efficacy of efegatran, a direct anti-thrombin (chapter 6), and abciximab, 
a platelet glycoprotein fIb-IlIa receptor blocker (chapter 7). 
Efegatran was studied in 432 patients with unstable angina. Five dose levels 
of efegatran sulphate were investigated and compared to heparin. Efficacy 
was assessed by measurement of the number of patients with recurrent ischemia, 
the number of episodes and the duration of episodes. Clinical endpoints were: 
episodes of recurrent angina, myocardial infarction, coronary intervention 
(PTCA or CABG), and death. Neither of the doses of efegatran studied were 
able to suppress myocardial ischemia during continuous ECG-ischemia 
monitoring to a greater extent than that seen with heparin. The study was 
hampered by the fact that a high number of patients with a myocardial infarction 
at the time of enrollment had been included into the study (13.4%). This 
was due to the fact that th~ majority of patients was enrolled directly after 
admission to hospital without knowledge of possibly elevated CK and CK-
MB enzyme levels. The incidence of subsequent infarction after enrollment 
into the study was low (3.2%). No significant difference between the efegatran 
and heparin treated groups was apparent with respect to clinical outcome. 
Furthermore, no relation could be demonstrated between clinical outcome 
and the presence of ischemic episodes or the ischemic burden detected during 
ECG-ischemia monitoring. 
Abciximab was studied in the CAPTURE trial (c7E3 Fab Anti Platelet 
Therapy in Unstable REfractory angina)s, in which 1265 patients with 
refractory unstable angina were treated with abciximab (c7E3 Fab, ReoPro) 
or placebo, on top of standard treatment from 16-24 hours preceding coronary 
intervention tiuough I hour post intervention. Treatment with abciximab 
resulted in a 50% reduction of myocardial infarction (from 8.2% to 4.1 %) 
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and 29% rcduction in the primary composite endpoint of death, myocardial 
infarction or urgent (re-)intervention in patients with refractOlY unstable angina 
(from 15.9% to 11.3%) at 30 days. 
In ordcr to investigate the incidence of recurrent ischemia and the ischemic 
burden, a subset of332 patients (26%) underwent continuous vector-derivcd 
12-lead ECG-ischemia monitoring. Although the incidence of ischemia in 
this substudy was less than expected in this group ofrefi'actOlY unstable patients 
(21 %), it could be demonstrated that treatment with abciximab was associated 
with a reduction offrequent ischemia and a reduction oftotal ischemic burden. 
Patients with recurrent ischemia during the ST monitoring period before PTCA 
had a greater probability to develop myocardial infarction or death within 
5 days follow-up. This association also remaincd apparent at 30 days follow-
up. 
The results of this ECG-ischemia monitoring substudy extended the 
obsclvation in the CAPTURE main trial that treatment with abciximab reduced 
the occurrence of myocardial infarction during the 16 to 24 hours medical 
treatment period beforc PTCA was performed. It is likely that the reduction 
of recurrent ischemia reflected rcsolution of thrombus and prevention of 
recurrent thrombosis by abciximab with ]Jossible stabilization of the plaque, 
which lead to the reduction of clinical events. This is supported by the 
observation that the presence of rccurrent ischemia during the ST monitoring 
period before PTCA appeared strongly predictive of myocardial infarction 
and death. 
The latter study demonstrates that ischemia, detected during vector-derived 
multilead ECG-ischcmia monitoring, can be used for risk assessment in patients 
with unstable coronary syndromes and as a study cndpoint in phase II trials. 
Recently we completed the ECG-ischemia monitoring substudy of the 
PURSUIT trial (Platelet lib-IlIa in Unstable angina: Receptor Suppression 
Using Integrilin Therapy)9 In this trial, 9461 paticnts with refractory unstable 
angina or evolving myocardial infarction without ST elevation were treatcd 
with eptifibatide, (a platelet glycoprotein fIb-lila reccptor blocker) or placebo 
during 3-4 days. Eptifibatide reduced the event rate of death or (re)infarction 
at 30 days from 15.7% to 14.2% (p 0.042). A subset of216 patients (2.3%) 
underwent continuous standard 12-lead ECG-ischcmia monitoring (Mortara 
system) fi'om start of treatment until 24 hours later. There was no demonstrable 
effect of cptifibatide on ischemic burdcn. At 7 days, 30 days and 6 months 
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follow-up, death or myocardial infarction occurred in 21,33, and 38 patients 
respectively. These patients had significantly more frequent recurrent ischemic 
episodes and a higher ischemic burden compared with those without events. 
Significance was greatest at 6 months follow-up. This study confirmed our 
results of the CAPTURE ECG-ischemia monitoring sub study, that recurrent 
ischemia and ischemic burden quantified by continuous 12-lead ECG-
monitoring are significant predictors of both death and myocardial infarction. 
TECHNICAL ASPECTS OF COMPUTER-ASSISTED CONTINUOUS 
ECG-ISCHEMIA MONITORING 
Computer-assisted continuous multilead and vectorcardiographic ECG-
ischemia monitoring use continuous ECG sampling and averaging techniques, 
which offer an accurate continuous real-time measurement ofthe QRS complex 
and ST segments. This has resulted in a major improvement in the quality 
of the analysis compared to conventional ECG recording- and monitoring 
teclmiques. However, the user should appreciate the differences that exist 
between conventional ECG recording techniques and the various computer-
assisted systems. Conventional techniques (e.g. Holter) measure the ST level 
from individual beats of the real-time ECG and subsequently average these 
measurements over fixed time intervals (generally 15 seconds to 1 minute). 
In contrast, computer-assisted techniques average a number ofECG complexes 
in a preset time interval and subsequently calculate the ST level. Proper beat 
selection with exclusion of noisy beats can be done before averaging, resulting 
in more robust and accurate measurements. Conventional techniques will be 
more sensitive to abl1lpt ST changes, thus more easily triggering on minor 
ECG variations. In a noisy ECG environment, such technique will also be 
most sensitive to noise. This is illustrated by the results of GUSTO-I ECG-
ischemia monitoring sub study (chapter 2). Holter ECG recording detected 
the moment of 50% ST recovery earlier (but not more accurately) than 
vectorcardiographic or 12-lead ECG-ischemia monitoring. It also detected more 
recurrent ST episodes (in 55% versus 33% of patients, chapter 3). Thus, for 
correct interpretation of the signal, users should be aware ofthe characteristics 
of the device used. Adaptation of the ST analysis criteria to the individual 
characteristics of each device and to the demands of the user and the site of 
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monitoring may result in optimal predictive perfollllance and clinical usefulness. 
In general, computer-assisted ECG-ischemia monitoring systems will render 
good quality ECG recordings and analyses at a preset time interval of I minute 
averaging. However, in some situations, such as ECG-ischemia monitoring 
during coronary angiography or PTCA, this time interval will be too long 
for detection of procedure related short episodes of ischemia. Fifteen seconds 
averaging may then be preferred. If the sampling time interval ofa computer-
assisted system is set at a too long interval (e.g. 5 minutes instead of I), the 
system will "overlook" shorter episodes of ischemia, resulting in less accurate 
detection of ischemic burden. 
THERAPEUTIC IMPLICATIONS AND FUTURE DIRECTIONS 
Continuous computer-assisted ECG-ischemia monitoring has become a mature 
noninvasive method to monitor of the perfusion status of the myocardium in 
patients with acute coronary syndromes. The teclmique may help to select 
patients at high risk for clinical events and assist the clinician to select optimal 
treatment. Such treatment should focus on rapid achievement of reperfusion 
or resolution of ischemia and should be tailored to the optimal risk benefit 
ratio in the individual patient. 
In patients with evolving myocardial infarction, ECG-ischemia monitoring 
can help discriminate patients with stable reperfusion from those who do 
not exhibit any signs of reperfusion or patients who reperfused but develop 
early re-ischemia, often caused by reocclusion. In the patients who have stable 
reperfusion early after initiation of thrombolytic therapy, it may be decided 
to stop infusion of the thrombolytic in order to reduce the hazard of intracranial 
bleeding and to save costs 10,11. Those patients with persistent occlusion may 
benefit from subsequent rescue PTCA, although this has not been proven 
definitely. Finally, patients with re-ischemia following initial reperfusion may 
benefit from subsequent treatment with a platelet glycoprotein Ilb-rna receptor 
blocker such as abciximab, and from immediate or early angiography and 
PTCAI2. 
Patients with unstable angina who exhibit recurrent ischemia during 
continuous ECG-ischemia monitoring may benefit from additional treatment 
with abciximab or other IIb-IIIa receptor blockers, followed by early PTCA. 
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In patients without recurrent ischemia, coronary angiography and I or PTCA 
may not be necessary, or may be deferred in order to allow for further plaque 
stabilization with subsequent reduction of procedural risk. 
The following case example illustrates the clinical power of continuous 
ECG-ischemia monitoring in a patient with an acute coronary syndrome l3 : 
Patient history 
A 48-year-old man was admitted to our cardiac care unit following a 
resuscitation procedure. An accompanyingji-iend i!!formed liS that complaints 
of chest painllOd been presentfor approximately 4 hours. The patient intended 
to visit our outpatient clinic bllt suddenly collapsed on his way to the reception 
desk. He was successfully resuscitated FOil/ ventricular fibrillation and 
subsequent~J' intubated because of respirato!J' arrest. The I2-lead ECG 
demonstrated ST elevations both in the i!!ferior leads and in VI, V2, and 
V3, suggesting acute i1!/erior wall myocardial i1!farction with right ventricular 
involvement. 
011 admission to the coronwJ' care Ullit, the patient was still unconscious 
and not breathing spontaneously, rendering respiration supportnecess{//J'. 
The l/ell/odynamic situation was not compromised. Subsequently, thrombo~J'tic 
therapy with rt-PA was initiated and the patient was connected to a continuous 
vectorcardiographic ECG monitoring 'J'stem (Coronet, Ortivus Medical, Tiiby, 
Sweden). 
One hOllr later, the patient again needed resuscitation, because (Jf episodes 
(Jfrecurrent ventriclliarfibrillation (Figure 1). Until the moment (Jfrecurrence 
(Jfventricularfibrillation, the continuolls ECG recording had not shown any 
ST segment recove!)' (Figure 2, ECG B). However, .follOWing resuscitation 
the ECG improved dramatically, with aill/ost cOll/plete ST segment recove!J' 
of all involved leads, suggesting that repe!jilsion actually had occurred on 
the moment (Jf recurrent ventricular fibrillatioll (Figure 2, ECG C). 
UI!fortunately, this repel.jilsion period only lastedfor afew minutes. Thereq/ier 
the ST segment re-elevated, with more pronounced involvement o(leads V2 
and V3, and lead V4 showing ST elevation instead (Jfdepression (Figure 2, 
ECG D). Subsequently angiography was pelformed with the intention to 
pel/orll/ PTCA if possible. 
At coron{//)' angiography, a proximally occluded right coron{//J' artelJ' was 
found, which opened up immediately at./irst injection (Jf contmst. As the vessel 
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Figure 1. EeG monitoring strip. recorded during the second resuscitation procedure, one 
hour following initiation ofthromboiytic therapy (see case report), Sinus rhythm is present 
with a sudden occurrence of ventricular fibrillation, terminated by DC shock. Subsequently 
a new episode of ventricular fibrillation occurs, again terminated by DC shock (the latter 
not shown). 
appeared to be diffusely narrowed and TIM1 2 flow was obtained (which 
was considered adequate at that time in 1994), noji/rther balloon dilatation 
was performed. The le:fi descending coron({1)' artel), demonstrated a 50-90% 
luminal narrowing directly following the first diagonal branch, which also 
had a 90-99% narrowing. The lefi circumflex artel), did not show any 
significant obst/'llctions. 
Upon retul'll to the cardiac care IIIlit, the EeG had recovered completely 
(Figure 2, EeG E). However, 10 minutes later ST elevation occurred again, 
accompanied by hJ'lJotension and 1011' le/i wntricular/illing pressures. Because 
of the diffuse two vessel coron({1)' artel)' disease, it was decided not to undertake 
a nell' invasive procedure. The patient was successfully treated with additional 
intravenous heparin, nitroglycerin andfluid-Ioading (Figure 2, EeG G). The 
next mOl'lling, the patient appeared alert and hemodynamically and 
electrocardiographically stable. He was success/idly weaned fi'om the 
respirator and extubated. No signs of post-anoxic cerebral dysjilllctionwere 
noted, and the patient was feeling well. A1aximal sel'lllli cardiac protein indices 
for creatine kinase, aHbDH and ASAT were 4100, 337 and 179 UIL, 
re~pectively. 
140 CHAPTER 8 
ST-VM (mV) 
10 I 
0.8 
0.6 If/s 
D 
0.4 
c G 
E 
---1 
6 hrs. 
Figure 2. ST vector-magnihlde trend (ST-VM) of the patient described. The ST vector-
magnitude is the magnitude of the sum ST vector, calculated from Frank's orthogonal X, 
Y and Z leads. Letters A-G indicate the moments of interest with actual 12-lcad EeG. For 
further explanation, see text. 
Three days later, the patient again experienced anginal pain. The continuous 
ECG recording demonstrated recurrent STsegment elevation in the precordial 
leads, but 1I0t ill/erior. The patient was treated with intravenous rt-PA. 
Subsequently, the paill subsided alld the ECG normalized, suggesting that 
stable repel.iilsion had been obtained. FO//OIVillg this recurrence ol cOl'On{ll)' 
reocclusion, the patient was relerred lor corollmy artel)1 bypass surgel)" 
which was successjitfly lYeI/ormed the next day. 
This case history clearly illustrates the clinical power of computer-assisted 
continuous ECG monitoring techniques for tailoring of therapeutic strategies 
in patients with acute myocardial infarction. It also demonstrates the limitations 
of other noninvasive markers such as chest pain and reperfusion arrhythmias. 
As the patient was connected to a respirator, the monitoring of presence or 
absence of residual chest pain was impossible. Complaints would have been 
difficult to interpret anyhow, because of additional complaints causcd by the 
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resuscitation procedure. Thc occurrence of ventricular fibrillation in the setting 
of acute coronary (re )occlusion has almost certainly been the cause of the 
first collapse of this patient at our outpatient clinic. The second period of 
ventricular fibrillation howevcr, resulted from reperfusion ofthe infarct-related 
artery. This is supported by the fact that complete ST recovery was present 
directly following this episode. Thus, both (re )occlusion and reperfusion 
induced ventricular fibrillation in this patient. 
Finally, this case report also demonstrates that predictive accuracy of 
continuous ECG monitoring is very accurate if high initial ST levels are 
encountered. Continuous ECG-ischemia monitoring may thus lead to selection 
of specific reperfusion and anti-ischemic strategies. As such, continuous 
computer-assisted ECG-ischemia monitoring should be an integrated part of 
the treatment protocols at emergency wards and coronary care units. The 
technique may also become of substantial value for the peri-operative monitoring 
of patients undergoing coronary bypass surgelY or major peripheral vascular 
surgeJyl4. 
Early risk assessment in patients with chest pain 
Evaluation of patients admitted with acute chest pain is time consuming and 
expensive, while a substantial proportion of these patients do not really suffer 
from an acute coronary syndrome 15 Van Miltenburg reported on a study of 
417 patients consecutively admitted for chest pain suggestive of an acute 
coronary syndrome. Thirty-eight of these patients (9%) eventually appeared 
to have a myocardial infarction, 270 patients (65%) had unstable angina and 
109 (26%) had non-cardiac or non-specific chest pain. The first two groups 
represent patients with an acute coronmy syndrome who are at risk for an 
adverse cardiac event, thus requiring high care treatment (74%), whereas 
the third group (26%) includes patients at low risk for cardiac events who 
might be discharged after appropriate risk stratification. Early risk stratification 
may thus both improve patient care and reduce costs. 
Such early risk stratification can be achieved through different bedside 
methods, including assessment of the clinical status and complaints of the 
patient, information obtained from the admission ECG, and bedside essays 
of chemical markers of myocardial damage such as creatine-kinase MB or 
troponin T and 116-21. Bedside tests for detection of these cardiac-specific 
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evolving infarction 
evolving infarction 
or 
unstable angina 
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evolving infarction 
discharge 
Figure 3. Early risk stratification in patients with chest pain suggestive of an acute coronary 
syndrome. 
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Table I. Prognostic value of the admission EeG for early risk stratification in 12.142 patients 
with an acute coronary syndrome. Death and (rc)infarction at 30 days follow-up (GUSTO 
lib trial)". 
ST-elev. +ST-dcpr. ST-elcvation ST -depression T -wave inversion P-value 
---.--•. _--------- .--, 
% of patients 15% 28% 35% 23% 
acute infarction on 87% 81 % 47% 31% < 0.0001 
admission 
death (%) 6.8% 5.0% 5.0% 1.8% < 0.001 
(rc-)infarction (%) 6.9% 5.1 % 6.7% 4.3% < 0.001 
troponins appear highly sensitive for the early detection of minimal myocardial 
cell injwy in acute coronary syndromes I6,18,21. Patients with unstable angina 
who present with elevated troponin T / I levels on admission have a worse 
short and long term prognosis 18,20. In contrast, negative troponin test results 
on admission and 6 hours latcr in patients with chest pain without ST elevation 
are associated with low risk of adverse cardiac events and may allow safe 
and early discharge ofthese patients 19 Recently, also early dobutamine-atropine 
stress echocardiography has been suggested for early risk assessment22 . 
The standard 12-lead admission ECG does provide direct prognostic 
information. In patients with an acute coronmy syndrome, the presence of 
ST elevation with or without concomitant ST depression most commonly 
reflects evolving myocardial infarction (87%, Table I) having the highest 
rate ofmOltality within 30 days (6.8%)Z3,24. Patients with isolated ST depression 
end up with mortality rates of5.0% and almost half of them (47%) have an 
evolving myocardial infarction on admission. In patients with unstable angina 
without evidence of an acute myocardial infarction, ST segment depression 
on the admission ECG (regardless its severity) is highly predictive of an in-
hospital adverse cardiac outcome, while the presence of isolated T wave 
inversion indicates a favorable prognosis, as well as a normal admission 
ECG25,26. 
In patients who present with chest pain suggestive of an acute coronary 
syndrome, the presence of transient ischemia during continuous ECG-ischemia 
monitoring after an initially inconclusive admission ECG may provide 
important additional infollnation for risk stratification (chapter 7). Continuous 
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ECG-ischemia monitoring can easily be combined with simultaneous serial 
creatine kinase MB and / or troponin T or I measurements. Recently, an 
cmergency department protocol for rapidly ruling out myocardial ischemia 
in patients admitted with chest pain has been proposed (Figure 3)22. Patients 
with negative findings of the different tests have a low risk profile and may 
thus be discharged from hospital within 12 hours following admission. If 
one of the tests is positive for ischemia, an acute coronary syndrome is 
diagnosed. The latter patients should receive intcnsive treatment with 
continuation ofECG-ischcmia monitoring. Patients who subsequently appear 
to stabilizc on medical therapy, not having recurrences of ischemia, as well 
as patients without elevated troponin T Icvels 18.20, have a low risk of myocardial 
infarction and death, particularly when trcated with a glycoprotein lIb-IlIa 
reccptor blocker27.29.It is questionable whether early angiography and PTCA 
is necessary in these patients30 In contrast, patients with recurrent ischemia 
during ECG-ischcmia monitoring (as well as patients with elevated troponin 
T levels) exhibit a higher risk of myocardial infarction or death (chapter 7)27 
This suggests that such patients will benefit from immediatc or urgcnt invasive 
thcrapy. 
Future study and systematic application of the combined use of ECG-
ischemia monitoring, serial measurement of troponin T levels and early 
dobutamine-atropine stress echocardiography may help to improve the early 
care of patients with a suspected acute coronmy syndrome. 
CONCLUSIONS 
Continuous ECG-ischemia monitoring should become an integrated part of 
the standard care protocols at emergency wards, pre-coronaly care or chest 
pain units and coronary care units. The technique is of use for early diagnosis 
and risk assessment in patients with chest pain suggestive of an acute coronary 
syndromc and for subsequent identification oflow and high risk patients with 
an acute coronary syndrome. It may guide medical and invasive therapy in 
thesc patients. 
The accuracy of continuous ECG-ischemia monitoring to prcdict vcssel 
status in paticnts with evolving myocardial infarction is bcst if high initial 
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ST elevation is present and an "ischemic reference ECG" can be obtained. 
Thus, continuous ECG monitoring should be started as soon as possible, 
preferably before the initiation of thrombolytic thcrapy (myocardial infarction) 
or at the moment of ischemia (unstable angina), although it should not delay 
the onset of therapy. Full integration ofcontilluous ECG-ischemia monitoring 
ill emergency wards and coronary care units will greatly enhance further clinical 
usefulness, predictive performance and monitoring possibilities of these 
systems. 
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Samenvatting 
Hoofdstuk 1 
Gezien de mogelijkheden voor behandeling met thrombolyse en intracoronaire 
interventie bij patienten met acute corona ire syndromen, is het voor de keuze 
en aanpassing van de therapie belangrijk om gelnformeerd te worden over 
de status van het betrokken coronair vat en de mate van myocard perfusie. 
Het ECG en met name het vervolgen van het ST segment in de tijd is hiervoor 
een eenvoudige methode. Continue computerondersteunde (digitale) multilead 
ECG monitoring technieken hebben inmiddels de beperkingen van eerdere 
ECG technieken overwonnen. Dit promotieonderzoek bestudeett de technische 
mogelijkheden (en beperkingen) also ok de klinische btuikbaarheid van deze 
nieuwe ECG systemen. 
Hoofdstuk 2 
Ais onderdeel van de GUSTO-I studie (Global Utilization of Streptokinase 
and Tissue plasminogen activator for Occluded coronary atteries), waarin 
vier verschillende thrombolytische regimes werden vergeleken bij patienten 
met een acuut hattinfarct, ondergingen 1064 patienten continue ECG monitoring: 
406 patienten met een vectorafgeleid 12-afleidingen ECG systeem, 373 patienten 
met een 12-afleidingen systeem en 288 patienten met een 3-afleidingen Holter 
systeem. Hiervan ondergingen 302 patienten 90 of 180 minuten na het statten 
van thrombolytische behandeling een coronair angiografie. In dit hoofdstuk 
wordt aangetoond dat een snelle afuame van de ST segment elevatie of depressie 
tijdens continue ECG monitoring een goede voorspeller is van reperfusie van 
het infarct gerelateerde coronair vat. Afwezigheid van herstel of laat herstel 
van het ST segment suggereelt persisterende occlusie. Continue ECG-ischemie 
monitoring is vooral informatief bij patienten met uitgebreide ST segment 
elevaties bij aanvang van de monitoring periode. Bij deze patientengroep, die 
het grootste risico heeft op cardiale complicaties en het meeste baat heeft van 
reperfusie therapie, bleek de voorspelling van de toestand van het betrokken 
coronair vat in 79-100% correct. Alhoewel de drie ECG systemen aanzienlijk 
verschilden in signaal bewerking werden geen belangrijke verschillen tussen 
betrouwbaarheid van de systemen aangetoond. De stu die laat zien dat het 
150 SAMENV ATTING 
mogelijk is om bij patienten met een acuut hmtinfarct de keuze en de intensiteit 
van de reperfusie behandeling te bepalen op geleide van de bevindingen van 
continue ECG-ischemie monitoring. 
Hoofdstuk 3 
In dit hoofdstuk wordt de snelheid en de stabiliteit van het herstel van het 
ST segment tijdens continue ECG monitoring vergeleken bij de vier 
verschillende thrombolytische strategieen in de GUSTO-I studie. De 
verwachting was dat patienten die werden behandeld volgens het protocol 
van versnelde It-PA toediening een sneller herstel van het ST segment zouden 
laten zien dan de patienten die werden behandeld volgens de andere protocollen. 
Van de patienten die werden behandeld met streptokinase werd een stabieler 
herstel van het ST segment verwacht. Alhoewel de angiografische substudie 
van GUSTO-I inderdaad aantoonde dat versnelde It-PA toediening resulteerde 
in een snellere opening van het infarct gerelateerde coronair vat, konden we 
deze bevinding niet correleren met een sneller herstel van het ST segment 
in deze patientengroep. Dit werd voomamelijk veroorzaakt door technische 
beperkingen en het gebruik van drie verschillende ECG monitOling technieken. 
Hoofdstuk 4 
In ongeveer 36% van de GUSTO-I ST monitoring substudie patienten 
ontstonden tijdens continue ECG monitoring na een initieel herstel van het 
ST segment opnieuw ST segment veranderingen (voomamelijk ST elevatie) 
suggestiefvoor re-ischemie ofre-occlusie van het infarct gerelateerde coronair 
vat. In dit hoofdstuk werd onderzocht of deze patienten een grotere kans 
hebben om te overlijden in vergelijking met patienten zonder re-ischemie of 
re-occlusie. Het bleek dat bij patienten met een initieel herstel van het ST 
segment (reperfusie), de sterftekans zowel na 30 dagen als na 1 jaar het grootst 
was als er opnieuw ST segment veranderingen waren opgetreden suggestief 
voor re-ischemie of re-occlusie. De dum van de ST segment verandering 
bleek direct gerelateerd aan de sterftekans. Continue ECG monitoring is 
derhalve niet aIleen bruikbaar voor de selectie van hoog risico patienten die 
geen tekenen van reperfusie vertonen, maar ook voor de selectie van hoog 
risico patienten met tekenen van reperfusie en vervolgens aanwijzingen voor 
re-ischemie en I of re-occlusie. 
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Hoofdstuk 5 
Bij patienten met onstabiele angina pectoris kan de plaats van het ischemische 
gebied varieren, afhankelijk van de verdeling van de doorstroming van het 
coronair systeem, de mate van de coronaire vaatwand beschadiging en de 
duur en ernst van de ischemie. Omdat het aantal en de keuze van de ECG 
afleidingen tijdens continue ECG monitoring de detectie en kwantificering 
van ischemie kunnen beinvloeden werd onderzocht in hOeVel1'e 12 afleidingen 
ECG monitoring bij deze patientengroep de voorkeur verdient. Continue 
48-uurs 12 afleidingen ECG monitoring (zonder a VR) werd bij 130 patienten 
met onstabiele angina pectoris vergeleken met de frequenter geblUikte 
3 afleidingen ECG monitoring. 
Twaalf afleidingen ECG monitoring bleek gevoeliger dan de 3 afleidingen 
techno logie, die over het algemeen wordt geblUikt op hartbewakings- en 
intensive care afdelingen. Met 3 afleidingen werd in 62% van de patienten 
ischemie gedetecteerd, terwij I dit met 12 afleidingen in 77% van de patienten 
het geval was. Ook het aantal en de duur van de ischemische episodes nam 
toe bij het geblUik van 12 afleidingen. Van belang was dat de ST veranderingen 
verspreid over de afleidingen optraden en in de tijd verschoven naar andere 
afleidingen bij ten minste 31 % van de patienten die ST episodes hadden. 
Dit bevestigde de noodzaak voor registratie van zoveel mogelijk afleidingen 
(of vectorcardiografische afleidingen) bij patienten met onstabiele angina 
pectoris. 
Hoofdstuk 6 
Bij patienten met onstabiele angina pectoris kan myocard ischemie ontstaan 
ten gevolge van bloedplaatjes aggregatie en intracoronaire thrombose tel' plaatse 
van een fissuUl' OflUPtuUl' van een plaque in een coronair arterie. Re-ischemie 
tijdens continue ECG monitoring zou derhalve episodes van bloedplaatjes 
aggregatie kunnen reflecteren. In dit en het volgende hoofdstuk worden twee 
studies met continue ECG monitoring beschreven bij patienten met onstabiele 
angina. In de eerste studie wordt de therapeutische effectiviteit van efegatran, 
een direct anti-thrombine, vergeleken met heparine, en in de tweede studie 
de effectiviteit van abciximab, een glycoproteine IIb-IIIa bloedplaatjes receptor 
blokker (hoofdstuk 7). 
Efegatran werd geevalueerd in 432 patienten met onstabiele angina. 
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Klinische eindpunten waren: nieuwe episodes van angina, ha11infarct, coronaire 
interventie (PTCA of CAB G), en dood. Er bleek geen aantoonbaar verschil 
in cardiovasculaire ofbloedingscomplicaties te bestaan tussen de met efegatran 
en heparine behandelde patienten. Ook was er vergeleken met heparine geen 
reductie van myocard ischemie tijdens continue ECG monitoring. De studie 
werd beperkt door het grote aantal patienten met een ha11infarct op het moment 
van inclusie in de studie (13.4%). Het optreden van een hartinfarct na inclusie 
was vervolgens laag (3.2%). Een relatie tussen klinische eindpunten en de 
aanwezigheid van ischemie of de ernst van de ischemie ("ischemic burden") 
tijdens ECG monitoring kon niet worden aangetoond. 
Hoofdstuk 7 
In the CAPTURE trial (c7E3 Fab Anti Platelet Therapy in Unstable REfractOlY 
angina) werden 1265 patienten met refractaire onstabiele angina pectoris 
behandeld met abciximab (c7E3 Fab, ReoPro) of placebo (toegevoegd aan 
de standaal'd behandeling) van 16-24 UUI' voorafgaand aan een cOl'Onail'e 
interventie (PTCA of stent implantatie) tot 1 uur el' na. Behandeling met 
abciximab resulteerde in 50% reductie van het aantal patienten met een 
hartinfarct (van 8.2% naal' 4.1 %) en 29% reductie van het primail'e 
samengestelde eindpunt van dood, hartinfal'ct of urgente (re-)interventie 
30 dagen later (van 15.9% naar 11.3%). 
Driehonderdtweeendertig van deze 1265 patienten (26%) ondergingen 
continue vectorafgeleide 12-afleidingen ECG monitoring. Het bleek dat 
behandeling met abciximab resulteerde in een reductie van frequente ischemie 
en een reductie van de totale ischemische last ("ischemic burden"). Patienten 
met re-ischemie tijdens de ST monitoring periode voorafgaand aan de PTCA 
hadden een grotere kans om binnen 5 dagen te overlijden of een harlinfarct 
te krijgen. Ook na 30 dagen follow-up bleek deze kans nog steeds verhoogd. 
Deze studie laat zien dat ischemie, gedetecteerd door middel van 
vectorafgeleide 12-afleidingen ECG monitoring kan worden gebmikt voor 
risico stratificatie bij patienten met onstabiele corona ire syndromen en als 
een studie eindpunt in fase II studies. 
Hoofdstuk 8 
In dit hoofdstuk worden de conclusies van het proefschrift samengevat. 
Continue ECG monitoring is btuikbaar voor snelle diagnose en risico stratificatie 
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bij patienten met pijn op de borst en voor identificatie van laag en hoog risico 
patienten met een acuut coronair syndroom. Continue ECG monitoring dient 
derhalve onderdeel te zijn van de behandelprotocollen op spoedeisende hulp 
afdelingen, pre-coronaly care en coronaty care units. Volledige integratie van 
continue ECG monitoring systemen op deze afdelingen zal de klinische 
bruikbaarheid en de toepassingen van deze systemen aanzienlijk do en 
toenemen. 

Danl{woord 
Old paint on conms, as it ages, sometimes becomes transparent. When 
that happens it is possible, ill some pic/llres, to see the origillallilles: 
II tree will sholl' through a \1'0111011 '.'0 dress, a child makes way for a 
dog, a/arge boat is no longer all an open sea. n,is is where the painter 
"repainted", changed his mind. Perhaps it lI'ould be as well 10 say that 
the old conception, replaced by a later choice, is a way oj seeing and 
then seeing again. 
Lillian Hellman 
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Als de tekst van dit proefschrift "transparant" zou zijn en de originele Iijnen 
zichtbaar, dan zouden de bijdragen van de vele mensen die direct of indirect 
betrokken waren bij de totstandkoming ervan nog goed te zien zijn. Maar de 
"verf' van dit proefschrift is vel'S en "The old conceptions are replaced by a 
later choice": de veranderingen en toevoegingen die in de loop del' tijd plaats 
vonden zijn veelal niet meer zichtbaar en gingen op in het geheel. Met dit 
gevoel en zonder volledig te kunnen zijn, wil ik graag een aantal mensen in 
het bijzonder bedanken: 
Allereerst wil ik mijn promotor Prof dr. M.L. Simoons bedanken. Beste 
Maarten, jouw onvermoeibare "drive", je voortdurende beschikbaarheid en 
niet te vergeten je vertrouwen in mij hebben uiteindelijk geleid tot de 
vervolmaking van dit proefschrift. Ik ben je dankbaar dat je me ooit in de 
gelegenheid stelde om mijn "Holter interesse" verdeI' uit te breiden in de 
richting van de nieuwe ST monitoring technieken die nu het onderwerp zijn 
geworden van dit proefsclll·ift. 
Dank ook aan Prof dr. JR.T.C. Roelandt. Beste Jos, "in den beginne", zowel 
in goede als in slechte tijden, was jij het die me stimuleerde en aan het schrijven 
kreeg. De Quarterly Holter verhalen voor het Thoraxcentre Journal werden 
een steeds grotere uitdaging, terwijl de drempel om te schrijven steeds kleiner 
werd. 
Ook Prof dr. E. O. Robles de Medina en Prof dr. HJJ Wellens wil ik bedanken 
voor het kritisch doorlezen van het manuscript en de nuttige opmerkingen. 
Simon 1vleij, zonder jou had dit proefschrift niet kunnen bestaan. Het 
programmeerwerk, de ST algoritmes, we hebben veel van elkaar gcleerd. Je 
bijdrage aan de publicaties die zijn opgenomen in dit proefschrift is substantieel. 
Ik ben blij dat je erbij bent als mijn paranymf. 
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Heather Hennessy, Nol Heijboer, Irene Keulen, Ellie van de Leur, Mukta Saxena, 
Astrid Spierings, en aile andere analystes van het ECG cOl'e!ab van Cardialysis: 
bedankt voorjullie inzet door de jaren heen en de kwaliteit van de vele ST analyses 
die de basis vonnden van dit proefschrift. 
In het bijzonder wi! ik mijn collegae en met name Aggie Balk en Coen van 
del' Zwaan van de afdeling Cardiologie bedanken. Ondanks onze drukte van 
de kliniek hebben jullie allen me in de gelegenheid gesteld dit proefschrift te 
voltooien. Aggie, je was vaak (zonder het te weten?) een behulpzame mentrix, 
die me op de belangrijke momenten de goede richting wees. Coen, bedankt 
voor de hannonieuze samenwerking, ook in de afgelopen drukke tijd. 
Ook de verpleging en secretaresses van de afdeling Algemene Hartziekten 
("3 Zuid") wil ik bedanken. Jullie geduld, de belangstelling en het me eleven 
met mijn vorderingen heb ik zeer gewaardeerd. Ik ben mij ervan bewust dat 
ik jullie en de afdeling de laatste tijd niet meer die aandacht en toewijding 
heb kunnen geven die nodig was. Hopelijk zal dat stmks snel verbeteren. 
Het zelfde geldt voor de Holter ("ritme analyse") afdeling. Marianne Blii1ll, 
Angela Peterse, Slize Schenderling, Sylvia van Winsen, bedankt voor jullie 
geduld en het spontaan invallen als tijdelijke "secretaresse van dokter 
Klootwijk" bij plotselinge telefoontjes of tijdens mijn afwezigheid. Het doet 
me goed dat inmiddels het ST monitoring "virus" ook op jullie afdeling is 
gesignaleerd en in ontwikkeling is. 
Marianne Eicholtz bedankt voor je nuttige adviezen, je praktische hulp en 
ondersteuning bij het afhandelen van al die formele administratieve zaken. 
Tells van Dam, Stefan Nelwan, bedankt voor jullie inspanningen en hulp bij 
het "bedenken" van de voorkant. Uiteindelijk is het maar een heel klein stukje 
uit een van die mooie Siemens ECG plaatjes geworden. 
Tenslotte gaat mijn grootste waat'dering uit naar mijn gezin. Bedankt voor de 
steun en het vetirouwen. Jullie kregen de laatste tijd niet meer die aandacht die 
jullie verdienen. Gezelligheid van mijn kant was soms vel' te zoeken, ondanks 
het feit dat ik dichtbij in de woonkamer zat te werken. Lieve Jolanda, bedankt 
voor al die uren die je samen met mij hebt besteed aan het afschrijven van dit 
proefschrift,je steun kwam altijd op de juiste momenten. Alex, Sandra en }';!al'k, 
jullie vee I gestelde vraag "wanneer is het nu eens klaar" is eindelijk beantwoord. 
157 
Curriculum vitae 
Peter Klootwijk was bom on FeblUaty 3, 1951 in Rotterdam, The Netherlands. 
He completed his preparatOlY academic education in 1969 at the Christelijk 
Lyceum "De Populier" (Gymnasium J3 division) in The Hague and started 
his medical training at the Erasmus University in Rotterdam that same year. 
In 1976 he passed his final examinations in medicine and became a fellow 
ofIntemal Medicine at the St. Franciscus Gasthuis in Rotterdam (supervisor 
dr. M. de Jong). In 1979 he statted his training in cardiology at the Thoraxcentre 
of the University Hospital Dijkzigt in Rotterdam under Professor P.G. 
Hugenholtz. In 1982 he received his celtificate as a cardiologist from the 
Committee for the Registration of Specialists of the Royal Netherlands Medical 
Association. 
Since 1982 until present, the author works as a staff member of the Department 
of Cardiology at the Thoraxcentre of the University Hospital Dijkzigt in 
Rotterdam, with special interest in the field of electrocardiography. He also 
supervises the central ambulatory Holter ECG scanning service of Cardiolab 
and the ECG core-laboratOlY of Cardialysis Rotterdam. 
The author is happily married to Jolanda Ruchti and together they have three 
children, Mark, Sandra and Alex, and a big black dog named Bobo. 

159 
Publications 
Roelandt J, Klootwijk P. Holter electrocardiografie. Cordiaal 1981; 2: 27-
32. 
Kloohvijk APJ, Roelandt JRTC. ECG registratie per telefoon voor de 
beoordeling van patienten met klachten verdacht voor ritmestoornissen. Ned 
Tijdschr Geneesk 1983; 127: 545-9. 
Roelandt J, Kloohvijk P, Lubsen J, Janse MJ. Sudden death during longterm 
ambulatOlY monitoring. Eur Heart J. 1984; 5: 7-20. 
Roeland! J, Kloo/wijk P, Lubsen J. Documentazione della morte improvvisa 
cardiaca mediante elettrocardiografia di Holter. Le IlUove fi·ontiere delle aJitmie. 
Padova 1984: 667-74. 
Kloohvijk P, Roelandt J, Telefonische ECG-registratie bij klachten verdacht 
voor ritmestoornissen. In: Roelandt en Lubsen, Ambulante 24-uurs 
electrocardiografie. 1985; 31-6. 
Kloohvijk P, Leenders CM, Roelandt J. Usefulness of transtelephonic 
documentation of the electrocardiogram during sporadic symptoms suggestive 
of cardiac arrhythmias. Int. 1. Card 1986; 13: 155-61. 
Koudstaal PJ, v. Gijn J, Kloo/wijk APJ, v. der Meche FGA, Kapelle L1. 
Holter monitoring in patients with transient and focal ischemic attacks of 
the brain. Stroke 1986; 17(2): 192-5. 
Kloo/wijk APJ, Simoons ML. Medicamenteuze behandeling van angina 
pectoris. Geneesmiddelenbulletin 1987, 21 (4) (28 maaJi 1987). 
Kloohvijk AP J. Quarterly Holter: Solving clinical problems with longtenn 
ambulatOlY ecg recordings. The Thoraxcentre Journal 1990; 2(1): 26-7. 
Kloohvijk AP J. Qualierly holter: Solving clinical problems with transtelephonic 
ecg recordings. The Thoraxcentre Journal 1990; 2(2): 24-5. 
Kloo/wijk AP J. Quarterly holter: Symptoms and cardiac arrhythmias, 
correlation or coincidence? The Thoraxcentre Journal 1990; 2(3): 22-3. 
160 PUBLICA nONS 
Klootwijk AP J. Quatierly Holter: Sudden cardiac death during longterm 
ambulatOlY ECG monitoring. The Thoraxcentre Journal 1990; 2: 18-20. 
Klootwijk AP J. QUaIierly Holter: Dmg-induced Torsade de Pointes documented 
during ambulatOlY ECG recording. The Thoraxcentre Journal 1991; 3: 
15-7. 
Klootwijk AP J. Quatierly Holter: Sick sinus syndrome, documented during 
long-term ambulatOlY ECG recording. The Thoraxcentre Journal 1991; 3: 
18-9. 
Klootwijk APJ. Qualierly Holter: Long term ambulatOlY continuous ST 
recording in a patient with atypical chest pain. The Thoraxcentre Journal 
1991; 3: 10-2. 
Klootwijk APJ. Quarterly Holter: Cardiac arrhythmias and topical drug 
application: the "overlooked" eye-drops. The Thoraxcentre Journal 1991; 3: 
16-8. 
Klootwijk AP J, Circadiaanse ritmen van cardiovasculaire aandoeningen. 
Cardiovisie Nederland, Excerpta Medica 1991; 8: 1-2. 
Kloohvijk AP J. QUaIierly Holter: Cardiac anhythmias as the first manifestation 
of heart disease. The Thoraxcentre Journal 1992; 4: 8-9. 
Kloo/wijk AP J. Quarterly Holter: A coachman who dropped dead from his 
coach. Physical training and cardiac arrhythmias. The Thoraxcentre Joumal 
1992; 4: 47-49. 
Kloo/wijk APJ. Quarterly Holter: Asymptomatic WPW syndrome becomes 
symptomatic during physical activities. The Thoraxcentre Journal 1992; 4: 
102-4. 
Kloohvijk APJ. Arrhythmia special: Caffeine and arrhythmias. The 
Thoraxcentre Journal 1993; 5: 38-9,41. 
Kloo/wijkAPJ, Roelandt JRTC. Systemische bijwerkingen van oogdruppels: 
een onopvallende oorzaak van hartritmestoornissen. Ned Tijdschr. Cardiol 
1992; 6: 145-8. 
Klootwijk P, Cobbaert C, Fioretti P, Kint PP, Simoons ML. Noninvasive 
assessment of reperfusion and reocclusion after thrombolysis in acute 
myocardial infarction. Am J Cardiol 1993; 72: 75G-84G. 
PUBLICATIONS 161 
KrucoffMW, Green CL, Langer A, Klootwijk P, Trollinger KM, Sawchek 
ST e/ al. Global utilization of streptokinase and tP A for occluded arteries 
(GUSTO) ECG-monitoring substudy. Study design and technical considera-
tions. J Electrocardiol 1993; 26(suppl): 249-55. 
Luyten HE, Klootwijk AP J. Syncope and repeated non-diagnostic ambulatOlY 
electrocardiographic recordings. The Thoraxcentre Journal 199311994; 6: 
15-6. 
Kloo/wijk APJ, Kint PP. ECG special: Dynamic computer assisted ECG 
monitoring of the coronmy mielY status in acute myocardial infarction. The 
Thoraxcentre Joumal 1994; 6: 28-30. 
Meij SH, Kloo/wijk P, Arends J, Roelandt JRTC. An algorithm for automatic 
beat-to-beat measurement of the QT-interval. Computers in Cardiology 
Proceedings 1994. 
Simoons ML, de Boer MJ, van den Brand MJBM, van Miltenburg AJM, 
Hoorntje JCA, Heyndrickx GR, v.der Wieken LR, de Bono D, Rutsch W, 
Schaible TF, Weisman HF, Kloo/wijk P, Nijssen KM, Stibbe J, de Fey tel' 
PJ, and the European Cooperative Study Group. Randomized trial of a lIB! 
IIIA platelet receptor blocker in refractOlY unstable angina. Circulation 1994; 
89: 596-603. 
Meij SH, Kloo/wijk P, van der Putten N, Lacle C, Arends J. Computer-aided 
analysis of ambulatory electrocardiograms. Cardiologie 1995; II: 409-13. 
Dekker 1M, Schouten EG, Kloo/wijk P, Pool J, Kromhout D. Association 
between QT interval and coronmy heartdisease in middle-aged and elderly 
men. The Zutphen Study. Circulation 1994;90(2):779-85. Comment in: 
Circulation 1995; 91: 564-65. 
Dekker 1M, Schouten EG, KloollVijk P, Pool J, Kromhout D. ST and T-
wave characteristics as indicators of coronalY heart disease risk. The Zutphen 
Study. J Am Coil Cardiol 1995; 25: 1321-6. 
Dekker 1M, Schouten EG, Kromhout D, Kloo/wijk P, Pool J. The Cardiac 
Infarction InjUly Score and coronmy hemt disease in middle-aged and elderly 
men: the Zutphen Study. J Clin Epidemiol 1995; 48: 833-40. 
Langer A, KrucoffMW, Klootwijk P, Veldkamp R, Simoons ML, Granger 
C, CaliffRM, Armstrong PW. Noninvasive assessment of speed and stability 
162 PUBLICATIONS 
of infarct-related artery reperfusion: results of the GUSTO ST segment 
monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen 
Activator for Occluded Coronmy Arteries. J Am Coli Cardiol 1995; 25: 
1552-7. 
Nelwan S, Meij S, van Dam T, Klootwijk P, Simoons ML. A new ST ischemia 
monitoring system. The Thoraxcentre Journal 1996; 8: 23-7. 
Dekker JM, Schouten EG, Pool J, Klootwijk P, Kromhout D. Het electro-
cardiogram en het risico op toekomstige coronarire hartziekten. Hmt Bull 
1996; 27: 57-60. 
Dekker JM, Feskens EJ, Schouten EG, Klootwijk P, Pool J, Kromhout D. 
QTc duration is associated with levels of insulin and glucose intolerance. 
The Zutphen Elderly Study. Diabetes 1996; 45: 376-80. 
KlootwijkP, Langer A,Meij S, Green C, Veldkamp RF, Ross AM, Armstrong 
PW,. Simoons ML, for the GUSTO-I ECG-ischemia monitoring substudy. 
Non-invasive prediction of reperfusion and coronary artery patency by 
continuous ST segment monitoring in the GUSTO-I trial., Eur Heart J 1996; 
17: 689-98. Erratum in Eur Heatt J 1996; 17: 1451; Comment in Eur Heart 
J 1997; 18: 348. 
Klootwijk P, Meij S, v. Es GA, Miiller EJ, Umans V A WM, Lenderink T, 
Simoons ML. Comparison of usefulness of computer assisted continuous 
48-h 3-lead with 12-lead ECG-ischemia monitoring for detection and 
quantitation of ischaemia in patients with unstable angina. Eur Hemt J 1997; 
18: 931-40. 
Klootwijk P, Kint PP. Dynamische computerondersteunde ECG ST-bewaking. 
Cordiaal 1997; 18: 83-5. 
Dekker JM; Schouten EG; Klootwijk P; Pool J; Swenne CA; Kromhout D. 
Heart rate variability from shott electrocardiographic recordings predicts 
mottality from all causes in middle-aged and elderly men. The Zutphen Study. 
Am J Epidemiol 1997; 145: 899-908. 
Cobbaert C, Hennens WT, Kint PP, Klootwijk PJ, Van de WerfF, Simoons 
ML. Thrombolysis-induced coronmy reperfusion causes acute and massive 
interstitial release of cardiac muscle cell proteins. Cardiovasc Res 1997; 33: 
147-55. 
PUBLICATIONS 163 
Langer A, Krucoff MW, Klootll'ijk P, Simoons ML, Granger CB, Barr A, 
CaliffRM, Annstrong PW. Prognostic significance ofST-segment shift early 
after resolution of ST elevation in patients with myocardial infarction treated 
with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Sub study. 
J Am Coli Cardiol 1998; 31: 783-9. 
van Domburg RT, KloollVijk P, Deckers JW, van Bergen PFMM, Jonker 
nc, Simoons ML. The Cardiac Infarction Injury Score as a predictor for 
long-term mortality in survivors ofa myocardial Infarction. Eur Heali J 1998; 
19: 1034-41. 
Klootll'ijk P, Meij S, Melketi R, Lenderink T, Simoons ML. Reduction of 
recurrent ischemia with abciximab during continuous ECG-ischemia 
monitoring in patients with unstable angina refractOlY to standard treatment 
(CAPTURE). Circulation 1998; in press. 
Moons KGM, Klootll'ijk P, Meij S, van Es, Baardman T, Lenderink T, van 
den Brand M, Habbema JDF, Grobbee DE, Simoons ML. Continuous ST-
segment monitoring for prediction of infarct size and left ventricular function. 
Submitted. 
Additional financial support by the following sponsors is gratefully acImowlcdgcd: 
Astra Phannaceutica; Boehringer Ingelheim; Bristol-Myers Squibb; Cardialysis; 
Cardio Control; Eli Lilly Nederland; Merck Sharp & Dohme; Mortara Instrument; 
Ortivus Medical; Schering-Plough; Siemens Nederland; Tramedico; Zeneca Farma. 
